<?xml version="1.0" standalone="yes"?>
<QueryArticlesSet>
  <T_Query>
    <QueryID>1</QueryID>
    <Name>isphumancell</Name>
    <ProteinID>1</ProteinID>
    <OrganismID>1</OrganismID>
    <KeywordListID>1</KeywordListID>
    <ResultCount>118</ResultCount>
  </T_Query>
  <T_Protein>
    <ProteinID>1</ProteinID>
    <Protein>isp</Protein>
  </T_Protein>
  <T_Organism>
    <OrganismID>1</OrganismID>
    <Organism>human</Organism>
  </T_Organism>
  <T_Keyword>
    <KeywordID>1</KeywordID>
    <Keyword>cell</Keyword>
  </T_Keyword>
  <T_QueryArticles>
    <QueryArticleID>1</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23543559</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>2</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23372719</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>3</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23352090</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>4</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23199969</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>5</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23189540</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>6</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>23024152</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>7</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22672275</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>8</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22659420</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>9</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22610699</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>10</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22592975</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>11</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22448717</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>12</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22337793</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>13</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22284237</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>14</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22274813</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>15</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22132161</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>16</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>22042512</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>17</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21920450</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>18</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21819665</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>19</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21480416</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>20</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21416629</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>21</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21401652</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>22</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21394107</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>23</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>21382056</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>24</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20849980</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>25</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20844581</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>26</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20805755</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>27</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20618558</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>28</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20506484</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>29</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20407012</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>30</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20198341</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>31</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20097674</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>32</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>20089839</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>33</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19937735</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>34</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19916082</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>35</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19906097</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>36</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19900588</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>37</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19350552</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>38</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19268713</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>39</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19259249</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>40</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19158945</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>41</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>19088704</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>42</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18952783</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>43</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18662621</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>44</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18652866</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>45</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18555888</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>46</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18520051</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>47</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18416311</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>48</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18400537</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>49</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18287049</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>50</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18279271</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>51</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18062244</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>52</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>18061950</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>53</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17914900</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>54</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17900215</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>55</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17895250</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>56</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17556392</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>57</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17530242</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>58</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17229855</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>59</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17027137</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>60</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17018115</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>61</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>17011585</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>62</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16549044</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>63</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16527606</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>64</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16410634</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>65</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16278235</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>66</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16257142</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>67</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>16172008</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>68</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>15979402</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>69</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>15966292</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>70</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>15951022</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>71</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>15531524</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>72</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>15339929</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>73</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>15229803</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>74</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>15020599</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>75</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>14986303</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>76</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>14573769</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>77</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12915133</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>78</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12732183</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>79</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12675508</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>80</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12648232</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>81</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12604687</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>82</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12578840</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>83</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12498721</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>84</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12213223</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>85</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>12069821</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>86</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>11942050</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>87</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>11856628</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>88</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>11709184</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>89</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>11440778</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>90</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>11208198</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>91</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>10924327</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>92</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>10886724</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>93</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>10813797</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>94</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>10461730</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>95</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>10099162</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>96</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>9782161</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>97</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>9698100</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>98</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>9562860</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>99</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>9473533</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>100</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>9373217</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>101</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>7844457</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>102</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>7752809</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>103</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>7933530</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>104</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>8150717</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>105</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>8351444</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>106</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>8097745</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>107</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>1316462</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>108</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>1402073</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>109</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>1999314</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>110</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>1695103</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>111</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>2760965</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>112</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>2428988</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>113</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>2433235</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>114</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>3002305</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>115</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>6356989</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>116</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>639073</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>117</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>949029</PMID>
  </T_QueryArticles>
  <T_QueryArticles>
    <QueryArticleID>118</QueryArticleID>
    <QueryID>1</QueryID>
    <PMID>4327576</PMID>
  </T_QueryArticles>
  <T_QuerySession>
    <QuerySessionID>1</QuerySessionID>
    <QueryID>1</QueryID>
    <ProteinID>1</ProteinID>
    <DateTime>2013-11-07T14:21:58.2027913-08:00</DateTime>
  </T_QuerySession>
  <T_Article>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <Title>Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.</Title>
    <PubDate>20130328</PubDate>
    <Language>eng</Language>
    <doi>10.1002/14651858.CD008054.pub2</doi>
    <Abstract>Atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intra-epithelial lesions (LSIL) are minor lesions of the cervical epithelium, detectable by cytological examination of cells collected from the surface of the cervix of a woman.Usually, women with ASCUS and LSIL do not have cervical (pre-) cancer, however a substantial proportion of them do have underlying high-grade cervical intra-epithelial neoplasia (CIN, grade 2 or 3) and so are at increased risk for developing cervical cancer. Therefore, accurate triage of women with ASCUS or LSIL is required to identify those who need further management.This review evaluates two ways to triage women with ASCUS or LSIL: repeating the cytological test, and DNA testing for high-risk types of the human papillomavirus (hrHPV) - the main causal factor of cervical cancer.Main objective To compare the accuracy of hrHPV testing with the Hybrid Capture 2 (HC2) assay against that of repeat cytology for detection of underlying cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) or grade 3 or worse (CIN3+) in women with ASCUS or LSIL. For the HC2 assay, a positive result was defined as proposed by the manufacturer. For repeat cytology, different cut-offs were used to define positivity: Atypical squamous cells of undetermined significance or worse (ASCUS+), low-grade squamous intra-epithelial lesions or worse (LSIL+) or high-grade squamous intra-epithelial lesions or worse (HSIL+).Secondary objective To assess the accuracy of the HC2 assay to detect CIN2+ or CIN3+ in women with ASCUS or LSIL in a larger group of reports of studies that applied hrHPV testing and the reference standard (coloscopy and biopsy), irrespective whether or not repeat cytology was done.We made a comprehensive literature search that included the Cochrane Register of Diagnostic Test Accuracy Studies; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE (through PubMed), and EMBASE (last search 6 January 2011). Selected journals likely to contain relevant papers were handsearched from 1992 to 2010 (December). We also searched CERVIX, the bibliographic database of the Unit of Cancer Epidemiology at the Scientific Institute of Public Health (Brussels, Belgium) which contains more than 20,000 references on cervical cancer.More recent searches, up to December 2012, targeted reports on the accuracy of triage of ASCUS or LSIL with other HPV DNA assays, or HPV RNA assays and other molecular markers. These searches will be used for new Cochrane reviews as well as for updates of the current review.Studies eligible for inclusion in the review had to include: women presenting with a cervical cytology result of ASCUS or LSIL, who had undergone both HC2 testing and repeat cytology, or HC2 testing alone, and were subsequently subjected to reference standard verification with colposcopy and colposcopy-directed biopsies for histologic verification.The review authors independently extracted data from the selected studies, and obtained additional data from report authors.Two groups of meta-analyses were performed: group I concerned triage of women with ASCUS, group II concerned women with LSIL. The bivariate model (METADAS-macro in SAS) was used to assess the absolute accuracy of the triage tests in both groups as well as the differences in accuracy between the triage tests.The pooled sensitivity of HC2 was significantly higher than that of repeat cytology at cut-off ASCUS+ to detect CIN2+ in both triage of ASCUS and LSIL (relative sensitivity of 1.27 (95% CI 1.16 to 1.39; P value &lt; 0.0001) and 1.23 (95% CI 1.06 to 1.4; P value 0.007), respectively. In ASCUS triage, the pooled specificity of the triage methods did not differ significantly from each other (relative specificity: 0.99 (95% CI 0.97 to 1.03; P value 0.98)). However, the specificity of HC2 was substantially, and significantly, lower than that of repeat cytology in the triage of LSIL (relative specificity: 0.66 (95% CI 0.58 to 0.75) P value &lt; 0.0001).HPV-triage with HC2 can be recommended to triage women with ASCUS because it has higher accuracy (significantly higher sensitivity, and similar specificity) than repeat cytology. When triaging women with LSIL, an HC2 test yields a significantly higher sensitivity, but a significantly lower specificity, compared to a repeat cytology. Therefore, practice recommendations for management of women with LSIL should be balanced, taking local circumstances into account.</Abstract>
    <JournalRelease>1469-493X</JournalRelease>
    <Pages>CD008054</Pages>
    <Affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. Marc.Arbyn@wiv-isp.be.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23543559&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <Title>Proteomic biomarkers associated with Streptococcus agalactiae invasive genogroups.</Title>
    <PubDate>20130123</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0054393</doi>
    <Abstract>Group B streptococcus (GBS, Streptococcus agalactiae) is a leading cause of meningitis and sepsis in newborns and an etiological agent of meningitis, endocarditis, osteoarticular and soft tissue infections in adults. GBS isolates are routinely clustered in serotypes and in genotypes. At present one GBS sequence type (i.e. ST17) is considered to be closely associated with bacterial invasiveness and novel proteomic biomarkers could make a valuable contribution to currently available GBS typing data. For that purpose we analyzed the protein profiles of 170 genotyped GBS isolates by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI). Univariate statistical analysis of the SELDI profiles identified four protein biomarkers significantly discriminating ST17 isolates from those of the other sequence types. Two of these biomarkers (MW of 7878 Da and 12200 Da) were overexpressed and the other two (MW of 6258 Da and 10463 Da) were underexpressed in ST17. The four proteins were isolated by mass spectrometry-assisted purification and their tryptic peptides analyzed by LC-MS/MS. They were thereby identified as the small subunit of exodeoxyribonuclease VII, the 50S ribosomal protein L7/L12, a CsbD-like protein and thioredoxin, respectively. In conclusion, we identified four candidate biomarkers of ST17 by SELDI for high-throughput screening. These markers may serve as a basis for further studies on the pathophysiology of GBS infection, and for the development of novel vaccines.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e54393</Pages>
    <Affiliation>Equipe Bact챕ries et risque materno-f흹tal, UMR 1282 ISP, Universit챕 Fran챌ois Rabelais de Tours, Tours, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23372719&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23352090</PMID>
    <AuthorListID>3</AuthorListID>
    <Title>Iron status and its determinants in a nationally representative sample of pregnant women.</Title>
    <PubDate>20130124</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.jand.2012.10.021</doi>
    <Abstract>Iron-deficiency anemia is associated with adverse neonatal health outcomes. Iron status and its determinants were assessed in a representative sample of Belgian pregnant women. Blood samples were collected and a questionnaire was completed face-to-face. Hemoglobin (Hb) and mean cell volume were measured using a Beckman Coulter Hematology Analyzer and serum ferritin (SF) and transferrin receptor (sTfr) concentrations by immunoassay. In total, 55 obstetric clinics and 1,311 pregnant women were included. Approximately 40% of third-trimester and 6% of first-trimester women had SF levels less than 15 關g/L. Approximately 21% of third-trimester and 4% of first-trimester women had anemia (Hb &lt;110 g/L). Of the third-trimester women, 23% were iron-deficient nonanemic (SF &lt;15 關g/L and Hb ??10 g/L), 16% had iron-deficiency anemia (SF &lt;15 關g/L and Hb &lt;110 g/L), and approximately 7% had tissue iron deficiency (sTfr &gt;8.5 mg/L). The median body iron stores were 8.1 mg/kg among first-trimester women, but only 3.6 mg/kg among third-trimester women. SF levels were significantly positively associated with age and education level, and were higher among nulliparous women and lower among North-African women. sTfr concentrations were significantly negatively associated with age and were lower among smokers, nulliparous women, and women who planned their pregnancy. Despite the fact that two thirds of Belgian pregnant women took iron-containing supplements, iron deficiency and iron-deficiency anemia were frequent in third-trimester women. The World Health Organization regards this as a moderate public health problem. National iron supplementation guidelines are needed in Belgium to optimize iron status during pregnancy.Copyright 짤 2013 Academy of Nutrition and Dietetics. Published by Elsevier Inc. All rights reserved.</Abstract>
    <JournalRelease>2212-2672</JournalRelease>
    <Pages>659-66</Pages>
    <Affiliation>Scientific Institute of Public Health, Department of Public Health and Surveillance, Brussels, Belgium. stefanie.vandevijvere@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23352090&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <Title>Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.vaccine.2012.06.095</doi>
    <Abstract>More than ever, clinicians need regularly updated reviews given the continuously increasing amount of new information regarding innovative cervical cancer prevention methods. A summary is given from recent meta-analyses and systematic reviews on 3 possible clinical applications of human papillomavirus (HPV) testing: triage of women with equivocal or low-grade cytologic abnormalities; prediction of the therapeutic outcome after treatment of cervical intraepithelial neoplasia (CIN) lesions, and last not but not least, primary screening for cervical cancer and pre-cancer. Consistent evidence is available indicating that HPV-triage with the Hybrid Capture(짰) 2 assay (Qiagen Gaithersburg, Inc., MD, USA [previously Digene Corp.] (HC2) is more accurate (higher sensitivity, similar specificity) than repeat cytology to triage women with equivocal Pap smear results. Several other tests show at least similar accuracy but mRNA testing with the APTIMA(짰) (Gen-Probe Inc., San Diego, CA, USA) test is similarly sensitive but more specific compared to HC2. In triage of low-grade squamous intraepithelial lesions (LSIL), HC2 is more sensitive but its specificity is substantially lower compared to repeat cytology. The APTIMA(짰) test is more specific than HC2 without showing a loss in sensitivity. Identification of DNA of HPV types 16 and/or 18, or RNA from the five most carcinogenic HPV types allow selecting women at highest risk for CIN3+ but the sensitivity and negative predictive value of these markers are lower than full-range high-risk HPV (hrHPV) testing. After conservative treatment of cervical pre-cancer, HPV testing picks up more quickly, with higher sensitivity and not lower specificity, residual or recurrent high-grade CIN than follow-up cytology. Primary screening for hrHPV generally detects more CIN2, CIN3 or cancer compared to cytology at cut-off atypical squamous cells of undetermined significance (ASC-US) or LSIL, but is less specific. Combined HPV and cytology screening provides a further small gain in sensitivity at the expense of a considerable loss in specificity if positive by either test is referred to colposcopy, in comparison with HPV testing only. Randomised trials and follow-up of cohort studies consistently demonstrate a significantly lower cumulative incidence of CIN3+ and even of cancer, in women aged 30 years or older, who were at enrollment hrHPV DNA negative compared to those who were cytologically negative. The difference in cumulative risk of CIN3+ or cancer for double negative (cytology &amp; HPV) versus only HPV-negative women is small. HC2, GP5+/6+ PCR (polymerase chain reaction), cobas(짰) 4800 PCR (Roche Molecular Systems Inc., Alameda, CA, USA) and Real Time PCR (Abbott Molecular, Des Plaines, IL, USA) can be considered as clinically validated for use in primary screening. The loss in specificity associated with primary HPV-based screening can be compensated by appropriate algorithms involving reflex cytology and/or HPV genotyping for HPV16 or 18. There exists a substantial evidence base to support that HPV testing is advantageous both in triage of women with equivocal abnormal cytology, in surveillance after treatment of CIN lesions and in primary screening of women aged 30 years or older. However, the possible advantages offered by HPV-based screening require a well organised program with good compliance with screening and triage policies. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.Copyright 짤 2012 Marc Arbyn. Published by Elsevier Ltd.. All rights reserved.</Abstract>
    <JournalRelease>1873-2518</JournalRelease>
    <Pages>F88-99</Pages>
    <Affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. marc.arbyn@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23199969&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23189540</PMID>
    <AuthorListID>5</AuthorListID>
    <Title>A national cohort of HIV-infected patients in Belgium: design and main characteristics.</Title>
    <Language>eng</Language>
    <Abstract>In Belgium, individual laboratory and treatment data of all HIV-infected patients seen in the 9 AIDS Reference Centres and 7 AIDS Reference Laboratories are collected prospectively since 2006. We present here an analysis of patients recorded in the cohort database between 1st of January 2006 and 31st of December 2008. During that period, 11982 patients were under medical follow-up in Belgium. Sixty-one percent of the patients were male and the median age was 39.8 at the time of first recorded viral load. Among the patients whose nationality or probable mode of transmission was recorded, nearly half (48.0%) were Belgian and 38.3% originated from Sub-Saharan Africa; heterosexual contacts were reported in the majority of cases (56.0%) followed by homosexual contacts (35.3%). A total of 145 deaths were reported. Around three quarters of the patients were on ART. The median CD4 cell count rose from 470 cells/mm3 in 2006 to 501 cells/mm3 in 2008. This cohort enabled us to obtain comprehensive information on the numbers and characteristics of HIV-infected patients currently being followed up in Belgium, and on trends in antiretroviral therapy and biological results. This will serve for planning purposes, evaluation of access to care and as a source of information for further studies.</Abstract>
    <JournalRelease>0001-5512</JournalRelease>
    <Pages>333-7</Pages>
    <Affiliation>O.D. Public Health and Surveillance, Scientific Institute of Public Health, Brussels, Belgium. dvanbeckhoven@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23189540&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>23024152</PMID>
    <AuthorListID>6</AuthorListID>
    <Title>Rotator cuff muscles lose responsiveness to anabolic steroids after tendon tear and musculotendinous retraction: an experimental study in sheep.</Title>
    <PubDate>20120928</PubDate>
    <Language>eng</Language>
    <doi>10.1177/0363546512460646</doi>
    <Abstract>Long-standing rotator cuff tendon tearing is associated with retraction, loss of work capacity, irreversible fatty infiltration, and atrophy of the rotator cuff muscles. Although continuous musculotendinous relengthening can experimentally restore muscular architecture, restoration of atrophy and fatty infiltration is hitherto impossible.Continuous relengthening with pharmacological stimulation of muscle growth using an anabolic steroid or insulin-like growth factor (IGF) can reverse atrophy and fatty infiltration as well as improve the work capacity of chronically retracted rotator cuff muscles in sheep.Controlled laboratory study.Sixteen weeks after tenotomy of the infraspinatus (ISP) tendon, atrophy and fatty infiltration had developed in the retracted ISP muscle. The musculotendinous unit was continuously relengthened in 14 sheep during 6 weeks: Four sheep were treated without pharmacological stimulation, 4 with intramuscular administration of an anabolic steroid, and 6 with IGF before final repair and rehabilitation (12 weeks). Changes were documented by intraoperative measurements of muscle work capacity, histology, and computed tomography/magnetic resonance imaging.Musculotendinous relengthening by continuous traction resulted in gains of length ranging from 0.7 cm in the IGF group to 1.3 cm in the control group. Fatty infiltration progressed in all groups, and the muscle's cross-sectional area ranged from 71% to 74% of the contralateral side at sacrifice and did not show any differences between groups in weight, volume, histological composition, or work capability of the muscle. The contralateral muscles in the anabolic steroid group, however, showed significantly higher (mean 짹 standard deviation) muscle work capacity of 10 짹 0.9 N쨌m than the contralateral muscles of the control group (6.8 짹 2.4 N쨌m) (P &lt; .05). This was accompanied by an increased mean muscle fiber area as well as by an unusual gain in the animals' weight after injection of the anabolic steroid.Subcutaneous continuous relengthening of a chronically retracted musculotendinous unit is feasible and advances the retracted musculotendinous junction toward its original position. This does not change the muscle work capacity. Whereas anabolic steroids have been shown to be effective in preventing classic degenerative muscle changes after tendon tears, neither an anabolic steroid nor IGF contributes to regeneration of the muscle once degenerative changes are established.The findings demonstrate that muscle cells lose reactiveness to an anabolic steroid and IGF once retraction has led to fatty infiltration and atrophy of the muscle. Retraction of the muscle after tendon tears must be avoided by early repair, particularly in an athlete, as no regeneration can be achieved by mechanical or pharmacological means at this time.</Abstract>
    <JournalRelease>1552-3365</JournalRelease>
    <Pages>2454-61</Pages>
    <Affiliation>Balgrist University Hospital, University of Z체rich, Switzerland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=23024152&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <Title>Skin presenting a higher level of caspase-14 is better protected from UVB irradiation according to in vitro and in vivo studies.</Title>
    <Language>eng</Language>
    <doi>10.1111/j.1473-2165.2012.00615.x</doi>
    <Abstract>Caspase-14, a cysteine endoproteinase belonging to the conserved family of aspartate-specific proteinases, was shown to play an important role in the terminal differentiation of keratinocytes and barrier function of the skin. In the present study, we developed a biofunctional compound that we described as a modulator of caspase-14 expression. Using normal human keratinocytes (NHK) in culture and human skin biopsies, this compound was shown to increase caspase-14 expression and partially reverse the effect of caspase-14-specific siRNA on NHK. Moreover, the increase in filaggrin expression visualized on skin biopsies and the recovery of the barrier structure after tape-stripping indicated that this compound could exhibit a beneficial effect on the skin barrier function. Considering the possible link between caspase-14 and the barrier function, a UVB irradiation on NHK and skin biopsies previously treated with the caspase-14 inducer, was performed. Results indicated that pretreated skin biopsies exhibited less signs of UV damage such as active caspase-3 and cyclobutane pyrimidine dimers (CPDs). Likewise, pretreated NHK were protected from UV-induced genomic DNA damage, as revealed by the Comet Assay. Finally, a clinical test showed a reduction of transepidermal water loss (TEWL) on the treated skin compared with placebo, under UV stress condition, confirming a protecting effect. Taken together, these results strongly suggest that, by increasing caspase-14 expression, the biofunctional compound could exhibit a protective effect on the skin barrier function, especially in case of barrier damage and UV irradiation.짤 2012 Wiley Periodicals, Inc.</Abstract>
    <JournalRelease>1473-2165</JournalRelease>
    <Pages>111-21</Pages>
    <Affiliation>ISP Vincience, ISP Global Skin Research Center, Sophia Antipolis, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22672275&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22659420</PMID>
    <AuthorListID>8</AuthorListID>
    <Title>Toxoplasma ISP4 is a central IMC sub-compartment protein whose localization depends on palmitoylation but not myristoylation.</Title>
    <PubDate>20120530</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.molbiopara.2012.05.002</doi>
    <Abstract>Apicomplexan parasites utilize a peripheral membrane system called the inner membrane complex (IMC) to facilitate host cell invasion and parasite replication. We recently identified a novel family of Toxoplasma IMC Sub-compartment Proteins (ISP1/2/3) that localize to sub-domains of the IMC using a targeting mechanism that is dependent on coordinated myristoylation and palmitoylation of a series of residues in the N-terminus of the protein. While the precise functions of the ISPs are unknown, deletion of ISP2 results in replication defects, suggesting that this family of proteins plays a role in daughter cell formation. Here we have characterized a fourth ISP family member (ISP4) and discovered that this protein localizes to the central IMC sub-compartment, similar to ISP2. Like ISP1/3, ISP4 is dispensable for the tachyzoite lytic cycle as the disruption of ISP4 does not produce any gross replication or growth defects. Surprisingly, targeting of ISP4 to the IMC membranes is dependent on residues predicted for palmitoylation but not myristoylation, setting its trafficking apart from the other ISP proteins and demonstrating distinct mechanisms of protein localization to the IMC membranes, even within a family of highly related proteins.Copyright 짤 2012 Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>1872-9428</JournalRelease>
    <Pages>99-108</Pages>
    <Affiliation>Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095-1489, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22659420&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <Title>The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.</Title>
    <PubDate>20120613</PubDate>
    <Language>eng</Language>
    <doi>10.1002/ijc.27636</doi>
    <Abstract>Testing for DNA of 13 high-risk HPV types with the Hybrid Capture 2 (HC2) test has consistently been shown to perform better in triage of women with cervical cytology results showing atypical squamous cells of undetermined significance (ASC-US) but often not in triage of low-grade squamous intraepithelial lesions (LSIL) detected in cervical cancer screening. In a meta-analysis, we compared the accuracy of the APTIMA HPV test, which identifies RNA of 14 high-risk HPV types, to HC2 for the triage of women with ASC-US or LSIL. Literature search-targeted studies where the accuracy of APTIMA HPV and HC2 for detection of underlying CIN2/3+ was assessed concomitantly including verification of all cases of ASC-US and LSIL. HSROC (Hierarchical Summary ROC) curve regression was used to compute the pooled absolute and relative sensitivity and specificity. Eight studies, comprising 1,839 ASC-US and 1,887 LSIL cases, were retrieved. The pooled sensitivity and specificity of APTIMA to triage ASC-US to detect underlying CIN3 or worse was 96.2% (95% CI = 91.7-98.3%) and 54.9% (95% CI = 43.5-65.9%), respectively. APTIMA and HC2 showed similar pooled sensitivity; however, the specificity of the former was significantly higher (ratio: 1.19; 95% CI = 1.08-1.31 for CIN2+). The pooled sensitivity and specificity of APTIMA to triage LSIL were 96.7% (95% CI = 91.4-98.9%) and 38.7% (95% CI = 30.5-47.6%) for CIN3+. APTIMA was as sensitive as HC2 but more specific (ratio: 1.35; 95% CI = 1.11-1.66). Results were similar for detection of CIN2 or worse. In both triage of ASC-US and LSIL, APTIMA is as sensitive but more specific than HC2 for detecting cervical precancer.Copyright 짤 2012 UICC.</Abstract>
    <JournalRelease>1097-0215</JournalRelease>
    <Pages>101-8</Pages>
    <Affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. marc.arbyn@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22610699&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22592975</PMID>
    <AuthorListID>10</AuthorListID>
    <Title>Investigation into the genotoxicity of water extracts from Hypoxis species and a commercially available Hypoxis preparation.</Title>
    <PubDate>20120517</PubDate>
    <Language>eng</Language>
    <doi>10.1002/ptr.4732</doi>
    <Abstract>We performed an in vitro evaluation of the genotoxic potential of water extracts from four Hypoxis species (Hypoxis hemerocallidea, H. colchicifolia, H. rigidula, H. acuminata) and a commercial preparation thereof using the neutral red uptake (NRU) assay, the alkaline comet assay and the cytome assay in human hepatoma HepG2 cells. The relative cytotoxicity of these samples was established by determining their NI50 values (50% inhibition of NRU), and these results were used for dose-finding in genotoxicity tests. None of the tested extracts were identified as genotoxic in both the alkaline comet assay and cytome assay.Copyright 짤 2012 John Wiley &amp; Sons, Ltd.</Abstract>
    <JournalRelease>1099-1573</JournalRelease>
    <Pages>350-6</Pages>
    <Affiliation>Scientific Institute of Public Health, Laboratory of Toxicology, B-1050, Brussels, Belgium. luc.verschaeve@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22592975&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22448717</PMID>
    <AuthorListID>11</AuthorListID>
    <Title>High recovery of cell-free methylated DNA based on a rapid bisulfite-treatment protocol.</Title>
    <PubDate>20120326</PubDate>
    <Language>eng</Language>
    <doi>10.1186/1471-2199-13-12</doi>
    <Abstract>Detection of cell-free methylated DNA in plasma is a promising tool for tumour diagnosis and monitoring. Due to the very low amounts of cell-free DNA in plasma, analytical sensitivity is of utmost importance. The vast majority of currently available methods for analysing DNA methylation are based on bisulfite-mediated deamination of cytosine. Cytosine is rapidly converted to uracil during bisulfite treatment, whereas 5-methylcytosine is only slowly converted. Hence, bisulfite treatment converts an epigenetic modification into a difference in sequence, amenable to analysis either by sequencing or PCR based methods. However, the recovery of bisulfite-converted DNA is very poor.Here we introduce an alternative method for the crucial steps of bisulfite treatment with high recovery. The method is based on an accelerated deamination step and alkaline desulfonation in combination with magnetic silica purification of DNA, allowing preparation of deaminated DNA from patient samples in less than 2 hours.The method presented here allows low levels of DNA to be easily and reliably analysed, a prerequisite for the clinical usefulness of cell-free methylated DNA detection in plasma.</Abstract>
    <JournalRelease>1471-2199</JournalRelease>
    <Pages>12</Pages>
    <Affiliation>Section of Molecular Diagnostics, Department of Clinical Biochemistry, Aalborg University Hospital, Denmark, DK. isp@rn.dk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22448717&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22337793</PMID>
    <AuthorListID>12</AuthorListID>
    <Title>Orthogonal chromatographic descriptors for modelling Caco-2 drug permeability.</Title>
    <Language>eng</Language>
    <doi>10.1093/chromsci/bmr044</doi>
    <Abstract>The use of chromatographic descriptors as alternative for Caco-2 permeability in drug absorption screening was evaluated. Therefore, retentions were measured on 17 Reversed-Phase Liquid Chromatographic systems, considered to be orthogonal or dissimilar, and an Immobilized Artificial Membrane (IAM) system. Retentions on a Micellar Liquid Chromatography system were taken from the literature. From this set of systems, those found dissimilar for the used data set were selected. The retention factors on these systems were then used as descriptors in QSAR modelling. Modelling was performed using Stepwise Multiple Linear Regression. This resulted in a model using only two chromatographic systems with good descriptive and acceptable predictive properties. A high qualitative model was obtained by combining both chromatographic systems selected in the previous model with a lipophilicity parameter (the squared Moriguchi n-octanol/water partition coefficient) and the molecular volume.</Abstract>
    <JournalRelease>1945-239X</JournalRelease>
    <Pages>175-83</Pages>
    <Affiliation>Department of Analytical Chemistry and Pharmaceutical Technology, Pharmaceutical Institute, Vrije Universiteit Brussel-VUB, Brussels, Belgium. Eric.Deconinck@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22337793&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22284237</PMID>
    <AuthorListID>13</AuthorListID>
    <Title>On the nature of sarcoidosis.</Title>
    <PubDate>20111012</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.ejim.2011.09.011</doi>
    <Abstract>More than 140 years since its recognition as a clinical entity, sarcoidosis remains enigmatic. Its classification as a disease vs. a syndrome is uncertain. Its etiology remains undefined. The "immune paradox" (delayed type hypersensitivity anergy in a setting of exuberant systemic granulomatous response) resists explanation. Its relationship to the Kveim test is poorly understood. Its prognostic determinants and treatment indications are among the unsolved or disputed problems. Immunological investigations generated the thesis that the characterizing systemic granuloma arise as a fallback reaction to inefficient cellular immune processing, due most often to impaired myeloid dendritic cell function of unknown cause. The concept that sarcoidosis represents a (genetically conditioned) default to a more primitive immunological response provides a unifying explanation for its development in persons with a variety of antigenic exposures and in individuals with cellular immune deficiencies. It furnishes a coherent explanation for the apparent paradox that individuals exhibiting the most intense cellular response experience the most favorable outcomes and for the adverse effect of corticosteroid-suppression in recent onset sarcoidosis.Copyright 짤 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.</Abstract>
    <JournalRelease>1879-0828</JournalRelease>
    <Pages>105-9</Pages>
    <Affiliation>Earle A Chiles Research Institute, Portland, OR, USA. Reichje@isp.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22284237&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <Title>Terpene alcohols inhibit de novo sphingolipid biosynthesis.</Title>
    <PubDate>20120124</PubDate>
    <Language>eng</Language>
    <doi>10.1055/s-0031-1298155</doi>
    <Abstract>The terpene alcohols geranyllinalool, phytol (diterpene alcohol), and farnesol (sesquiterpene alcohol) were newly found to inhibit sphingolipid de novo biosynthesis in LLC-PK??cells (pig kidney epithelial cells). A simple chromatographic bioassay was established for the screening of inhibitory compounds able to reduce the amount of sphinganine, an intermediate metabolite of sphingolipid biosynthesis. The screening strategy was based on the degree of suppression of fumonisin B??(FB??induced sphinganine accumulation following co-treatment with selected terpene alcohols. L-cycloserine and ISP-1, specific serine palmitoyltransferase (SPT) inhibitors, were used as positive controls. Our results show that measuring reduced sphinganine levels after treatment with 2 쨉M FB??in combination with the putative inhibitory compounds provides a useful screening bioassay for evaluating compounds causing sphingolipid depletion. Intracellular sphinganine concentrations were analyzed using the fluorescent peak areas of the O-phthalaldehyde (OPA) derivatives of sphinganine eluted with 87 % acetonitrile on a reversed-phase column. Geranyllinalool, phytol, and farnesol were identified as novel SPT inhibitors that reduce FB??induced sphinganine accumulation and thus inhibit the first step of sphingolipid de novo synthesis.짤 Georg Thieme Verlag KG Stuttgart 쨌 New York.</Abstract>
    <JournalRelease>1439-0221</JournalRelease>
    <Pages>434-9</Pages>
    <Affiliation>College of Pharmacy and MRC, Chungbuk National University, Chongju, Korea.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22274813&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <Title>Implantation serine proteinase 1 exhibits mixed substrate specificity that silences signaling via proteinase-activated receptors.</Title>
    <PubDate>20111123</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0027888</doi>
    <Abstract>Implantation S1 family serine proteinases (ISPs) are tryptases involved in embryo hatching and uterine implantation in the mouse. The two different ISP proteins (ISP1 and ISP2) have been detected in both pre- and post-implantation embryo tissue. To date, native ISP obtained from uterus and blastocyst tissues has been isolated only as an active hetero-dimer that exhibits trypsin-like substrate specificity. We hypothesised that in isolation, ISP1 might have a unique substrate specificity that could relate to its role when expressed alone in individual tissues. Thus, we isolated recombinant ISP1 expressed in Pichia pastoris and evaluated its substrate specificity. Using several chromogenic substrates and serine proteinase inhibitors, we demonstrate that ISP1 exhibits trypsin-like substrate specificity, having a preference for lysine over arginine at the P1 position. Phage display peptide mimetics revealed an expanded but mixed substrate specificity of ISP1, including chymotryptic and elastase activity. Based upon targets observed using phage display, we hypothesised that ISP1 might signal to cells by cleaving and activating proteinase-activated receptors (PARs) and therefore assessed PARs 1, 2 and 4 as potential ISP1 targets. We observed that ISP1 silenced enzyme-triggered PAR signaling by receptor-disarming. This PAR-disarming action of ISP1 may be important for embryo development and implantation.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e27888</Pages>
    <Affiliation>Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada. navsharm@ucalgary.ca</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22132161&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>22042512</PMID>
    <AuthorListID>16</AuthorListID>
    <Title>Transcallosal sensorimotor fiber tract structure-function relationships.</Title>
    <PubDate>20111031</PubDate>
    <Language>eng</Language>
    <doi>10.1002/hbm.21437</doi>
    <Abstract>Recent studies have demonstrated neuroanatomically selective relationships among white matter tract microstructure, physiological function, and task performance. Such findings suggest that the microstructure of transcallosal motor fibers may reflect the capacity for interhemispheric inhibition between the primary motor cortices, although full characterization of the transcallosal inhibitory sensorimotor network is lacking. Thus, the goal of this study was to provide a comprehensive description of transcallosal fibers connecting homologous sensorimotor cortical regions and to identify the relationship(s) between fiber tract microstructure and interhemispheric inhibition during voluntary cortical activity. To this end, we assessed microstructure of fiber tracts connecting homologous sensorimotor regions of the cortex with diffusion tensor imaging. We also assessed interhemispheric inhibition by eliciting the ipsilateral silent period (iSP) within the same participants. We mapped mutually exclusive transcallosal connections between homologous sensorimotor regions and computed quantitative metrics of each fiber tract. Paralleling work in non-human primates, we found the densest interhemispheric sensorimotor connections to be between the medial motor areas. Additionally, we provide a midsagittal callosal atlas in normalized Montreal Neurological Institute (MNI) space for future studies to use when investigating callosal fiber tracts connecting primary and secondary sensorimotor cortices. Finally, we report a strong, positive relationship (r = 0.76) between strength of interhemispheric inhibition (iSP) and microstructure of interhemispheric fibers that is specific to tracts connecting the primary motor cortices. Thus, increased fiber microstructure in young adults predicts interhemispheric inhibitory capacity.Copyright 짤 2011 Wiley Periodicals, Inc.</Abstract>
    <JournalRelease>1097-0193</JournalRelease>
    <Pages>384-95</Pages>
    <Affiliation>School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=22042512&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <Title>Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines.</Title>
    <PubDate>20110831</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.micinf.2011.08.011</doi>
    <Abstract>Novel vaccines are needed to control tuberculosis (TB), the bacterial infectious disease that together with malaria and HIV is worldwide responsible for high levels of morbidity and mortality. TB can result from the reactivation of an initially controlled latent infection by Mycobacterium tuberculosis (Mtb). Mtb proteins for which a possible role in this reactivation process has been hypothesized are the five homologs of the resuscitation-promoting factor of Micrococcus luteus, namely Mtb Rv0867c (rpfA), Rv1009 (rpfB), Rv1884c (rpfC), Rv2389c (rpfD) and Rv2450c (rpfE). Analysis of the immune recognition of these 5 proteins following Mtb infection or Mycobacterium bovis BCG vaccination of mice showed that Rv1009 (rpfB) and Rv2389c (rpfD) are the most antigenic in the tested models. We therefore selected rpfB and rpfD for testing their vaccine potential as plasmid DNA vaccines. Elevated cellular immune responses and modest but significant protection against intra-tracheal Mtb challenge were induced by immunization with the rpfB encoding DNA vaccine. The results indicate that rpfB is the most promising candidate of the five rpf-like proteins of Mtb in terms of its immunogenicity and protective efficacy and warrants further analysis for inclusion as an antigen in novel TB vaccines.Copyright 짤 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</Abstract>
    <JournalRelease>1769-714X</JournalRelease>
    <Pages>86-95</Pages>
    <Affiliation>Scientific Institute of Public Health (WIV-ISP), Scientific Service Immunology, 642 Engelandstraat, B-1180 Brussels, Belgium. marta.romano@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21920450&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21819665</PMID>
    <AuthorListID>18</AuthorListID>
    <Title>Survival of Listeria innocua in rainbow trout protein recovered by isoelectric solubilization and precipitation with acetic and citric acids.</Title>
    <Language>eng</Language>
    <doi>10.4315/0362-028X.JFP-10-543</doi>
    <Abstract>During mechanical fish processing, a substantial amount of protein is discarded as by-products. Isoelectric solubilization and precipitation (ISP) is a process that uses extreme pH shifts to solubilize and precipitate protein from by-products to recover previously discarded protein. Typically, strong acids are used for pH reduction, but these acids do not have a pasteurization effect (6 log reduction) on bacterial load; therefore, organic acids were used during ISP processing to test the impact on Listeria innocua concentrations. Headed and gutted rainbow trout (Oncorhynchus mykiss) were inoculated with L. innocua, homogenized, and brought to the target pH with granular citric acid (pH 2.0 and 2.5) or glacial acetic acid (pH 3.0 and 3.5). Proteins were solubilized for 10 min at 4째C, and insoluble components (e.g., skin and insoluble protein) were removed by centrifugation. The remaining solution was pH shifted to the protein isoelectric point (pH 5.5) with sodium hydroxide, and precipitated protein was separated from the water. Microbial cells for each component (proteins, insolubles, and water) were enumerated on modified Oxford agar (MOX) and tryptic soy agar with 6% yeast extract (TSAYE). The sums of the surviving cells from each component were compared with the initial inoculum levels. No significant differences were observed between results obtained from TSAYE and from MOX (P &gt; 0.05). Significant reductions in microbial populations were detected, regardless of pH or acid type (P &lt; 0.05). The greatest reduction was at pH 3.0 with glacial acetic acid, resulting in a mean reduction of 6.41 log CFU/g in the recovered protein and 5.88 log CFU/g in the combined components. These results demonstrate the antimicrobial potential of organic acids in ISP processing.</Abstract>
    <JournalRelease>1944-9097</JournalRelease>
    <Pages>1348-52</Pages>
    <Affiliation>Division of Animal and Nutritional Sciences, West Virginia University, Morgantown, West Virginia 26506, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21819665&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21480416</PMID>
    <AuthorListID>19</AuthorListID>
    <Title>Effects of astaxanthin on oxidative stress in overweight and obese adults.</Title>
    <PubDate>20110408</PubDate>
    <Language>eng</Language>
    <doi>10.1002/ptr.3494</doi>
    <Abstract>Oxidative stress is caused by an imbalance between the antioxidant and the reactive oxygen species, which results in damage to cells or tissues. Recent studies have reported that oxidative stress is involved in obesity, in addition to many other human diseases and aging. A prospective, randomized, double-blind study was performed to investigate the effect of astaxanthin (ASX), which is known to be a potent antioxidant, on oxidative stress in overweight and obese adults in Korea. Twenty-three adults with BMI??gt;??5.0?뎚g/m(2) enrolled in this study and were randomly assigned to two dose groups: ASX 5?뎜g and 20?뎜g once daily for 3?뎩eeks. Malondialdehyde (MDA), isoprostane (ISP), superoxide dismutase (SOD) and total antioxidant capacity (TAC), as oxidative stress biomarkers, were measured at baseline and 1, 2 and 3?뎩eeks after ASX administration. Compared with baseline, the MDA (by 34.6% and 35.2%) and ISP (by 64.9% and 64.7%) levels were significantly lowered, whereas SOD (by 193% and 194%) and TAC (by 121% and 125%) levels were significantly increased in two dose groups after the 3?뎩eek intervention. This study revealed that supplemental ASX for 3?뎩eeks improved oxidative stress biomarkers by suppressing lipid peroxidation and stimulating the activity of the antioxidant defense system.Copyright 짤 2011 John Wiley &amp; Sons, Ltd.</Abstract>
    <JournalRelease>1099-1573</JournalRelease>
    <Pages>1813-8</Pages>
    <Affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, San 56-1, Sillim-Dong, Gwanak-Gu, Seoul, 151-742, South Korea.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21480416&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21416629</PMID>
    <AuthorListID>20</AuthorListID>
    <Title>Calretinin and somatostatin immunoreactivities label different human submucosal neuron populations.</Title>
    <PubDate>20110317</PubDate>
    <Language>eng</Language>
    <doi>10.1002/ar.21365</doi>
    <Abstract>In human myenteric plexus, calretinin (CALR) and somatostatin (SOM) coexist in Dogiel Type II neurons, which were considered as intrinsic primary afferent neurons in the guinea pig. The aims of this study were to test if also human submucosal neurons costain immunohistochemically for CALR and SOM and whether these or other neurons display Type II morphology. Two sets of submucosal wholemounts of small and large intestine from 29 patients (median age 65 years) were triple stained for CALR, SOM, and human neuronal protein Hu C/D (HU, a pan-neuronal marker) as well as for CALR, SOM, and peripherin (PER), respectively. Only exceptionally, neurons coreactive for both CALR and SOM were found. The three major groups of neurons were CALR-/HU-coreactive (CALR-neurons), SOM-/HU-coreactive (SOM-neurons), and HU-alone-positive neurons. We observed significantly more CALR-neurons in the external submucosal plexus (ESP) of all regions and more SOM-neurons in the internal submucosal plexus (ISP), although with substantial interindividual variations. Comparisons of small vs. large intestine revealed more SOM-neurons (ESP: 29% vs. 4%, ISP: 40% vs. 13%) but fewer CALR-neurons (ESP: 37% vs. 77%, ISP: 21% vs. 67%) in small intestine. Morphologically, CALR-neurons had multiple processes; in some cases, we identified multidendritic/uniaxonal neurons. In contrast, SOM-neurons had mostly only one process. The functions of both populations as possible primary afferent neurons, interneurons, secretomotor neurons, or vasomotor neurons are discussed. Future morphochemical distinction of these groups may reveal different subgroups.Copyright 짤 2011 Wiley-Liss, Inc.</Abstract>
    <JournalRelease>1932-8494</JournalRelease>
    <Pages>858-69</Pages>
    <Affiliation>Institute of Anatomy I, Erlangen, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21416629&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <Title>Impact of AQP3 inducer treatment on cultured human keratinocytes, ex vivo human skin and volunteers.</Title>
    <PubDate>20110315</PubDate>
    <Language>eng</Language>
    <doi>10.1111/j.1468-2494.2011.00651.x</doi>
    <Abstract>One of the main functions of the skin is to protect the organism against environmental threats, such as thermal stress. Aquaporin-3 (AQP3) facilitates water and glycerol transport across cell membranes and therefore regulates osmotic balance in different situations of stress. This mechanism seems to be particularly important for the resistance of different organisms to cold stress. Consequently, we were interested in investigating the effect of cold and osmotic stress on AQP3 expression in normal human keratinocytes. We developed a new active ingredient to stimulate aquaporins in skin and demonstrated the partial restoration of AQP3 expression in keratinocytes transfected with AQP3 siRNA. Moreover, we examined the effect of cold stress on cell morphology and the impact of a pre-treatment with the active ingredient. Our results indicated that induction of AQP3 helped maintain a correct organization of the actin cytoskeleton, preserving cell morphology and preventing cells from rounding. Immunofluorescent staining revealed cytoplasmic localization of AQP3 and its translocation to the cell membrane following osmotic stress. Histological ex vivo studies of skin under different conditions, such as cold environment and tape-stripping, indicated that increase in AQP3 expression appears to be involved in skin protection and showed that the pattern of AQP3 expression was more enhanced in the active ingredient-treated samples. In vivo confocal microscopy by Vivascope showed a generally healthier appearance of the skin in the treated areas. These results attest to the potential value of the active ingredient in optimizing environmental stress resistance and protecting the skin from stratum corneum damage.짤 2011 The Authors. ICS 짤 2011 Society of Cosmetic Scientists and the Soci챕t챕 Fran챌aise de Cosm챕tologie.</Abstract>
    <JournalRelease>1468-2494</JournalRelease>
    <Pages>432-42</Pages>
    <Affiliation>ISP Vincience, Global Skin Research Center, Sophia Antipolis, France. ngarcia@ispcorp.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21401652&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <Title>Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models.</Title>
    <PubDate>20110311</PubDate>
    <Language>eng</Language>
    <doi>10.1038/cgt.2011.8</doi>
    <Abstract>Tumor-associated antigens (TAAs) include overexpressed self-antigens (for example, Her2/neu) and tumor virus antigens (for example, HPV-16 E6/E7). Although in cancer patients, TAA-specific CD4+ and CD8+ cells are often present, they are not able to control tumor growth. In recent studies, it became apparent that tumor site-located immune evasion mechanisms contribute to this phenomenon and that regulatory T cells have a major role. We tested in Her2/neu+ breast cancer and HPV-16 E6/E7+ cervical cancer mouse models, whether intratumoral expression of immunostimulatory proteins (ISPs), for example, recombinant antibodies (慣CTLA-4, 慣CD137, 慣CD3), cyto/chemokines (IL-15, LIGHT, mda-7) and costimulatory ligands (CD80), through adenovirus(Ad)-mediated gene transfer would overcome resistance. In both the breast and cervical cancer model, none of the Ad.ISP vectors displayed a significant therapeutic effect when compared with an Ad vector that lacked a transgene (Ad.zero). However, the combination of Ad.ISP vectors with systemic T regulatory (Treg) depletion, using anti-CD25?뎜Ab (breast cancer model) or low-dose cyclophosphamide (cervical cancer model) resulted in a significant delay of tumor growth in mice treated with Ad.慣CTLA4. In the cervical cancer model, we also demonstrated the induction of a systemic antitumor immune response that was able to delay the growth of distant tumors. Ad.慣CTLA4-mediated tumor-destructive immune responses involved NKT and CD8+ T cells. In both models no autoimmune reactions were observed. This study shows that Ad.慣CTLA4 in combination with systemic Treg depletion has potentials in the immunotherapy of cancer.</Abstract>
    <JournalRelease>1476-5500</JournalRelease>
    <Pages>407-18</Pages>
    <Affiliation>Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21394107&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>21382056</PMID>
    <AuthorListID>23</AuthorListID>
    <Title>Microarray profiling of gene expression in human keratinocytes suggests a new protective activity against UV-induced DNA damage for a compound previously known to interact with SCF-KIT signalling pathway.</Title>
    <PubDate>20110308</PubDate>
    <Language>eng</Language>
    <doi>10.1111/j.1468-2494.2011.00641.x</doi>
    <Abstract>The stem cell factor (SCF) and its protein-tyrosine kinase receptor KIT are together implicated in the regulation of diverse biological processes and particularly in melanogenesis. Indeed, this signalling pathway controls melanoblast migration from the neural crest during embryogenesis and allows the communication between keratinocytes and melanocytes in the adult. In melanocytes, the binding of SCF to its transmembrane receptor leads to the activation of signalling pathways implicating protein kinases which finally control the expression of pigmentation-related genes. We have developed a biological compound called IV09.007, which we previously described as a modulator of the SCF/KIT signalling pathway with a pro-pigmenting effect. In the present work, we have studied the expression and localization of both SCF and KIT mRNAs and proteins in the skin or skin-derived cell lines. Then, we explored with a microarray approach the ability of IV09.007 to modulate the expression of genes in human keratinocytes and melanocytes in culture. Thereby, we observed the regulation of genes implicated in DNA repair, mainly related to base/nucleotides excision pathways. A modulated transcriptional response was also observed for some genes implicated in the response against oxidative stress, in apoptosis inhibition and in lowering inflammatory immune response. These microarray results predicted a conferred protective effect of IV09.007 and we verified this hypothesis by performing comet assays on UVB-irradiated keratinocytes or melanocytes, to demonstrate the efficacy of IV09.007 on preventing DNA damage.짤 2011 The Authors. ICS 짤 2011 Society of Cosmetic Scientists and the Soci챕t챕 Fran챌aise de Cosm챕tologie.</Abstract>
    <JournalRelease>1468-2494</JournalRelease>
    <Pages>398-407</Pages>
    <Affiliation>ISP VINCIENCE, Sophia Antipolis, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=21382056&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20849980</PMID>
    <AuthorListID>24</AuthorListID>
    <Title>Altered redox status of coenzyme Q9 reflects mitochondrial electron transport chain deficiencies in Caenorhabditis elegans.</Title>
    <PubDate>20100916</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.mito.2010.09.002</doi>
    <Abstract>Mitochondrial disorders are often associated with primary or secondary CoQ10 decrease. In clinical practice, Coenzyme Q10 (CoQ10) levels are measured to diagnose deficiencies and to direct and monitor supplemental therapy. CoQ10 is reduced by complex I or II and oxidized by complex III in the mitochondrial respiratory chain. Therefore, the ratio between the reduced (ubiquinol) and oxidized (ubiquinone) CoQ10 may provide clinically significant information in patients with mitochondrial electron transport chain (ETC) defects. Here, we exploit mutants of Caenorhabditis elegans (C. elegans) with defined defects of the ETC to demonstrate an altered redox ratio in Coenzyme Q9 (CoQ9), the native quinone in these organisms. The percentage of reduced CoQ9 is decreased in complex I (gas-1) and complex II (mev-1) deficient animals, consistent with the diminished activity of these complexes that normally reduce CoQ9. As anticipated, reduced CoQ9 is increased in the complex III deficient mutant (isp-1), since the oxidase activity of the complex is severely defective. These data provide proof of principle of our hypothesis that an altered redox status of CoQ may be present in respiratory complex deficiencies. The assessment of CoQ10 redox status in patients with mitochondrial disorders may be a simple and useful tool to uncover and monitor specific respiratory complex defects.Copyright 짤 2010 Elsevier B.V. and Mitochondria Research Society. All rights reserved.</Abstract>
    <JournalRelease>1872-8278</JournalRelease>
    <Pages>136-8</Pages>
    <Affiliation>Seattle Children's Research Institute, Seattle, WA, United States.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20849980&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20844581</PMID>
    <AuthorListID>25</AuthorListID>
    <Title>A novel family of Toxoplasma IMC proteins displays a hierarchical organization and functions in coordinating parasite division.</Title>
    <PubDate>20100909</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.ppat.1001094</doi>
    <Abstract>Apicomplexans employ a peripheral membrane system called the inner membrane complex (IMC) for critical processes such as host cell invasion and daughter cell formation. We have identified a family of proteins that define novel sub-compartments of the Toxoplasma gondii IMC. These IMC Sub-compartment Proteins, ISP1, 2 and 3, are conserved throughout the Apicomplexa, but do not appear to be present outside the phylum. ISP1 localizes to the apical cap portion of the IMC, while ISP2 localizes to a central IMC region and ISP3 localizes to a central plus basal region of the complex. Targeting of all three ISPs is dependent upon N-terminal residues predicted for coordinated myristoylation and palmitoylation. Surprisingly, we show that disruption of ISP1 results in a dramatic relocalization of ISP2 and ISP3 to the apical cap. Although the N-terminal region of ISP1 is necessary and sufficient for apical cap targeting, exclusion of other family members requires the remaining C-terminal region of the protein. This gate-keeping function of ISP1 reveals an unprecedented mechanism of interactive and hierarchical targeting of proteins to establish these unique sub-compartments in the Toxoplasma IMC. Finally, we show that loss of ISP2 results in severe defects in daughter cell formation during endodyogeny, indicating a role for the ISP proteins in coordinating this unique process of Toxoplasma replication.</Abstract>
    <JournalRelease>1553-7374</JournalRelease>
    <Pages>e1001094</Pages>
    <Affiliation>Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, United States of America.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20844581&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20805755</PMID>
    <AuthorListID>26</AuthorListID>
    <Title>Cytological screening for cervical cancer in the province of Limburg, Belgium.</Title>
    <Language>eng</Language>
    <doi>10.1097/CEJ.0b013e32833ecbc6</doi>
    <Abstract>Cervical cancer screening in Belgium is mainly opportunistic with periodic attempts to organize it according to the European guidelines. In the province of Limburg (north-east Belgium), a cervical cytology registry was set up in collaboration with local cytopathological laboratories, provincial health authorities and the Limburg Cancer Registry. Laboratories regularly communicated coded results of Pap smears from women residents in Limburg to the provincial cytological registry. All individual records contained a virtually unique identifying code allowing the study of longitudinal histories and linkage with the cancer registry. The screening coverage (percentage of women with a Pap smear in a defined period), the prevalence and incidence of squamous intraepithelial lesions and changes over time and geographical area were evaluated using a database of more than 600 000 Pap smear interpretations between 1996 and 2005. In 2000, 47% of women aged between 25 and 64 years had at least one Pap smear recorded in the last 3 years, and the average number of smears screened for each woman was 1.5. On account of incomplete registration, the coverage was 8% lower than estimated from health insurance data. The modal screening interval was in the range of 12-14 months; the first quartile, median and third quartile were 355, 440 and 676 days, respectively. Over the 10 years, 82% of the target population had their Pap smear recorded. The prevalence of cytological abnormalities was 3.7% (atypical squamous cells of undetermined significance: 2.2%, atypical glandular cells of undetermined significance: 0.1%, low-grade squamous intraepithelial lesion: 1.1%, high-grade squamous intraepithelial lesion or more serious lesions: 0.4%), but varied substantially among laboratories. The prevalence of atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion increased significantly over time. Pathologists from Limburg have pioneered cytology registration in the context of opportunistic screening in Belgium. The estimated screening coverage was slightly underestimated. Obligatory registration, use of a uniform terminology and linkage with population and follow-up data are needed to give a cytology registry its full role in an organized screening programme.</Abstract>
    <JournalRelease>1473-5709</JournalRelease>
    <Pages>18-24</Pages>
    <Affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. marc.arbyn@wiv-isp.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20805755&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20618558</PMID>
    <AuthorListID>27</AuthorListID>
    <Title>Mitochondria: a new focus as an anti-aging target in skin care.</Title>
    <Language>eng</Language>
    <doi>10.1111/j.1473-2165.2010.00496.x</doi>
    <Abstract>Mitochondria, long considered to have the primary role in cellular energetic, have been the center of much research interest in the recent past. Technological advances in microscopy and development of new and specific fluorescent dyes for visualization of mitochondrial dynamics in living cells have facilitated the newfound interest in these fascinating organelles, which are now implicated in diverse cellular functions crucial in health and disease. Mitochondria play crucial roles in several age-related diseases, and in the physiology of normal aging. In this review, we discuss the structural and functional aspects of mitochondria and their implications to the aging process, as well as its significance to skin aging. Available information on active molecules that can impact the mitochondrial functions, and their potential use in skin care products is also discussed, highlighting these organelles as a new focus for anti-aging strategies in personal care.</Abstract>
    <JournalRelease>1473-2165</JournalRelease>
    <Pages>122-31</Pages>
    <Affiliation>Global R&amp;D, ISP Corporation, Wayne, NJ, USA. Gmenon@ispcorp.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20618558&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <Title>PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.</Title>
    <Language>eng</Language>
    <doi>10.1002/jcb.22691</doi>
    <Abstract>FTY720, a new immunosuppressant, derived from ISP-1, has been studied for its putative anti-cancer properties in the recent years. In this study, we have reported that FTY720 greatly inhibited gastric cancer cell proliferation for the first time, and found this effect was associated with G1 phase cell cycle arrest and apoptosis. Results from our Western blotting and Real-time PCR showed that FTY720 induced obvious PTEN expression in a p53-independent way, consistent with a substantial decrease in p-Akt and MDM2. FTY720 dramatically increased the expression of Cip1/p21, p27, and BH3-only proteins through the accumulation of p53 by PTEN-mediated inhibition of the PI3K/Akt/MDM2 signaling. Suppression of PTEN expression with siRNA significantly reduced the p53 and p21 levels and activated Akt, resulting in decreased apoptosis and increased cell survival. Furthermore, we have observed an additive effect of FTY720 in killing gastric cancer cells when in combination with Cisplatin, partly through PTEN-mediated Akt/MDM2 inhibition. In vivo study has also shown that tumor growth was significantly suppressed after FTY720 treatment. In conclusion, our results suggest that FTY720 induces a significant increase of PTEN, which inhibits p-Akt and MDM2, and then increases the level of p53, thereby inducing G1 phase arrest and apoptosis. We have characterized a novel immunosuppressant, for the first time, which shows potential anti-tumor effects on gastric cancer by PTEN activation through p53-independent mechanism, especially in combination with Cisplatin. This PTEN target-based therapy is worth further investigation and warrants clinical evaluation.(c) 2010 Wiley-Liss, Inc.</Abstract>
    <JournalRelease>1097-4644</JournalRelease>
    <Pages>218-28</Pages>
    <Affiliation>Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China. zhengtongsen@hotmail.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20506484&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20407012</PMID>
    <AuthorListID>29</AuthorListID>
    <Title>Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells.</Title>
    <PubDate>20100420</PubDate>
    <Language>eng</Language>
    <doi>10.1158/1541-7786.MCR-09-0493</doi>
    <Abstract>The epidermal growth factor receptor (EGFR) is an important chemotherapeutic target for tyrosine kinase inhibitors and antibodies that block the extracellular domain of EGFR. Betulinic acid (BA) and curcumin inhibited bladder cancer cell growth and downregulated specificity protein (Sp) transcription factors, and this was accompanied by decreased expression of EGFR mRNA and protein levels. EGFR, a putative Sp-regulated gene, was also decreased in cells transfected with a cocktail (iSp) containing small inhibitory RNAs for Sp1, Sp3, and Sp4, and RNA interference with individual Sp knockdown indicated that EGFR expression was primarily regulated by Sp1 and Sp3. BA, curcumin, and iSp also decreased phosphorylation of Akt in these cells, and downregulation of EGFR by BA, curcumin, and iSp was accompanied by induction of LC3 and autophagy, which is consistent with recent studies showing that EGFR suppresses autophagic cell death. The results show that EGFR is an Sp-regulated gene in bladder cancer, and drugs such as BA and curcumin that repress Sp proteins also ablate EGFR expression. Thus, compounds such as curcumin and BA that downregulate Sp transcription factors represent a novel class of anticancer drugs that target EGFR in bladder cancer cells and tumors by inhibiting receptor expression.(c)2010 AACR.</Abstract>
    <JournalRelease>1557-3125</JournalRelease>
    <Pages>739-50</Pages>
    <Affiliation>Department of Veterinary Physiology and Pharmacology, Texas A&amp;M University, 4466 TAMU, Veterinary Research Building 410, College Station, TX 77843-4466, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20407012&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <Title>Isostrychnopentamine, an indolomonoterpenic alkaloid from Strychnos usambarensis, with potential anti-tumor activity against apoptosis-resistant cancer cells.</Title>
    <Language>eng</Language>
    <Abstract>Isostrychnopentamine (ISP) is an indolomonoter-penic alkaloid that is present in the leaves of Strychnos usambarensis, an East African small tree. We have reported previously pro-apoptotic effects induced in vitro by ISP in the human HCT-116 colon cancer cell line, a model that displays relative sensitivity to apoptosis. In the present study, we observed that the in vitro growth inhibitory activities of ISP are similar in cancer cells that display sensitivity versus resistance to apoptosis. We made use of the U373 glioblastoma and the A549 non-small cell lung cancer (NSCLC) cell lines as models relatively resistant to apoptosis, and the human PC-3 prostate cancer cell line as a model relatively sensitive to apoptosis. While ISP induced transient decreases in [ATP]i and apoptosis in human U373 GBM cells, it did not provoke such features in A549 NSCLC cells. It thus seems that ISP-induced anti-cancer activity can lead to pro-apoptotic effects as a consequence, while apoptosis seems not to be the main cause by which ISP induces cancer cell death. ISP is a compound that merits further investigations in order to: i) identify the mechanism(s) of action by which it kills cancer cells, and ii) hemisynthesize novel ISP derivatives aiming to overcome, at least partly, the resistance of metastatic cancers to apoptosis.</Abstract>
    <JournalRelease>1791-2423</JournalRelease>
    <Pages>961-5</Pages>
    <Affiliation>Laboratoire de Toxicologie, D챕partement de BioAnalyse et Toxicologie Pharmaceutique, Institut de Pharmacie, Universit챕 Libre de Bruxelles, 1050 Brussels, Belgium.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20198341&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20097674</PMID>
    <AuthorListID>31</AuthorListID>
    <Title>FGF-16 is a target for adrenergic stimulation through NF-kappaB activation in postnatal cardiac cells and adult mouse heart.</Title>
    <PubDate>20100122</PubDate>
    <Language>eng</Language>
    <doi>10.1093/cvr/cvq025</doi>
    <Abstract>The fibroblast growth factor (FGF) family plays an important role in cardiac growth and development. However, only FGF-16 RNA levels are reported to increase during the perinatal period and to be expressed preferentially in the myocardium, suggesting control at the transcriptional level and a role for FGF-16 in the postnatal heart. Beyond the identification of two TATA-like elements (TATA1 and TATA2) in the mouse FGF-16 promoter region and the preferential cardiac activity of TATA2, there is no report of Fgf-16 gene regulation. Assessment of promoter sequences, however, reveals putative nuclear factor-kappaB (NF-kappaB) elements, suggesting that Fgf-16 is regulated via NF-kappaB activation and thereby implicated in a number of cardiac events. Thus, the Fgf-16 gene was investigated as a target for NF-kappaB activation in cardiac cells.Assessments of Fgf-16 promoter activity were made using truncated and transfected hybrid genes with NF-kappaB inhibitors and/or beta-adrenergic stimulation via isoproterenol (IsP) treatment (a known NF-kappaB activator) in culture, and on endogenous mouse and human Fgf-16 genes in situ. The mouse Fgf-16 promoter region was stimulated in response to IsP treatment, but this response was lost with NF-kappaB inhibitor pretreatment. Deletion analysis revealed IsP responsiveness linked to sequences between TATA2 and TATA1 and, more specifically, a NF-kappaB element upstream and adjacent to TATA1 that associates with NF-kappaB p50/p65 subunits in chromatin. Finally, TATA1 and the proximal NF-kappaB element are conserved in the human genome and responsive to IsP.The mouse and human Fgf-16 gene is a target for NF-kappaB activation in the postnatal heart.</Abstract>
    <JournalRelease>1755-3245</JournalRelease>
    <Pages>102-10</Pages>
    <Affiliation>Department of Physiology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, MB, Canada R3E 0J9.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20097674&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>20089839</PMID>
    <AuthorListID>32</AuthorListID>
    <Title>Mitochondrial dysfunction confers resistance to multiple drugs in Caenorhabditis elegans.</Title>
    <PubDate>20100120</PubDate>
    <Language>eng</Language>
    <doi>10.1091/mbc.E09-08-0673</doi>
    <Abstract>In a previous genetic screen for Caenorhabditis elegans mutants that survive in the presence of an antimitotic drug, hemiasterlin, we identified eight strong mutants. Two of these were found to be resistant to multiple toxins, and in one of these we identified a missense mutation in phb-2, which encodes the mitochondrial protein prohibitin 2. Here we identify two additional mutations that confer drug resistance, spg-7 and har-1, also in genes encoding mitochondrial proteins. Other mitochondrial mutants, isp-1, eat-3, and clk-1, were also found to be drug-resistant. Respiratory complex inhibitors, FCCP and oligomycin, and a producer of reactive oxygen species (ROS), paraquat, all rescued wild-type worms from hemiasterlin toxicity. Worms lacking mitochondrial superoxide dismutase (MnSOD) were modestly drug-resistant, and elimination of MnSOD in the phb-2, har-1, and spg-7 mutants enhanced resistance. The antioxidant N-acetyl-l-cysteine prevented mitochondrial inhibitors from rescuing wild-type worms from hemiasterlin and sensitized mutants to the toxin, suggesting that a mechanism sensitive to ROS is necessary to trigger drug resistance in C. elegans. Using genetics, we show that this drug resistance requires pkc-1, the C. elegans ortholog of human PKCepsilon.</Abstract>
    <JournalRelease>1939-4586</JournalRelease>
    <Pages>956-69</Pages>
    <Affiliation>Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9038, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=20089839&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <Title>Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis.</Title>
    <Language>eng</Language>
    <doi>10.1002/jcp.21969</doi>
    <Abstract>Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) uniquely displays broad cancer-specific apoptosis-inducing activity through induction of endoplasmic reticulum (ER) stress. We hypothesize that ceramide, a promoter of apoptosis, might contribute to mda-7/IL-24 induction of apoptosis. Ad.mda-7-infected tumor cells, but not normal cells, showed increased ceramide accumulation. Infection with Ad.mda-7 induced a marked increase in various ceramides (C16, C24, C24:1) selectively in prostate cancer cells. Inhibiting the enzyme serine palmitoyltransferase (SPT) using the potent SPT inhibitor myriocin (ISP1), impaired mda-7/IL-24-induced apoptosis and ceramide production, suggesting that ceramide formation caused by Ad.mda-7 occurs through de novo synthesis of ceramide and that ceramide is required for mda-7/IL-24-induced cell death. Fumonisin B1 (FB1) elevated ceramide formation as well as apoptosis induced by Ad.mda-7, suggesting that ceramide formation may also occur through the salvage pathway. Additionally, Ad.mda-7 infection enhanced expression of acid sphingomyelinase (ASMase) with a concomitant increase in ASMase activity and decreased sphingomyelin in cancer cells. ASMase silencing by RNA interference inhibited the decreased cell viability and ceramide formation after Ad.mda-7 infection. Ad.mda-7 activated protein phosphatase 2A (PP2A) and promoted dephosphorylation of the anti-apoptotic molecule BCL-2, a downstream ceramide-mediated pathway of mda-7/IL-24 action. Pretreatment of cells with FB1 or ISP-1 abolished the induction of ER stress markers (BiP/GRP78, GADD153 and pospho-eIF2alpha) triggered by Ad.mda-7 infection indicating that ceramide mediates ER stress induction by Ad.mda-7. Additionally, recombinant MDA-7/IL-24 protein induced cancer-specific production of ceramide. These studies define ceramide as a key mediator of an ER stress pathway that may underlie mda-7/IL-24 induction of cancer-specific killing.</Abstract>
    <JournalRelease>1097-4652</JournalRelease>
    <Pages>546-55</Pages>
    <Affiliation>Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19937735&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19916082</PMID>
    <AuthorListID>34</AuthorListID>
    <Title>Altered callosal function in cerebral microangiopathy.</Title>
    <PubDate>20091116</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s00415-009-5379-9</doi>
    <Abstract>Callosal dysfunction is known to be evident in a variety of neurodegenerative and inflammatory diseases of the central nervous system. Cerebral microangiopathy (CMA) may also affect callosal pathways by chronic demyelination. The aim of the present study was to investigate callosal function with respect to the extent of CMA. Callosal function was tested by a bimanual tapping task and by analysis of the ipsilateral silent period (iSP) and the transcallosal conduction time (TCT) using transcranial magnetic stimulation. Results were correlated to the extent of CMA measured by cranial magnetic resonance imaging (cMRI) in 44 patients with CMA compared to 10 control subjects. The extent of CMA was quantified by a cMRI score. Additionally, callosal atrophy was quantified by cMRI morphometry. Frequency of pathological iSP findings or disturbed bimanual tapping was significantly correlated to a higher CMA score. Moreover, the extent of CMA was significantly correlated to the degree of callosal atrophy. It is concluded that CMA considerably affects callosal pathways, possibly by chronic demyelination of callosal fibres. As the extent of CMA and atrophy of the corpus callosum is correlated to callosal dysfunction, analysis of the iSP can be used to assess the clinical impact of CMA detected by cMRI.</Abstract>
    <JournalRelease>1432-1459</JournalRelease>
    <Pages>590-7</Pages>
    <Affiliation>Human Cortical Physiology Laboratory, Department of Neurology, University of Rostock, Gehlsheimer Str. 20, 18147, Rostock, Germany. matthias.wittstock@med.uni-rostock.de</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19916082&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <Title>In vitro photodynamic activity of 5,15-bis(3-hydroxyphenyl)porphyrin and its halogenated derivatives against cancer cells.</Title>
    <PubDate>20091110</PubDate>
    <Language>eng</Language>
    <doi>10.1111/j.1751-1097.2009.00622.x</doi>
    <Abstract>5,15-Diarylporphyrins (1-5) with hydroxyl groups and halogens as substituents were prepared by condensation between unsubstituted dipyrromethane and halogenated m-hydroxybenzaldehydes. Photophysical properties show that the nonhalogenated porphyrin 1 has higher fluorescence yield but lower singlet oxygen formation quantum yield than the halogenated derivatives due to the heavy atom effect. The in vitro activity of these derivatives was tested against WiDr colorectal adenocarcinoma and A375 melanoma cancer cells. All porphyrins present a much higher phototoxicity than Photofrin with IC(50) values lower than the 50 nM level for WiDr cells and 25 nM level for A375 cancer cells. The most photoactive compound is the nonhalogenated porphyrin 1 which also presents the highest uptake. Halogenated derivatives present much lower uptakes than 1. However, their photoactivity is similar to compound 1 showing that their intrinsic photoactivity (ISP) is very high. Iodinated compound 4 presents the highest ISP. The greater ability of these porphyrins to destroy cancer cells could be related to their photophysical and photochemical properties.</Abstract>
    <JournalRelease>1751-1097</JournalRelease>
    <Pages>206-12</Pages>
    <Affiliation>Chymiotechnon, Departamento de Qu챠mica, Universidade de Coimbra, 3049-535, Coimbra, Portugal.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19906097&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <Title>Mitochondrial respiratory chain dysfunction variably increases oxidant stress in Caenorhabditis elegans.</Title>
    <PubDate>20091110</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.mito.2009.11.003</doi>
    <Abstract>Mitochondrial dysfunction and associated oxidant stress have been linked with numerous complex diseases and aging largely by in vitro determination of mitochondria oxidant production and scavenging. We applied targeted in vivo fluorescence analyses of mitochondria-dense pharyngeal tissue in Caenorhabditis elegans to better understand relative mitochondrial effects, particularly on matrix oxidant burden, of respiratory chain complex, MnSOD, and insulin receptor mutants displaying variable longevity. The data demonstrate significantly elevated in vivo matrix oxidant burden in the short-lived complex I mutant, gas-1(fc21), which was associated with limited superoxide scavenging capacity despite robust MnSOD induction, as well as decreased mitochondria content and membrane potential. Significantly increased MnSOD activity was associated with in vivo matrix oxidant levels similar to wild-type in the long-lived respiratory chain complex III mutant, isp-1(qm150). Yet, despite greater superoxide scavenging capacity in the complex III mutant than in the significantly longer-lived insulin receptor mutant, daf-2(e1368), only the former showed modest oxidative stress sensitivity. Furthermore, increased longevity was seen in MnSOD knockout mutants (sod-2(ok1030) and sod-2(gk257)) that had decreased MnSOD scavenging capacity and increased in vivo matrix oxidant burden. Thus, factors beside oxidant stress must underlie RC mutant longevity in C. elegans. This work highlights the utility of the C. elegans model as a tractable means to non-invasively monitor multi-dimensional in vivo consequences of primary mitochondrial dysfunction.</Abstract>
    <JournalRelease>1872-8278</JournalRelease>
    <Pages>125-36</Pages>
    <Affiliation>Division of Human Genetics, Department of Pediatrics, The Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA 19104, USA. stephen.dingley@gmail.com &lt;stephen.dingley@gmail.com&gt;</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19900588&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <Title>Notch ligands potentiate IL-7-driven proliferation and survival of human thymocyte precursors.</Title>
    <Language>eng</Language>
    <doi>10.1002/eji.200838765</doi>
    <Abstract>Notch and IL-7 are both well-characterized factors involved in T-cell development. In contrast to the mouse model, their precise requirements in the differentiation and/or proliferation of various stages of human thymic development have not been fully explored. Here, we demonstrate that IL-7 alone is sufficient to induce the differentiation of ex vivo purified CD34(+) triple negative (TN) surface (s) CD3(-) CD4(-)CD8(-) (CD3(-)CD4(-)CD8(-)), CD4 immature single positive (ISP) (sCD3(-)CD4(+)CD8(-)) and double positive (DP) (sCD3(-)CD4(+)CD8(+)) human thymic precursors to mature DP expressing sCD3 (sCD3(+)CD4(+)CD8(+)). We show that activation of Notch signaling by its ligands Delta-1 or Delta-4 potentiates IL-7-driven proliferation and survival of CD34(+) TN and to a lesser extent of CD4(+) ISP precursors. This effect of Notch is related to a sustained induction of IL-7 receptor alpha chain expression on thymocytes through a decreased methylation of its gene promoter. Thus, we show here that proliferation and differentiation of T-cell precursors are differentially modulated by IL-7 depending on the presence or absence of external signals. These results may have important implications for the clinical use of this cytokine as a strategy aimed at improving immune restoration.</Abstract>
    <JournalRelease>1521-4141</JournalRelease>
    <Pages>1231-40</Pages>
    <Affiliation>Inserm U 955, Universit챕 Paris XII, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19350552&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <Title>Exogenous insulin stimulates glycogen accumulation in Rhipicephalus (Boophilus) microplus embryo cell line BME26 via PI3K/AKT pathway.</Title>
    <PubDate>20090305</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.cbpb.2009.02.016</doi>
    <Abstract>Ticks are obligatory blood-feeding arthropods and important vectors of both human and animal disease agents. Besides its metabolic role, insulin signaling pathway (ISP) is widely described as crucial for vertebrate and invertebrate embryogenesis, development and cell survival. In such cascade, Phosphatidylinositol 3-OH Kinase (PI3K) is hierarchically located upstream Protein Kinase B (PKB). To study the insulin-triggered pathway and its possible roles during embryogenesis we used a culture of embryonic Rhipicephalus microplus cells (BME26). Exogenous insulin elevated cell glycogen content in the absence of fetal calf serum (FCS) when compared to cells without treatment. Moreover, in the presence of PI3K inhibitors (Wortmannin or LY294002) these effects were blocked. We observed an increase in the relative expression level of PI3K's regulatory subunit (p85), as determined by qRT-PCR. In the presence of PI3K inhibitors these effects on transcription were also reversed. Additionally, treatment with Wortmannin increased the expression level of the insulin-regulated downstream target glycogen synthase kinase 3 beta (GSK3beta). The p85 subunit showed elevated transcription levels in ovaries from fully engorged females, but was differentially expressed during tick embryogenesis. These results strongly suggest the presence of an insulin responsive machinery in BME26 cells, and its correlation with carbohydrate/glycogen metabolism also during embryogenesis.</Abstract>
    <JournalRelease>1879-1107</JournalRelease>
    <Pages>185-90</Pages>
    <Affiliation>Laborat처rio de Qu챠mica e Fun챌찾o de Prote챠nas e Pept챠deos, CBB, Universidade Estadual Norte Fluminense, 28013-620, Campos dos Goytacazes, RJ, Brazil.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19268713&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <Title>Volumetric retinal imaging with ultrahigh-resolution spectral-domain optical coherence tomography and adaptive optics using two broadband light sources.</Title>
    <Language>eng</Language>
    <Abstract>Ultrabroadband sources, such as multiplexed superluminescent diodes (SLDs) and femtosecond lasers, have been successfully employed in adaptive optics optical coherence tomography (AO-OCT) systems for ultrahigh resolution retinal imaging. The large cost differential of these sources, however, motivates the need for a performance comparison. Here, we compare the performance of a Femtolasers Integral Ti:Sapphire laser and a Superlum BroadLighter T840, using the same AO-OCT system and the same subject. In addition, we investigate the capability of our instrument equipped with the Integral to capture volume images of the fovea and adjacent regions on a second subject using the AO to control focus in the retina and custom and freeware image registration software to reduce eye motion artifacts. Monochromatic ocular aberrations were corrected with a woofer-tweeter AO system. Coherence lengths of the Integral and BroadLighter were measured in vivo at 3.2 microm and 3.3 microm, respectively. The difference in dynamic range was 5 dB, close to the expected variability of the experiment. Individual cone photoreceptors, retinal capillaries and nerve fiber bundles were distinguished in all three dimensions with both sources. The acquired retinal volumes are provided for viewing in OSA ISP, allowing the reader to data mine at the microscope level.</Abstract>
    <JournalRelease>1094-4087</JournalRelease>
    <Pages>4095-111</Pages>
    <Affiliation>Indiana University, School of Optometry, 800 E. Atwater Avenue, Bloomington, Indiana 47405, USA . bcense@indiana.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19259249&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <Title>Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia.</Title>
    <PubDate>20090122</PubDate>
    <Language>eng</Language>
    <doi>10.1371/journal.pone.0004253</doi>
    <Abstract>Friedreich ataxia originates from a decrease in mitochondrial frataxin, which causes the death of a subset of neurons. The biochemical hallmarks of the disease include low activity of the iron sulfur cluster-containing proteins (ISP) and impairment of antioxidant defense mechanisms that may play a major role in disease progression.We thus investigated signaling pathways involved in antioxidant defense mechanisms. We showed that cultured fibroblasts from patients with Friedreich ataxia exhibited hypersensitivity to oxidative insults because of an impairment in the Nrf2 signaling pathway, which led to faulty induction of antioxidant enzymes. This impairment originated from previously reported actin remodeling by hydrogen peroxide.Thus, the defective machinery for ISP synthesis by causing mitochondrial iron dysmetabolism increases hydrogen peroxide production that accounts for the increased susceptibility to oxidative stress.</Abstract>
    <JournalRelease>1932-6203</JournalRelease>
    <Pages>e4253</Pages>
    <Affiliation>Inserm, U676, H척pital Robert Debr챕, B창t. Ecran, Paris, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19158945&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <Title>Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency.</Title>
    <PubDate>20081216</PubDate>
    <Language>eng</Language>
    <doi>10.1038/mt.2008.273</doi>
    <Abstract>RNA interference (RNAi) can be an effective antiviral agent; however, overexpression of RNAi can be toxic through competition with the endogenous microRNA (miRNA) machinery. We used rational design to identify highly potent RNAi that is effective at nontoxic doses. A statistical analysis was conducted to pinpoint thermodynamic characteristics correlated with activity. Sequences were selected that conformed to a consensus internal stability profile (ISP) associated with active RNAi, and RNAi triggers were expressed in the context of an endogenous miRNA. These approaches yielded highly active hepatitis B virus (HBV) RNAi. A statistical analysis found a correlation between activity and nucleation by binding within the seed sequence to accessible regions in the target RNA. Guide strands were selected for favorable strand biasing, but increased strand biasing did not correlate with potency, suggesting a threshold effect. Exogenous short hairpin RNAs (shRNAs), but not miRNAs were previously reported to compete with miRNAs for the miRNA/RNAi machinery. In contrast, we show that exogenous Polymerase III- but not Polymerase II-driven miRNAs compete with exogenous miRNAs, at multiple steps in the miRNA pathway. Exogenous miRNAs also compete with endogenous miR-21. Thus, competition with endogenous miRNAs should be monitored even when using miRNA-based therapeutics. However, potent silencing was achieved at doses where competition was not observed.</Abstract>
    <JournalRelease>1525-0024</JournalRelease>
    <Pages>538-47</Pages>
    <Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=19088704&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18952783</PMID>
    <AuthorListID>42</AuthorListID>
    <Title>Role of SP transcription factors in hormone-dependent modulation of genes in MCF-7 breast cancer cells: microarray and RNA interference studies.</Title>
    <PubDate>20081024</PubDate>
    <Language>eng</Language>
    <doi>10.1677/JME-08-0088</doi>
    <Abstract>17beta-estradiol (E(2)) binds estrogen receptor alpha (ESR1) in MCF-7 cells and increases cell proliferation and survival through induction or repression of multiple genes. ESR1 interactions with DNA-bound specificity protein (SP) transcription factors is a nonclassical genomic estrogenic pathway and the role of SP transcription factors in mediating hormone-dependent activation or repression of genes in MCF-7 cells was investigated by microarrays and RNA interference. MCF-7 cells were transfected with a nonspecific oligonucleotide or a cocktail of small inhibitory RNAs (iSP), which knockdown SP1, SP3, and SP4 proteins, and treated with dimethylsulfoxide or 10 nM E(2) for 6 h. E(2) induced 62 and repressed 134 genes and the induction or repression was reversed in approximately 62% of the genes in cells transfected with iSP (ESR1/SP dependent), whereas hormonal activation or repression of the remaining genes was unaffected by iSP (SP independent). Analysis of the ESR1/SP-dependent and SP-independent genes showed minimal overlap with respect to the GO terms (functional processes) in genes induced or repressed, suggesting that the different genomic pathways may contribute independently to the hormone-induced phenotype in MCF-7 cells.</Abstract>
    <JournalRelease>1479-6813</JournalRelease>
    <Pages>19-33</Pages>
    <Affiliation>Department of Biochemistry and Biophysics, Texas A&amp;M University, College Station, Texas 77843, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18952783&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18662621</PMID>
    <AuthorListID>43</AuthorListID>
    <Title>Cortical excitability and transcallosal inhibition in chronic tinnitus: transcranial magnetic study.</Title>
    <PubDate>20080423</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.neucli.2008.03.004</doi>
    <Abstract>It has been proposed that tinnitus may be caused by maladaptive plasticity of processing in the central auditory pathways, and that this may be due in part to a generalised deficit in NMDA-dependent glutamatergic synapses.To test this hypothesis, we used transcranial magnetic stimulation to assess the excitability of a number of well-defined synaptic connections in the motor cortex of patients with tinnitus.Thirty-seven patients with chronic tinnitus and 12 normal age- and sex-matched volunteers were used as a control group. We measured resting and active motor thresholds (rMT/aMT) and the duration of the contralateral and ipsilateral cortical silent periods (CSP and ISP). Short interval intracortical inhibition (SICI) and intracortical facilitation (ICF) were evaluated using a paired pulse stimulation paradigm in the left (dominant) hemisphere.There was no difference between patients and healthy subjects in rMT or aMT or the onset latency of the ISP. The CSP was shorter in patients (P=0.046) whereas the ISP was longer than in healthy subjects (P=0.048) but there was no difference between the hemispheres nor any relation to tinnitus side in patients with predominantly unilateral symptoms. There was no difference in the time course of SICI/ICF between patients and control groups and no significant correlation between tinnitus handicap inventory (THI) score and any of the measures of cortical excitability.There are small changes incortical excitability in patients with chronic tinnitus. However, given the number of factors we examined in each individual, such minor changes seem unlikely to be an important factor in development of clinical symptoms.</Abstract>
    <JournalRelease>0987-7053</JournalRelease>
    <Pages>243-8</Pages>
    <Affiliation>Department of Neurology, Assiut University Hospital, Assiut, Egypt. emankhedr99@yahoo.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18662621&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <Title>Immunogenicity and protective efficacy of DNA vaccines encoding MAP0586c and MAP4308c of Mycobacterium avium subsp. paratuberculosis secretome.</Title>
    <PubDate>20080722</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.vaccine.2008.07.009</doi>
    <Abstract>Mycobacterium avium subsp. paratuberculosis (MAP), the etiological agent of chronic enteritis of the small intestine in domestic and wild ruminants, causes substantial losses to livestock industry. Control of this disease is seriously hampered by the lack of adequate diagnostic tools, vaccines and therapies. In this study, we have evaluated the vaccine potential of two MAP proteins, i.e. MAP0586c and MAP4308c, previously identified by postgenomic and immunoproteomic analysis of MAP secretome as novel serodiagnostic antigens. Immunizations of BALB/c and C57BL/6 mice with plasmid DNA encoding MAP0586c and MAP4308c induced strong Th1 type immune responses to both antigens, whereas antibody responses were only induced upon immunization with DNA encoding MAP4308c. Homologous boosting of DNA vaccinated mice with recombinant protein resulted in strong antibody responses against both proteins. Using synthetic overlapping peptides, immunodominant H-2(d) and H-2(b) restricted Th1 T cell epitopes were identified. Finally, MAP infected mice generated strong MAP0586c-specific T cell responses and MAP0586c DNA vaccination could protect BALB/c but not C57BL/6 mice against MAP challenge mice to the same extent as the Mycobacterium bovis BCG vaccine, indicating that this putative transglycosylase is an interesting vaccine candidate that warrants further investigation.</Abstract>
    <JournalRelease>0264-410X</JournalRelease>
    <Pages>4783-94</Pages>
    <Affiliation>Laboratory of Mycobacterial Immunology, Department Pasteur Institute, Scientific Institute of Public Health IPH-WIV-ISP, 642 Engelandstraat, B1180 Brussels, Belgium.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18652866&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <Title>HIV-1 Nef protein expression in human CD34+ progenitors impairs the differentiation of an early T/NK cell precursor.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.virol.2008.04.009</doi>
    <Abstract>HIV-1 impairs the production of T cells, through mechanisms that are still unknown. Here, we investigated the effect of the expression of HIV-1 Nef on the T-cell potential of human hematopoietic CD34(+) precursors. Those progenitors were transduced by using lentiviral vectors expressing Nef and cultured on OP9-DL1 cells allowing the differentiation of T cell from human hematopoietic precursors. We demonstrate that Nef impairs the generation of a CD3epsilon(+)CD5(+) CD1a(+) precursor stage that has initiated a D-J rearrangement of the TCRbeta locus. Onward stages of T-cell development were also affected with a quantitative reduction of CD4(+) intraCD3epsilon(+) Immature single positive cells (ISP), Double Positive (DP) CD4(+)CD8(+) TCRalphabeta T cells and CD56(+) NK cells. But B cell production was not affected. Limiting dilution analyses demonstrated a significant reduction in the frequency of T/NK progenitors among Nef-expressing CD34(+) cells. Altogether, these data demonstrate that Nef interferes with the differentiation of a primitive lymphoid human precursor with a T/NK potential.</Abstract>
    <JournalRelease>0042-6822</JournalRelease>
    <Pages>207-15</Pages>
    <Affiliation>INSERM U 841, Facult챕 de M챕decine, Cr챕teil, France.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18555888&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18520051</PMID>
    <AuthorListID>46</AuthorListID>
    <Title>Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.</Title>
    <Language>eng</Language>
    <Abstract>FTY720 (fingolimod), a novel immunosuppressant, was found to become biologically activated by phosphorylation into FTY720-1-phosphate (FTY720-P), which is a high-affinity agonist for sphingosine-1-phosphate (sphingosine-1-P)-receptors. FTY720 has also been reported to have a strong antitumor activity. The association between the phosphorylation of FTY720 and the growth inhibition of FTY720 against cancer cells are still not completely understood. In this study, we investigated the effects of FTY720, sphingosine, and their related compounds on the proliferation of human breast cancer cell lines (MCF-7, MDA-MB-231 and Sk-Br-3) and human colon cancer cell lines (HCT-116 and SW620). Non-phosphorylated FTY720, sphingosine and an FTY720 derivative, ISP-I-55, showed significant growth inhibition against these cells, with IC50 values of 5-20 microM at 48 h post-drug treatment. We confirmed that FTY720 induces the activation of a major mitogen-activated protein kinase, JNK, without the activation of p38 and down-regulation of phospho-ERK in MCF-7 breast cancer cells. In contrast, the phosphorylated derivatives, FTY720-P and sphingosine-1-P, as well as a phosphinane FTY720 derivative, cFTY720-P, did not inhibit the growth of the cells in the concentration range of 5-50 microM, whereas FTY720-P and sphingosine-1-P slightly induced the growth of MCF-7 cells. Combining FTY720 with dimethylsphingosine, a sphingosine kinase inhibitor, augmented the inhibitory effect of FTY720. These results indicate that the antiproliferative activity of FTY720 does not result from its phosphorylation, either endogenous or exogenous.</Abstract>
    <JournalRelease>0918-6158</JournalRelease>
    <Pages>1177-81</Pages>
    <Affiliation>Faculty of Chemistry, Materials and Bioengineering, Kansai University, Osaka, Japan. ynagaoka@ipcku.kansai-u.ac.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18520051&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18416311</PMID>
    <AuthorListID>47</AuthorListID>
    <Title>Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.</Title>
    <Language>eng</Language>
    <Abstract>Fingolimod (FTY720) represents the first in a new class of immune-modulators whose target is sphingosine-1-phosphate (S1P) receptors. It was first identified by researchers at Kyoto University and Yoshitomi Pharmaceutical as a chemical derivative of the ascomycete metabolite ISP-1 (myriocin). Unlike its natural product parent, FTY720 does not interfere with sphingolipid biosynthesis. Instead, its best characterized mechanism of action upon in vivo phosphorylation, leading to the active principle FTY720-P, is the rapid and reversible inhibition of lymphocyte egress from peripheral lymph nodes. As a consequence of S1P1 receptor internalization, tissue-damaging T-cells can not recirculate and infiltrate sites of inflammation such as the central nervous system (CNS). Furthermore, FTY720-P modulation of S1P receptor signaling also enhances endothelial barrier function. Due to its mode of action, FTY720 effectively prevents transplant rejection and is active in various autoimmune disease models. The most striking efficacy is in the multiple sclerosis (MS) model of experimental autoimmune encephalomyelitis, which has now been confirmed in the clinic. FTY720 demonstrated promising results in Phase II trials and recently entered Phase III in patients with relapsing MS. Emerging evidence suggests that its efficacy in the CNS extends beyond immunomodulation to encompass other aspects of MS pathophysiology, including an influence on the blood-brain-barrier and glial repair mechanisms that could ultimately contribute to restoration of nerve function. FTY720 may represent a potent new therapeutic modality in MS, combined with the benefit of oral administration.</Abstract>
    <JournalRelease>0071-786X</JournalRelease>
    <Pages>361, 363-81</Pages>
    <Affiliation>Novartis Pharma AG, Lichtstrasse 35, 4002 Basel, Switzerland.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18416311&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <Title>De novo N-palmitoylsphingosine synthesis is the major biochemical mechanism of ceramide accumulation following p53 up-regulation.</Title>
    <PubDate>20080304</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.prostaglandins.2008.02.004</doi>
    <Abstract>The tumor suppressor protein p53 and the putative lipid tumor suppressor ceramide play pivotal roles in inducing cell cycle arrest or in driving the cell towards apoptosis. Previously we had shown that, in a p53-dependent model of cell death, ceramide accumulated in a p53-dependent manner [Dbaibo GS, Pushkareva MY, Rachid RA, Alter N, Smyth MJ, Obeid LM, Hannun YA. J Clin Invest 1998;102:329-339]. In the current study, we investigated the biochemical pathways by which ceramide accumulated following p53 up-regulation. In both Molt-4 LXSN leukemia cells exposed to gamma-irradiation and in EB-1 colon cancer cells treated with ZnCl(2), p53 up-regulation led to de novo ceramide synthesis with predominance of N-palmitoylsphingosine (C16-ceramide) synthesis. The activation of the de novo pathway was not associated with increased activity of the key enzyme serine palmitoyltransferase (SPT) but rather with the increased activity of ceramide synthase. Furthermore, transcriptional up-regulation of the palmitoyl-specific Lass5 ceramide synthase gene was observed in Molt-4 but not in EB-1 cells. The SPT inhibitor ISP-1 or the ceramide synthase inhibitor fumonisin B1 led to substantial inhibition of ceramide accumulation in response to p53 up-regulation. Other biochemical pathways of ceramide generation such as sphingomyelinase activation were examined and found unlikely to contribute to p53-dependent ceramide formation. These studies indicate that p53 specifically drives de novo ceramide synthesis by activation of a ceramide synthase that favors the synthesis of N-palmitoylsphingosine.</Abstract>
    <JournalRelease>1098-8823</JournalRelease>
    <Pages>41-8</Pages>
    <Affiliation>Department of Biochemistry, American University of Beirut, P.O. Box 113/6044, Beirut, Lebanon.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18400537&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <Title>Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells.</Title>
    <PubDate>20080219</PubDate>
    <Language>eng</Language>
    <doi>10.1073/pnas.0708381104</doi>
    <Abstract>The protein kinase encoded by the Tpl2 protooncogene plays an obligatory role in the transduction of Toll-like receptor and death receptor signals in macrophages, B cells, mouse embryo fibroblasts, and epithelial cells in culture and promotes inflammatory responses in animals. To address its role in T cell activation, we crossed the T cell receptor (TCR) transgene 2C, which recognizes class I MHC presented peptides, into the Tpl2(-/-) genetic background. Surprisingly, the TCR2C(tg/tg)/Tpl2(-/-) mice developed T cell lymphomas with a latency of 4-6 months. The tumor cells were consistently TCR2C(+)CD8(+)CD4(-), suggesting that they were derived either from chronically stimulated mature T cells or from immature single positive (ISP) cells. Further studies showed that the population of CD8(+) ISP cells was not expanded in the thymus of TCR2C(tg/tg)/Tpl2(-/-) mice, making the latter hypothesis unlikely. Mature peripheral T cells of Tpl2(-/-) mice were defective in ERK activation and exhibited enhanced proliferation after TCR stimulation. The same cells were defective in the induction of CTLA4, a negative regulator of the T cell response, which is induced by TCR signals via ERK. These findings suggest that Tpl2 functions normally in a feedback loop that switches off the T cell response to TCR stimulation. As a result, Tpl2, a potent oncogene, functions as a tumor suppressor gene in chronically stimulated T cells.</Abstract>
    <JournalRelease>1091-6490</JournalRelease>
    <Pages>2987-92</Pages>
    <Affiliation>Department of Clinical Chemistry, and Graduate Program on the Molecular Basis of Human Disease, School of Medicine, University of Crete, Heraklion, 710 03 Crete, Greece. tsatsani@med.uoc.gr</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18287049&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18279271</PMID>
    <AuthorListID>50</AuthorListID>
    <Title>Y chromosome STR haplotypes and allele frequencies in a southern Indian male population.</Title>
    <Language>eng</Language>
    <doi>10.1111/j.1556-4029.2007.00633.x</doi>
    <JournalRelease>0022-1198</JournalRelease>
    <Pages>248-51</Pages>
    <Affiliation>Illinois State Police, Research and Development Laboratory, 2060 Hill Meadows Drive, Springfield, IL 62702, USA. william_frank@isp.state.il.us</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18279271&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18062244</PMID>
    <AuthorListID>51</AuthorListID>
    <Title>[Micirobial diversity and screening of antitumor activity of actinomycete strains from saline and alkaline environments in the Qinghai Province, P. R. China].</Title>
    <Language>chi</Language>
    <Abstract>Soil and sediment samples were collected from saline and alkaline soils or lakes in the Qinghai Province, northwestern China. 145 actinomycete strains were isolated using Glucose-Peptone-Yeast extract agar (GPY) and ISP medium 2 agar supplemented with 1.0 - 3.0 mol/L NaCl at pH 7.5 - 10. The antitumor activities in vitro of the fermentation broth extracts from the 145 test strains were detected in 6 human tumor cell lines (gastric cancer GXF251L, lung cancer LXFL529L, mammary cancer MAXF401NL, melanoma cancer MEXF462NL, renal cancer RXF486L and uterus cancer UXF1138L). Out of 145 test strains, 26 strains were positive in antitumor activities (17.9%), among them 19 strains belong to the genus Nocardiopsis, 7 strains belong to the genus Streptomyces. Then 8 antitumor-positive strains were submitted for 16S rRNA gene amplification and phylogenetic analysis after a comparison of antitumor activities, morphological, physiological characteristics and whole cell amino acids analysis. The results suggested that strain YIM 80139 is a member of a known Streptomyces species S. griseus, while strain YIM 80038 may represent a potential new Streptomyce species, and that the other 6 strains may represent 4 potential new species of the genus Nocardiopsis. The results presented above showed that actinomycetes isolated from saline and alkaline samples are important resources for bioactive compounds, and the abundant microbial diversity in the saline and alkaline environments in the Qinghai Province, Northwestern China is attractive for further investigation.</Abstract>
    <JournalRelease>0001-6209</JournalRelease>
    <Pages>757-62</Pages>
    <Affiliation>Key Laboratory for Conservation and Utilization of Bio-resources, Yunnan Institute of Microbiology, Yunnan University, Kunming 650091, China. mchenjsu@yahoo.com.cn</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18062244&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>18061950</PMID>
    <AuthorListID>52</AuthorListID>
    <Title>The role of flow cytometry in the interferon-gamma-based diagnosis of active tuberculosis and its coinfection with HIV-1--A technically oriented review.</Title>
    <Language>eng</Language>
    <doi>10.1002/cyto.b.20381</doi>
    <Abstract>TB remains uncontrolled. In resource-rich countries, only approximately 60% of diagnoses are confirmed by culture. The number is lower in resource-poor environments. Huge scope therefore exists for alternative diagnostic strategies. Counting antigen-specific lymphocytes by virtue of cytokine production following 8-16 h stimulation with tuberculosis antigens is currently the strategy of choice. Several methods exist, including ELISA, ELISpots, and flow cytometry. Although it is clear that blood samples stimulated by ESAT-6 and CFP-10 antigens discriminate between TB infection and BCG vaccination, it is flow-cytometry that seems to be able to distinguish active TB disease from mere TB exposure. Of the various flow-protocols including four-color tests (CD45-CD3-CD4-IFNgamma), three-color tests (CD3-CD4-IFNgamma) and two-color tests (CD4-IFNgamma), even the simplest is performing well, provided that the results are expressed as percentage of IFN-gamma+ cells per CD4+ lymphocytes (%IFNgamma/CD4+). Studies using broncho-alveloar lavage (BAL) and Induced-Sputum (ISp) show that TB-specific CD4+IFN-gamma+ T cells accumulate in the lung in pulmonary and extra-pulmonary TB at frequencies &gt;5-20-fold more frequent than in blood. This pulmonary homing is absent following BCG immunization. The use of PPD to stimulate CD4+IFN-gamma+ cells in the lung in active TB leads to &gt;3-12-fold greater responses than seen with CFP-10 or ESAT-6, and any interference from BCG vaccination is absent. This method is unaffected by HIV coinfection, which has always been the problem for other immune-based diagnostics. Further, lung-based samples provide material for rapid tests of both the IFN-gamma assay and bacteriology, and importantly, these tests are amenable for future simplification with automated fluorescence-image cytometers.Another development of the multiparameter analytical power of flow-cytometry is to use markers for "lung-seeking" populations of CD4+ T cells in blood, obviating lung sampling. In active TB, but not in BCG vaccinees, TB-specific memory CD4+ T cells can be found in blood that are dominantly CD27-negative and probably lung seeking and can be diagnostically useful.Copyright 2008 Clinical Cytometry Society.</Abstract>
    <JournalRelease>1552-4957</JournalRelease>
    <Pages>S141-51</Pages>
    <Affiliation>Department of Immunology, Royal Free and University College Medical School, London, United Kingdom. janossy@rfhsm.u-net.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=18061950&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17914900</PMID>
    <AuthorListID>53</AuthorListID>
    <Title>Relationship between mitochondrial electron transport chain dysfunction, development, and life extension in Caenorhabditis elegans.</Title>
    <Language>eng</Language>
    <doi>10.1371/journal.pbio.0050259</doi>
    <Abstract>Prior studies have shown that disruption of mitochondrial electron transport chain (ETC) function in the nematode Caenorhabditis elegans can result in life extension. Counter to these findings, many mutations that disrupt ETC function in humans are known to be pathologically life-shortening. In this study, we have undertaken the first formal investigation of the role of partial mitochondrial ETC inhibition and its contribution to the life-extension phenotype of C. elegans. We have developed a novel RNA interference (RNAi) dilution strategy to incrementally reduce the expression level of five genes encoding mitochondrial proteins in C. elegans: atp-3, nuo-2, isp-1, cco-1, and frataxin (frh-1). We observed that each RNAi treatment led to marked alterations in multiple ETC components. Using this dilution technique, we observed a consistent, three-phase lifespan response to increasingly greater inhibition by RNAi: at low levels of inhibition, there was no response, then as inhibition increased, lifespan responded by monotonically lengthening. Finally, at the highest levels of RNAi inhibition, lifespan began to shorten. Indirect measurements of whole-animal oxidative stress showed no correlation with life extension. Instead, larval development, fertility, and adult size all became coordinately affected at the same point at which lifespan began to increase. We show that a specific signal, initiated during the L3/L4 larval stage of development, is sufficient for initiating mitochondrial dysfunction-dependent life extension in C. elegans. This stage of development is characterized by the last somatic cell divisions normally undertaken by C. elegans and also by massive mitochondrial DNA expansion. The coordinate effects of mitochondrial dysfunction on several cell cycle-dependent phenotypes, coupled with recent findings directly linking cell cycle progression with mitochondrial activity in C. elegans, lead us to propose that cell cycle checkpoint control plays a key role in specifying longevity of mitochondrial mutants.</Abstract>
    <JournalRelease>1545-7885</JournalRelease>
    <Pages>e259</Pages>
    <Affiliation>Institute for Behavioral Genetics, University of Colorado at Boulder, Boulder, Colorado, [corrected] United States of America. reas3@uthscsa.edu [corrected]</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17914900&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17900215</PMID>
    <AuthorListID>54</AuthorListID>
    <Title>Reactivation of latent DNA viruses during immunosuppression: basic contemplation.</Title>
    <Language>eng</Language>
    <Abstract>Immunosuppression (ISP) affects the outcome of acute virus primoinfection as well as the course of virus latency. ISP may result from viral infection of the immune cells. This infection can be either transient, as in measles virus infection, or progressive as in Human immunodeficiency virus (HIV-1, 2) infections, which proceed to acquired immunodeficiency syndrome (AIDS). Innate ISP occurs due to various congenital defects of cells, participating within immune response. In the majority of cases, ISP may be initiated by physical causes (e.g. irradiation) or by chemical substances including drugs used for post-transplantation therapeutic regimens. The hallmark of ISP is the impairment of B or T lymphocyte functions. Helper T lymphocytes produce a great variety of cytokines providing B lymphocyte proliferation and cytotoxic T cell maturation. The mature and/or activated memory cytotoxic T lymphocytes destroy the target cells, which synthesize virus-specific proteins. Since many ISP drugs hamper or downregulate the proliferation of B and T lymphocytes, their administration creates favorable conditions for the replication of reactivated DNA viruses otherwise produced in low amounts. Thus, ISP causes an extensive increase in the low-grade production of persisting virus, which might regularly occur during latency. In addition to reactivation of virus latency, ISP potentiates the replication and spread of any intercurrent infectious agent, whether bacterial, parasitic, yeast or fungal origin.</Abstract>
    <JournalRelease>0001-723X</JournalRelease>
    <Pages>77-100</Pages>
    <Affiliation>Institute of Virology, Slovak Academy of Sciences, 84505 Bratislava, Slovak Republic. viruraj@savba.sk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17900215&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17895250</PMID>
    <AuthorListID>55</AuthorListID>
    <Title>Recycling of sphingosine is regulated by the concerted actions of sphingosine-1-phosphate phosphohydrolase 1 and sphingosine kinase 2.</Title>
    <PubDate>20070925</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M703329200</doi>
    <Abstract>In yeast, the long-chain sphingoid base phosphate phosphohydrolase Lcb3p is required for efficient ceramide synthesis from exogenous sphingoid bases. Similarly, in this study, we found that incorporation of exogenous sphingosine into ceramide in mammalian cells was regulated by the homologue of Lcb3p, sphingosine-1-phosphate phosphohydrolase 1 (SPP-1), an endoplasmic reticulum resident protein. Sphingosine incorporation into endogenous long-chain ceramides was increased by SPP-1 overexpression, whereas recycling of C(6)-ceramide into long-chain ceramides was not altered. The increase in ceramide was inhibited by fumonisin B(1), an inhibitor of ceramide synthase, but not by ISP-1, an inhibitor of serine palmitoyltransferase, the rate-limiting step in the de novo biosynthesis of ceramide. Mass spectrometry analysis revealed that SPP-1 expression increased the incorporation of sphingosine into all ceramide acyl chain species, particularly enhancing C16:0, C18:0, and C20:0 long-chain ceramides. The increased recycling of sphingosine into ceramide was accompanied by increased hexosylceramides and, to a lesser extent, sphingomyelins. Sphingosine kinase 2, but not sphingosine kinase 1, acted in concert with SPP-1 to regulate recycling of sphingosine into ceramide. Collectively, our results suggest that an evolutionarily conserved cycle of phosphorylation-dephosphorylation regulates recycling and salvage of sphingosine to ceramide and more complex sphingolipids.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>34372-80</Pages>
    <Affiliation>Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17895250&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17556392</PMID>
    <AuthorListID>56</AuthorListID>
    <Title>Intracortical circuits modulate transcallosal inhibition in humans.</Title>
    <PubDate>20070607</PubDate>
    <Language>eng</Language>
    <doi>10.1113/jphysiol.2007.134510</doi>
    <Abstract>Previous results using paired-pulse transcranial magnetic stimulation (TMS) have suggested that the excitability of transcallosal (TC) connections between the hand areas of the two motor cortices is modulated by intracortical inhibitory circuits in the same way as corticospinal tract (CTS) projections to spinal motoneurons. Here we describe two further similarities in TC and CTS control using (1) an I-wave facilitation protocol and (2) preconditioning with rTMS. In experiment 1, excitability of TC pathways was measured using interhemispheric inhibition (IHI) and the ipsilateral silent period (iSP), whilst excitability of CTS pathways was measured by recording the EMG response evoked in the first dorsal interosseous muscle contralateral to the conditioning stimulus (cMEP). The intensity of the conditioning stimulus was first adjusted to threshold for evoking IHI and iSP, then pairs of conditioning stimuli were applied randomly at interstimulus intervals (ISIs) from 1.3 to 4.3 ms. IHI and iSP were facilitated at ISI=1.5 ms and 3.0 ms, respectively, as was the MEP evoked by the conditioning stimuli in the contralateral hand. We suggest that TC projections receive I-wave-like facilitation similar to that seen in CTS projections. In experiment 2, short interval inhibition of the iSP (SICIiSP), and short interval intracortical inhibition of the cMEP (SICIcMEP) were examined before and after 600 pulses of 5 Hz rTMS at 90% resting motor threshold. Both SICIiSP and SICIcMEP were reduced, as was the iSP; the cMEP was unchanged. This shows that the population of inhibitory interneurons that control TC neurons respond in the same way to 5 Hz rTMS as those that control CTS neurons. Taken together, the data from the two experiments suggest that the layer III and layer V pyramidal neurons that give rise to TC and CTS pathways, respectively, are controlled by neuronal circuitry with similar properties.</Abstract>
    <JournalRelease>0022-3751</JournalRelease>
    <Pages>99-114</Pages>
    <Affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Box 66, Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17556392&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17530242</PMID>
    <AuthorListID>57</AuthorListID>
    <Title>Cloning, sequencing, and cell surface expression pattern of bovine immunoreceptor NKG2D and adaptor molecules DAP10 and DAP12.</Title>
    <PubDate>20070526</PubDate>
    <Language>eng</Language>
    <doi>10.1007/s00251-007-0226-6</doi>
    <Abstract>NKG2D is an activating lectin-like receptor that initiates natural killer (NK) cell responses against transformed tumor cells expressing its ligands, i.e., molecules related to major histocompatibility complex (MHC) class I molecules. NKG2D lacks signaling elements in its cytoplasmic domain and can deliver stimulatory signals only in association with transmembrane adaptor proteins DAP10 or DAP12. The complementary DNAs (cDNAs) encoding the bovine homologues of NKG2D and the adaptor proteins DAP10 and DAP12 were cloned by reverse transcriptase-polymerase chain reaction (RT-PCR) from resting bovine peripheral blood mononuclear cells (PBMC) and sequenced. Comparison with human, pig, and mouse sequences showed that bovine NKG2D is most similar to pig NKG2D and short mouse NKG2D (NKG2D-S). Similar to its human, mouse, and pig homologues, the cDNA for bovine DAP10 codes for a phosphatidyl-inositol-3 (PI-3) kinase-binding site (YxxM) in its cytoplasmic region. Finally, similar to its human, mouse, and pig homologues, the cDNA encoding bovine DAP12 demonstrates one tyrosine-based activated motif (ITAM) in its cytoplasmic domain. Bovine NKG2D cell surface expression was analyzed by flow cytometry on HEK 293 cells transiently transfected with cDNA expression vectors encoding COOH-terminal polyhistidine-tagged NKG2D and NH(2)-terminal Flag-tagged DAP10 and DAP12. Confirming previous findings for short mouse NKG2D-S, bovine NKG2D immunoreceptor could associate with either DAP10 or DAP12 adaptor protein for its cell surface expression.</Abstract>
    <JournalRelease>0093-7711</JournalRelease>
    <Pages>653-9</Pages>
    <Affiliation>ISP-Institut Pasteur de Bruxelles, Rue Engeland 642, 1180 Bruxelles, Belgium.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17530242&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <Title>Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens.</Title>
    <PubDate>20070117</PubDate>
    <Language>eng</Language>
    <doi>10.1128/JCM.02098-06</doi>
    <Abstract>A strategy combining human papillomavirus general primer (mainly the PGMY primers)-directed PCR sequencing and type-specific PCR is presented. DNA samples were first tested in general primer-mediated PCR. The amplified fragments of positive samples after ethidium bromide-stained DNA gel analysis were further sequenced, and corresponding DNA samples were further analyzed by PCR using type-specific primers for human papillomavirus (HPV) types 16, 18, 31, and 52. The comparison of the results of 157 samples analyzed by this strategy in parallel with the Hybrid Capture 2 tests and with the HPV INNO-LiPA (Innogenetics line probe assay) shows that this method is suitable for HPV detection and genotyping in cervical cell samples. Although the PCR sequencing method is as sensitive as the HPV INNO-LiPA for HPV detection, our method allows the identification of a broader range of HPV types. In contrast, the HPV INNO-LiPA was less time-consuming and better identified coinfections.</Abstract>
    <JournalRelease>0095-1137</JournalRelease>
    <Pages>928-34</Pages>
    <Affiliation>Laboratory of Molecular Virology, ISP/Institut Pasteur, rue Engeland 642, 1180 Brussels, Belgium. vfontaine@pasteur.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17229855&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <Title>Lack of immunogenicity of ice structuring protein type III HPLC12 preparation administered by the oral route to human volunteers.</Title>
    <PubDate>20060822</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.fct.2006.07.020</doi>
    <Abstract>Before a novel protein can be used in foods, its potential allergenicity must be assessed. In this study, healthy volunteers consumed ice structuring protein (ISP) Type III preparation or a control material 5 days a week for a total of 8 weeks. General measures of health were recorded during the study, and the immunogenicity of the protein was assessed by monitoring the levels of IgG and IgE antibodies specific for ISP Type III. The participants remained in good health throughout the study and during the 4 week follow-up period. No IgG or IgE antibodies specific for ISP Type III were detected in the blood of the participants. Investigations of immunogenicity in man have not been previously applied in the context of safety evaluation and they do not form part of the regimens proposed for the evaluation of protein allergenicity. Consequently no standardised protocols exist for such studies, nor any background against which to interpret the results. Nevertheless, the absence of an immune response using a protocol which could have been expected to result in a response with a strongly immunogenic protein, confirms the conclusions of earlier published work, and attests to the lack of allergenicity of ISP Type III preparation.</Abstract>
    <JournalRelease>0278-6915</JournalRelease>
    <Pages>79-87</Pages>
    <Affiliation>Safety and Environmental Assurance Centre, Sharnbrook, Unilever Colworth, Bedford MK44 1LQ, UK, and Allergy Center, Odense University Hospital, Denmark. rene.crevel@unilever.com</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17027137&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17018115</PMID>
    <AuthorListID>60</AuthorListID>
    <Title>Y chromosome STR haplotypes and allele frequencies in Illinois Caucasian, African American, and Hispanic males.</Title>
    <Language>eng</Language>
    <doi>10.1111/j.1556-4029.2006.00248.x</doi>
    <JournalRelease>0022-1198</JournalRelease>
    <Pages>1207-15</Pages>
    <Affiliation>Illinois State Police, Research and Development Laboratory, 2060 Hill Meadows Drive, Springfield, IL 62702, USA. william_frank@isp.state.il.us</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17018115&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>17011585</PMID>
    <AuthorListID>61</AuthorListID>
    <Title>Ipsilateral silent period: a marker of callosal conduction abnormality in early relapsing-remitting multiple sclerosis?</Title>
    <PubDate>20061002</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.jns.2006.08.008</doi>
    <Abstract>The corpus callosum (CC) is commonly affected in multiple sclerosis (MS). The ipsilateral silent period (iSP) is a putative electrophysiological marker of callosal demyelination. The purpose of this study was to re-assess, under recently established optimised protocol conditions [Jung P., Ziemann U. Differences of the ipsilateral silent period in small hand muscles. Muscle Nerve in press.], its diagnostic sensitivity in MS, about which conflicting results were reported in previous studies.ISP measurements (onset, duration, and depth) were obtained in the abductor pollicis brevis (APB) muscle of either hand in 49 patients with early relapsing-remitting MS (RRMS) (mean EDSS, 1.3). Standard central motor conduction times to the APB (CMCT(APB)) and tibial anterior muscles (CMCT(TA)), and magnetic resonance images (MRI) were also obtained.ISP measurements showed a similar diagnostic sensitivity (28.6%) as CMCT(APB) (24.5%), while diagnostic sensitivities of CMCT(TA) (69.4%) and MRI of the CC (78.6%) were much higher. Prolongation of iSP duration was the most sensitive single iSP measure. ISP prolongation occurred more frequently when CMCT(APB) to the same hand was also prolonged (40.0% vs. 8.4%, p&lt;0.0001). The correlation between iSP duration and CMCT(APB) was significant (Pearson's r=0.24, p&lt;0.02), suggesting that iSP duration can be contaminated by demyelination of the contralateral corticospinal tract. ISP duration did not correlate with MRI abnormalities of the CC.ISP measures are neither a sensitive nor a specific marker of callosal conduction abnormality in early RRMS.</Abstract>
    <JournalRelease>0022-510X</JournalRelease>
    <Pages>133-9</Pages>
    <Affiliation>Department of Neurology, Johann Wolfgang Goethe-University, Schleusenweg 2-16, D-60528 Frankfurt am Main, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=17011585&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16549044</PMID>
    <AuthorListID>62</AuthorListID>
    <Title>Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.</Title>
    <Language>eng</Language>
    <Abstract>Circulation of mature lymphocytes between blood and secondary lymphoid tissues plays a central role in the immune system. Homing of lymphocytes from blood into secondary lymphoid tissues beyond high endothelial venules is highly dependent on the interaction between the chemokines CCL19, CCL21, CXCL12, and CXCL13, and their receptors CCR7, CXCR4 and CXCR5. However, the molecular mechanism(s) of lymphocyte egress from secondary lymphoid tissues to lymph remained unclear. We have found a new class of immunomodulator, FTY720 by chemical modification of vegetative wasp-derived natural product, ISP-I (myriocin). FTY720 has been shown to be highly effective in experimental allograft and autoimmune disease models. A striking feature of FTY720 is the induction of a marked decrease in peripheral blood lymphocytes at doses that show immunomodulating activity in these models. The reduction of circulating lymphocytes by FTY720 is caused by sequestration of lymphocytes into secondary lymphoid tissues and thymus. FTY720 is rapidly converted to (S)-enantiomer of FTY720-phosphate [(S)-FTY720-P] by sphingosine kinase 2 in vivo. (S)-FTY720-P acting as a potent agonist of S1P receptor type 1 (S1P1), induces long-term down-regulation of S1P1 on lymphocytes, and thereby inhibits the migration of lymphocytes toward S1P. Thus, it is presumed that FTY720-induced lymphocyte sequestration is due to the inhibition of S1P/S1P1-dependent lymphocyte egress from secondary lymphoid tissues and thymus by its active metabolite (S)-FTY720-P. Throughout the analysis of the mechanism of action of FTY720, it is clarified that S1P/S1P1 interaction plays an important role for lymphocyte egress from secondary lymphoid tissues and thymus.</Abstract>
    <JournalRelease>1672-7681</JournalRelease>
    <Pages>11-9</Pages>
    <Affiliation>Research Laboratory III (Immunology), Pharmaceutical Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Yokohama, Japan. Chiba.Kenji@mk.m-pharma.co.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16549044&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16527606</PMID>
    <AuthorListID>63</AuthorListID>
    <Title>Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.cancergencyto.2005.08.009</doi>
    <Abstract>Intratumoral heterogeneity and genetic instability within gliomas may allow intrinsically immunoresistant (IR) cells to escape alloreactive cytotoxic T lymphocyte (aCTL) cellular immunotherapy. The potential existence of aCTL-resistant variants prompted us to investigate whether cellular immunotherapy resistant glioma models could be isolated. To generate the models, repeated intermittent or continuous selective pressure (ISP or CSP) with multiple aCTL populations was applied to a low-passage glioblastoma cell explant, 13-06-MG, obtained from a patient at initial diagnosis. IL-6 and IL-8 secretion was greater in coincubates of aCTL cells with 13-06-ISP and 13-06-CSP immunoselected cells than those with 13-06-MG parental cells. Initially, the immunoselected cells were less sensitive to aCTL lysis; however, the reduced aCTL-sensitivity was not maintained upon further selection. We therefore isolated IR clones from continuously immunoselected cells (13-06-CSP). The frequency of IR clones was 1-6 cells per 10,000 immunoselected cells. Two clones selected for further study, 13-06-IR29 and 13-06-IR30, resisted aCTL lysis in the absence of immunoselective pressure. Cytogenetic analyses revealed structural anomalies and genomic imbalances unique to the IR clones. Based on these findings, a hypothetical model is proposed that traces the origin of the IR clones to a clonal variant within the 13-06-CSP and 13-06-MG populations.</Abstract>
    <JournalRelease>0165-4608</JournalRelease>
    <Pages>121-34</Pages>
    <Affiliation>Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16527606&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <Title>Phosphorylation of peptides derived from isolated soybean protein: effects on calcium binding, solubility and influx into Caco-2 cells.</Title>
    <Language>eng</Language>
    <Abstract>Calcium homeostasis in the human body is maintained primarily via the absorption of calcium through the intestine. In order to maintain an efficient absorption of calcium with minimal calcium loss due to the formation of calcium phosphate precipitates in the small intestinal lumen, we developed a calcium-binding mediator using peptides derived from isolated soybean protein (ISP). ISP was modified via tryptic digestion and chemical phosphorylation using sodium trimetaphosphate, thereby generating soybean phosphopeptides (SPP), and this was followed by conducting a binding reaction with calcium chloride. We have established an optimized procedure and reaction conditions for maximal phosphorylation and calcium binding. Consequently, the phosphorylation of soybean peptides resulted in considerable improvement in their calcium binding activities. Next, we demonstrated that SPP was able to render calcium ions resistant to precipitate formation with inorganic phosphates, which suggested the enhancement of calcium bioavailability. Finally, we noted that the addition of calcium-bound SPP induced an increase in cytosolic calcium concentration in the intestinal Caco-2 cells, due to an influx of calcium. These findings provide a new basis by which we may assess the possibility that SPP, as a potent calcium carrier, can be utilized in the prevention of poor absorption of dietary calcium in animals.</Abstract>
    <JournalRelease>0951-6433</JournalRelease>
    <Pages>121-8</Pages>
    <Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16410634&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <Title>Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice.</Title>
    <PubDate>20051108</PubDate>
    <Language>eng</Language>
    <doi>10.1093/hmg/ddi410</doi>
    <Abstract>We have disrupted expression of the mitochondrial Friedreich ataxia protein frataxin specifically in murine hepatocytes to generate mice with impaired mitochondrial function and decreased oxidative phosphorylation. These animals have a reduced life span and develop multiple hepatic tumors. Livers also show increased oxidative stress, impaired respiration and reduced ATP levels paralleled by reduced activity of iron-sulfur cluster (Fe/S) containing proteins (ISP), which all leads to increased hepatocyte turnover by promoting both apoptosis and proliferation. Accordingly, phosphorylation of the stress-inducible p38 MAP kinase was found to be specifically impaired following disruption of frataxin. Taken together, these findings indicate that frataxin may act as a mitochondrial tumor suppressor protein in mammals.</Abstract>
    <JournalRelease>0964-6906</JournalRelease>
    <Pages>3857-64</Pages>
    <Affiliation>German Institute of Human Nutrition Potsdam-Rehbr체cke, Nuthetal-Berlin, and Charit챕 University Medicine, Berlin, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16278235&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16257142</PMID>
    <AuthorListID>66</AuthorListID>
    <Title>Murine implantation serine proteinases 1 and 2: structure, function and evolution.</Title>
    <PubDate>20051027</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.gene.2005.07.041</doi>
    <Abstract>Implantation is a vital phase in pregnancy whereupon the hatched embryo invades into the uterine wall to establish intimate contacts with the mother for further development. Although it is generally believed that proteinases are major factors that confer the embryo its invasive character, the nature of proteinases involved in implantation remain mostly elusive. In this article, we review the organization, structure and postulated function of the implantation serine proteinase (ISP1 and 2) genes. The ISPs are embedded within a cluster of tryptase genes on mouse chromosome 17. They are most closely related to members of the mast cell tryptase family, indicating that they may possess some properties characteristic of tryptases including multimerization-dependent activation. The significant similarities found in regulatory regions of ISP genes, together with the observation that ISP proteins are co-expressed and heterodimerize in the embryo and uterus suggests that they are intimately co-regulated during implantation. Inhibition of ISP proteolytic function has implicated this enzyme in the processes of embryo hatching and implantation.</Abstract>
    <JournalRelease>0378-1119</JournalRelease>
    <Pages>30-6</Pages>
    <Affiliation>Department of Oncology, University of Calgary, Calgary, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16257142&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <Title>Increased rat alveolar macrophage expression of functional iNOS induced by a Dirofilaria immitis immunoglobulin superfamily protein.</Title>
    <PubDate>20050919</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.niox.2005.06.003</doi>
    <Abstract>Dirofilaria immitis is a worldwide filarial nematode causing heartworm disease in dogs and cats. Several mosquito species, which are able to feed both on humans and animals, can transmit this parasite. Inflammatory progression of host tissues induced by parasites are mediated by several molecules, including nitric oxide (NO), which usually exerts deleterious effects on parasites and occasionally on the host. We analyze the in vitro effect of total D. immitis adult worm somatic antigens on na챦ve rat alveolar macrophage NO production and further separation of parasite proteins to define specific D. immitis somatic molecules influencing host cell NO secretion. Additionally, we address the possible influence of Wolbachia spp. on the in vitro production of NO by macrophages. Our results demonstrate that D. immitis adult worm soluble antigens are able to specifically induce NO production from host macrophages. Furthermore, we demonstrated that this effect is due to nematode antigens rather than to defined components (LPS and metabolic molecules) derived from its endosymbiont, Wolbachia spp. In addition, we were able to isolate and identify one of the parasite specific components from the DiSo extract, denominated DiID35.3 and putatively belonging to the Immunoglobulin Superfamily Protein (ISP) group, triggering NO release from macrophages in a dose-dependent and specific manner.</Abstract>
    <JournalRelease>1089-8603</JournalRelease>
    <Pages>217-25</Pages>
    <Affiliation>Laboratorio de Parasitolog챠a, Facultad de Farmacia, Universidad de Salamanca, Avda, Campo Charro s/n 37007 Salamanca, Spain.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=16172008&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <Title>The ipsilateral silent period in boys with attention-deficit/hyperactivity disorder.</Title>
    <Language>eng</Language>
    <doi>10.1016/j.clinph.2005.03.018</doi>
    <Abstract>Characterize maturation of transcallosal inhibition (ipsilateral silent period [iSP]) in attention deficit/hyperactivity disorder (ADHD) using transcranial magnetic stimulation (TMS).Maturation of the iSP is related to acquisition of fine motor skills in typically developing children suggesting that dexterous fine motor skills depend upon mature interhemispheric interactions. Since neuromotor maturation is abnormal in boys with ADHD we hypothesized that iSP maturation in these children would be abnormal. We studied iSP maturation in 12 boys with ADHD and 12 age-matched, typically developing boys, 7-13 years of age.Surface electromyographic activity was recorded from right first dorsal interosseus (FDI). During background activation, focal TMS was delivered at maximal stimulator output over the ipsilateral motor cortex.Maturation of finger speed in boys with ADHD was significantly slower than that in the control group. The iSP latency decreased with age in the control group but not in the ADHD group.These findings suggest the presence of a complex relationship between abnormalities of certain interhemispheric interactions (as represented by iSP latency) and delayed maturation of neuromotor skills in boys with ADHD.These data provide preliminary physiologic evidence supporting delayed or abnormal development of interhemispheric interactions in boys with ADHD.</Abstract>
    <JournalRelease>1388-2457</JournalRelease>
    <Pages>1889-96</Pages>
    <Affiliation>Pediatric Movement Disorders Unit, Human Motor Control Section, MNB, NINDS, National Institutes of Health, Bethesda, MD 20892, USA. marjorie.garvey@medstar.net</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=15979402&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>15966292</PMID>
    <AuthorListID>69</AuthorListID>
    <Title>Improving recognition of thyroid carcinoma in rapid-consultation specimens.</Title>
    <Language>eng</Language>
    <Abstract>To improve recognition of thyroid carcinoma in rapid consultation on Diff-Quik-stained (Fisher Diagnostics, Middletown, Virginia, USA.) fine-needle aspiration (FNA) and rapid hematoxylin-eosin (H-E)-stained intraoperative scrape preparation (ISP) specimens by assessing 3 variables (anisokaryosis, nuclear overlap [NO] and scant/absent colloid) in cases of cellular follicular lesions (CFL), an indeterminate diagnostic category.Thirty-seven FNAs and 28 ISPs diagnosed as CFL, with histologic follow-up, were evaluated in blinded fashion by 3 cytopathologists assessing the 3 variables.Over 90% of the malignant cases showed NO in both FNA and ISP, while only 22% of the benign cases did; positive and negative predictive values (PPV and NPV) were 82% and 100%. All malignant cases showed significant anisokaryosis in both FNA and ISP in contrast to 24% of benign cases; PPV and NPV were 74% and 100%. Scant/absent colloid was seen in 87% and 39% of malignancies in FNA and ISP, respectively, as compared to 55% and 20% of the benign cases. PPV and NPV were 52% and 83% in FNA and 63% and 60% in ISP, respectively.Application of these variables improves recognition of thyroid carcinoma, particularly in fine needle aspirates, while additional material may be requested. With ISP, their absence supports recommending against further surgery. Together, optimal surgical planning and outcome may be obtained.</Abstract>
    <JournalRelease>0001-5547</JournalRelease>
    <Pages>291-6</Pages>
    <Affiliation>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107, USA. moira.wood@mail.tju.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=15966292&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>15951022</PMID>
    <AuthorListID>70</AuthorListID>
    <Title>FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.</Title>
    <PubDate>20050613</PubDate>
    <Language>eng</Language>
    <doi>10.1016/j.pharmthera.2005.05.002</doi>
    <Abstract>FTY720 is the first of a new immunomodulator class: sphingosine 1-phosphate (S1P) receptor agonist. In 1994, an immunosuppressive natural product, ISP-I (myriocin), was isolated from the culture broth of Isaria sinclairii, a type of vegetative wasp. The chemical modification of ISP-I yielded a new compound, FTY720, which has more potent immunosuppressive activity and less toxicity than ISP-I does. FTY720 has been shown to be highly effective in experimental allotransplantation models and autoimmune disease models. A striking feature of FTY720 is the induction of a marked decrease in peripheral blood T- and B-cells at doses that show immunosuppressive activity in these models. Reportedly, FTY720 is rapidly converted to FTY720-phosphate (FTY720-P) by sphingosine kinase 2 in vivo, and FTY720-P acts as a potent agonist at S1P receptors. Recently, it has been suggested that FTY720-P internalizes S1P1 on lymphocytes and thereby inhibits the migration of lymphocytes toward S1P. Thus, it is likely that the reduction of circulating lymphocytes by FTY720 is due to the inhibition of S1P/S1P1-dependent lymphocyte egress from secondary lymphoid tissues and thymus. Because FTY720 displays a novel mechanism of action that has not been observed with other immunosuppressive agents and shows a synergism with cyclosporin A (CsA) and tacrolimus, it is presumed that FTY720 provides a useful tool for the prevention of transplant rejection and a new therapeutic approach for autoimmune diseases including multiple sclerosis and rheumatoid arthritis.</Abstract>
    <JournalRelease>0163-7258</JournalRelease>
    <Pages>308-19</Pages>
    <Affiliation>Research Laboratory III (Immunology), Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Japan. Chiba.Kenji@mk.m-pharm.co.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=15951022&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>15531524</PMID>
    <AuthorListID>71</AuthorListID>
    <Title>Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function.</Title>
    <Language>eng</Language>
    <doi>10.1210/jc.2004-0884</doi>
    <Abstract>The dominant mechanism for hypopituitarism and hyperprolactinemia commonly observed in patients with pituitary macroadenomas was postulated to be increased intrasellar pressure (ISP) caused by the slow and gradual expansion of adenomas within the sella turcica. Hemorrhagic infarction of adenomas (pituitary tumor apoplexy) is associated with a rapid, rather than gradual, increase in intrasellar contents. The impacts of the sudden increase in intrasellar contents on ISP and pituitary function are unknown. ISP and pituitary function were determined in 13 patients with pituitary tumor apoplexy who had surgical decompression within 1 wk of symptoms' onset. ISP measurements were remarkably high (median, 47 mm Hg), whereas serum prolactin (PRL) concentrations were generally low (median, 3.5 microg/liter). There was an inverse correlation (r = -0.76; P &lt; 0.01) between ISP measurements and serum PRL concentrations. Postoperatively, partial recovery or maintenance of pituitary function was noted in seven of 13 patients. These seven patients had higher (P = 0.013) serum PRL levels (9.3 +/- 7.4 microg/liter) and lower (P &lt; 0.001) ISP measurements (35.9 +/- 7.3 mm Hg) than the respective values in the remaining six with persistent postoperative hypopituitarism (1.6 +/- 0.6 microg/liter and 55.9 +/- 2.4 mm Hg, respectively). The low serum PRL levels in patients with tumor apoplexy suggested that ischemic necrosis of the anterior pituitary resulting from sudden and extreme elevation of ISP was commonly observed in this setting. A normal or elevated serum PRL level in patients with non-PRL-secreting macroadenomas indicates the presence of viable pituitary cells and the high likelihood of postoperative recovery of pituitary function.</Abstract>
    <JournalRelease>0021-972X</JournalRelease>
    <Pages>5649-54</Pages>
    <Affiliation>Division of Clinical and Molecular Endocrinology, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio 44106, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=15531524&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>15339929</PMID>
    <AuthorListID>72</AuthorListID>
    <Title>The role of extra fragment at the C-terminal of cytochrome b (Residues 421-445) in the cytochrome bc1 complex from Rhodobacter sphaeroides.</Title>
    <PubDate>20040830</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M406497200</doi>
    <Abstract>Sequence alignment of cytochrome b of the cytochrome bc1 complex from various sources reveals that bacterial cytochrome b contain an extra fragment at the C terminus. To study the role of this fragment in bacterial cytochrome bc1 complex, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome bc1 complexes with progressive deletion from this fragment (residues 421-445) were generated and characterized. The cytbDelta-(433-445) bc1 complex, in which 13 residues from the C-terminal end of this fragment are deleted, has electron transfer activity, subunit composition, and physical properties similar to those of the complement complex, indicating that this region of the extra fragment is not essential. In contrast, the electron transfer activity, binding of cytochrome b, ISP, and subunit IV to cytochrome c1, redox potentials of cytochromes b and c1 in the cytbDelta-(427-445), cytbDelta-(425-445), and cytbDelta-(421-445) mutant complexes, in which 19, 21, or all residues of this fragment are deleted, decrease progressively. EPR spectra of the [2Fe-2S] cluster and the cytochromes b in these three deletion mutant bc1 complexes are also altered; the extent of spectral alteration increases as this extra fragment is shortened. These results indicate that the first 12 residues (residues 421-432) from the N-terminal end of the C-terminal extra fragment of cytochrome b are essential for maintaining structural integrity of the bc1 complex.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>47363-71</Pages>
    <Affiliation>Department of Biochemistry &amp; Molecular Biology, Oklahoma State University, Stillwater, Oklahoma 74078, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=15339929&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <Title>In vitro and in vivo antimalarial properties of isostrychnopentamine, an indolomonoterpenic alkaloid from Strychnos usambarensis.</Title>
    <Language>eng</Language>
    <doi>10.1055/s-2004-827151</doi>
    <Abstract>Isostrychnopentamine (ISP) is an asymmetric indolomonoterpenic alkaloid isolated from the leaves of Strychnos usambarensis. The in vitro antiplasmodial activities against five Plasmodium falciparum cell lines were evaluated: ISP possessed an in vitro IC (50) near 0.1 microM against all P. falciparum cell lines tested (chloroquine-resistant and chloroquine-sensitive lines) and showed antiplasmodial selectivity compared to cytotoxicity on human cell lines. The stage-dependent susceptibility to a short exposure of ISP was then investigated. The ring stage was shown to be the most sensitive one, but all stages were affected by ISP treatment. By means of fluorescence microscopy, it was shown that ISP was not accumulated inside the food vacuole of the parasite. Finally, the in vivo antimalarial activities against the P. berghei NK173 and P. vinckei petteri murine strains were determined. The ED (50) in vivo was about 30 mg/kg/day by the intraperitoneal route (after 4 days treatment).</Abstract>
    <JournalRelease>0032-0943</JournalRelease>
    <Pages>520-5</Pages>
    <Affiliation>Natural and Synthetic Drug Research Center, Laboratory of Pharmacognosy, University of Li챔ge, Avenue de l'h척pital 1,B36, 4000 Li챔ge, Belgium. M.Frederich@ulg.ac.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=15229803&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <Title>De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells.</Title>
    <PubDate>20040312</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M311974200</doi>
    <Abstract>The oxidative stress induced by photodynamic therapy (PDT) with the photosensitizer phthalocyanine 4 is accompanied by increases in ceramide mass. To assess the regulation of de novo sphingolipid metabolism during PDT-induced apoptosis, Jurkat human T lymphoma and Chinese hamster ovary cells were labeled with [14C]serine, a substrate of serine palmitoyltransferase (SPT), the enzyme catalyzing the initial step in the sphingolipid biosynthesis. A substantial elevation in [14C]ceramide with a concomitant decrease in [14C]sphingomyelin was detected. The labeling of [14C]ceramide was completely abrogated by the SPT inhibitor ISP-1. In addition, ISP-1 partly suppressed PDT-induced apoptosis. Pulse-chase experiments showed that the contribution of sphingomyelin degradation to PDT-initiated increase in de novo ceramide was absent or minor. PDT had no effect on either mRNA amounts of the SPT subunits LCB1 and LCB2, LCB1 protein expression, or SPT activity in Jurkat cells. Moreover in Chinese hamster ovary cells LCB1 protein underwent substantial photodestruction, and SPT activity was profoundly inhibited after treatment. We next examined whether PDT affects conversion of ceramide to complex sphingolipids. Sphingomyelin synthase, as well as glucosylceramide synthase, was inactivated by PDT in both cell lines in a dose-dependent manner. These results are the first to show that in the absence of SPT up-regulation PDT induces accumulation of de novo ceramide by inhibiting its conversion to complex sphingolipids.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>23238-49</Pages>
    <Affiliation>Occupational and Environmental Health Sciences, The Department of Fundamental and Applied Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan 48201, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=15020599&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>14986303</PMID>
    <AuthorListID>75</AuthorListID>
    <Title>Cytologic-histologic correlations in the diagnosis of inverted sinonasal papilloma.</Title>
    <Language>eng</Language>
    <doi>10.1002/dc.20020</doi>
    <Abstract>We present cytologic data from multiple samples from two cases of inverted sinonasal papilloma (ISP). These samples displayed the entire spectrum of squamous cell changes, including benign squamous papilloma, variable degrees of dysplasia, and invasive squamous cell carcinoma. In all instances, the cytologic impression coincided with the final diagnosis based on frozen and/or permanent histologic sections from the same samples. We suggest that cytologic examination be viewed as a useful initial approach in the diagnosis of ISP, and in the differential diagnosis of other tumors that occur in the same sites.Copyright 2004 Wiley-Liss, Inc.</Abstract>
    <JournalRelease>8755-1039</JournalRelease>
    <Pages>201-7</Pages>
    <Affiliation>Department of Pathology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA. pgattu@sis.rpslmc.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=14986303&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>14573769</PMID>
    <AuthorListID>76</AuthorListID>
    <Title>Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells.</Title>
    <Language>eng</Language>
    <doi>10.1124/mol.64.5.1189</doi>
    <Abstract>Cannabinoids have recently been shown to induce the expression of the cyclooxygenase-2 (COX-2) isoenzyme in H4 human neuroglioma cells. Using this cell line, the present study investigates the contribution of the second messenger ceramide to this signaling pathway. Incubation of cells with the endocannabinoid analog R(+)-methanandamide (R(+)-MA) was associated with an increase of intracellular ceramide levels. Enhancement of ceramide formation by R(+)-MA was abolished by fumonisin B1, a ceramide synthase inhibitor, whereas inhibitors of neutral sphingomyelinase (spiroepoxide, glutathione) and serine palmitoyltransferase (l-cycloserine, ISP-1) were inactive in this respect. R(+)-MA caused a biphasic activation of the p38 and p42/44 mitogen-activated protein kinases (MAPKs), with phosphorylation peaks occurring after 15-min and 4- to 8-h treatments, respectively. Inhibition of ceramide synthesis with fumonisin B1 was associated with a suppression of R(+)-MA-induced delayed phosphorylations of p38 and p42/44 MAPKs and subsequent COX-2 expression. The involvement of ceramide in COX-2 expression was corroborated by findings showing that C2-ceramide and neutral sphingomyelinase from Bacillus cereus caused concentration-dependent increases of COX-2 expression that were suppressed in the presence of 4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)imidazol (SB203580, a p38 MAPK inhibitor) or 2'-amino-3'-methoxyflavone (PD98059, a p42/44 MAPK activation inhibitor). In contrast, dihydro-C2-ceramide being used as a negative control did not induce MAPK phosphorylation and COX-2 expression. Collectively, our results demonstrate that R(+)-MA induces COX-2 expression in human neuroglioma cells via synthesis of ceramide and subsequent activation of p38 and p42/44 MAPK pathways. Induction of COX-2 expression via ceramide represents a hitherto unknown mechanism by which cannabinoids mediate biological effects within the central nervous system.</Abstract>
    <JournalRelease>0026-895X</JournalRelease>
    <Pages>1189-98</Pages>
    <Affiliation>Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen, Erlangen, Germany.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=14573769&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12915133</PMID>
    <AuthorListID>77</AuthorListID>
    <Title>Reactive oxygen species generation is independent of de novo sphingolipids in apoptotic photosensitized cells.</Title>
    <Language>eng</Language>
    <Abstract>Our recent studies have shown that the de novo sphingolipids play a role in apoptosis of photosensitized cells. To elucidate the involvement of the de novo sphingolipids in reactive oxygen species (ROS) production and mitochondrial depolarization during apoptosis, the stress inducer photodynamic therapy (PDT) with the photosensitizer Pc 4 was used. In Jurkat cells PDT-triggered ROS production or mitochondrial membrane potential (deltapsi(m)) loss was not prevented by the de novo sphingolipid synthesis inhibitor ISP-1. However, PDT + C16-ceramide led to enhanced mitochondrial depolarization and DEVDase activation. The superoxide dismutase mimic manganese (III) tetrakis (4-benzoic acid) porphyrin (MnTBAP) protected Jurkat cells from ROS generation and apoptosis, but not from deltapsi(m) reduction. Sphinganine or C16-ceramide counteracted MnTBAP-induced protection from apoptosis in Jurkat, as well as CHO cells. In LY-B cells, CHO-derived mutants deficient in serine palmitoyltransferase (SPT) activity and the de novo sphingolipid synthesis, mitochondrial depolarization, but not ROS generation, was suppressed post-PDT. In LY-B cells transfected with the SPT component LCB1, deltapsi(m) collapse post-PDT was restored. The data support the following hypotheses: MnTBAP protects against apoptosis via steps downstream of deltapsi(m) loss; de novo sphingolipids are not required for ROS generation, but can play a role in deltapsi(m) dissipation in photosensitized apoptotic cells.</Abstract>
    <JournalRelease>0014-4827</JournalRelease>
    <Pages>425-36</Pages>
    <Affiliation>Department of Occupational and Environmental Health Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI 48201, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12915133&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <Title>The Runx genes as dominant oncogenes.</Title>
    <Language>eng</Language>
    <Abstract>We have shown previously that Runx2 is a frequent target (approximately equal to 30%) for proviral insertion in murine leukemia virus (MLV) induced T cell tumors in CD2-MYC transgenic mice. Further investigation of a large panel of these tumors revealed that a small number also contain insertions at either Runx3 or Runx1. None of the tumors contained insertions at more than one family member, but in each case proviral insertion was associated with a high level of expression from the upstream (P1) promoter of the respective target gene. Moreover, we confirmed that transcriptional activation of Runx1 does not affect the integrity of the coding sequence, as previously observed for Runx2. These observations suggest that the three Runx genes act as functionally redundant oncogenes in T-cell lymphoma development. To explore the oncogenic potential of Runx2 further we created transgenic mice that over-express this gene in the T cell compartment. These CD2-Runx2 animals show a preneoplastic enlargement of the CD8 immature single positive (ISP) thymocyte pool and develop lymphomas at a low incidence. Although the CD8 ISP population is greatly increased, unlike their wild type counterparts these cells are largely non-cycling. Co-expression of c-MYC in this lineage accentuates the CD8 ISP skew and induces rapid tumor development, confirming the potent synergy that exists between these two oncogenes. Experiments designed to understand the nature of the observed synergy are ongoing and are based on the hypothesis that Runx2 may exert a survival effect in c-MYC expressing tumors in vivo while c-MYC may rescue cells from the antiproliferative effects of Runx2. The oncogenic potential of Runx1 is also being assessed using primary murine embryonic fibroblasts (MEFs). These studies have revealed that while Runx1 exerts a growth suppressive effect in wild type cells a growth promoting effect is seen in the absence of p53, suggesting that the Runx genes may harbor latent oncogene-like properties.</Abstract>
    <JournalRelease>1079-9796</JournalRelease>
    <Pages>194-200</Pages>
    <Affiliation>Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow Veterinary School, Glasgow G61 1QH, UK. E.R.Cameron@vet.gla.ac.uk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12732183&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12675508</PMID>
    <AuthorListID>79</AuthorListID>
    <Title>Medical management of hypopituitarism in patients with pituitary adenomas.</Title>
    <Language>eng</Language>
    <Abstract>Hypopituitarism is a disease complex with variable clinical manifestations. Recent studies have improved our understanding of its pathophysiology, particularly in patients with pituitary adenomas. In that setting, hypopituitarism was previously considered a permanent and irreversible process, requiring life-long hormone replacement therapy. While this could be true in some instances, recent data demonstrated recovery of pituitary function in a large number of patients with hypopituitarism following surgical decompression. Mechanical compression of portal vessels and the pituitary stalk, by the expanding adenoma was postulated to be the predominant mechanism causing hypopituitarism in this setting. Since portal vessels also provide blood supply to the anterior lobe, ischemic necrosis of portions of the pituitary can occur as a result of increased and prolonged compression by the expanding adenoma. Recent data demonstrated increases in intrasellar pressure (ISP) in patients with pituitary macroadenomas, particularly those with hypopituitarism. The data showed that ISP measurements correlated positively with the serum prolactin levels but not with tumor sizes. It is postulated that increased ISP has predominant role in the pathogenesis of hypopituitarism in patients with pituitary adenomas while. The increase in ISP results in decreased blood flow through the portal vessels and the pituitary stalk. The latter will result in diminished delivery of hypothalamic hormones to the anterior pituitary and may also cause ischemia and/or necrosis in some portions of the normal gland. Recovery of pituitary function can thus be anticipated after surgical decompression, in patients who have viable pituitary cells. Understanding the pathophysiology of hypopituitarism and recognizing the probability for recovery of function should be emphasized in the management of patients with this disease. An important aspect of the management is patients' education about their disease, including the use of medic alert identification. The managing physician should appreciate the variable clinical manifestations of the disease and the possible occurrence of other associated neuroendocrine, neurological and neuro-ophthalmologic signs and symptoms. Treatment of hypopituitarism should not be rigid but instead, always individualized. Management should take into consideration the patients' age, sex, education, original disease process and clinical history.</Abstract>
    <JournalRelease>1386-341X</JournalRelease>
    <Pages>109-17</Pages>
    <Affiliation>Division of Clinical and Molecular Endocrinology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106, USA. bxa@po.cwru.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12675508&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12648232</PMID>
    <AuthorListID>80</AuthorListID>
    <Title>De novo ceramide synthesis participates in the ultraviolet B irradiation-induced apoptosis in undifferentiated cultured human keratinocytes.</Title>
    <Language>eng</Language>
    <doi>10.1046/j.1523-1747.2003.12098.x</doi>
    <Abstract>Ultraviolet irradiation is a major environmental cause of skin cancers, whereas ultraviolet-induced DNA repair and apoptosis are defense mechanisms that rescue and/or protect keratinocytes from this risk. Multiple pathways are involved in ultraviolet-induced keratinocyte apoptosis, including activation of p38-mitogen-activated protein kinase, protein kinase C, and CD95, each of which are associated with caspase activation. Alternatively, ceramides could serve as ultraviolet-induced, second messenger lipids, because they induce cell cycle arrest and apoptosis in a variety of cell types, including keratinocytes. We investigated the role of ceramide versus caspase, and the responsible pathway for ceramide generation in ultraviolet B-induced apoptosis of cultured normal human keratinocytes maintained in low calcium (0.07 mm) medium. Ultraviolet B (40 mJ per cm2) significantly inhibited cultured normal human keratinocyte proliferation, assessed as [3H-methyl]thymidine-thymidine incorporation into DNA, 2 h after irradiation. Terminal nick deoxynucleotide end-labeling-positive apoptotic cells (14.8% at 24 h and 34.4% at 48 h) and trypan blue-positive apoptotic cells (8.4% at 24 h and 28.6% at 48 h) became evident in a time-dependent manner after ultraviolet B irradiation, in parallel with activation of caspase-3. The ceramide content of irradiated cultured normal human keratinocytes increased significantly by 8 h, whereas glucosylceramide only modestly increased, and sphingomyelin content remained unaltered. Metabolic studies with radiolabeled serine, palmitic acid, and phosphorylcholine revealed that the ultraviolet B-induced increase in ceramide results primarily from increased de novo synthesis rather than accelerated sphingomyelin hydrolysis. Increased ceramide synthesis, in turn, could be attributed to increased activity of ceramide synthase (i.e., 1.7-fold increase 8 h after ultraviolet B irradiation), whereas serine palmitoyltransferase activity did not change. Both fumonisin B1, an inhibitor of ceramide synthase, and ISP-1, myriocin an inhibitor of serine palmitoyltransferase, significantly attenuated the ultraviolet B-induced apoptosis in a caspase-3-independent fashion, whereas co-incubation with a caspase-3 inhibitor (Ac-DEVD-chloromethyl-ketone) further attenuated the ultraviolet B-induced apoptosis. Thus, increased de novo ceramide synthesis signals ultraviolet B-induced apoptosis, by a pathway independent of, but in concert with, caspase-3 activation.</Abstract>
    <JournalRelease>0022-202X</JournalRelease>
    <Pages>662-9</Pages>
    <Affiliation>Dermatology Service and Research Unit, Department of Veterans Affairs Medical Center, School of Medicine, University of California, San Francisco, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12648232&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12604687</PMID>
    <AuthorListID>81</AuthorListID>
    <Title>Isostrychnopentamine, an indolomonoterpenic alkaloid from Strychnos usambarensis, induces cell cycle arrest and apoptosis in human colon cancer cells.</Title>
    <Language>eng</Language>
    <doi>10.1124/jpet.102.044867</doi>
    <Abstract>Isostrychnopentamine (ISP) is an indolomonoterpenic alkaloid that is present in the leaves of Strychnos usambarensis, a well known African shrub or little tree. The roots contain quaternary alkaloids, which are used to make a curare-like arrow poison. However, tertiary alkaloids isolated from the same plant possess cytotoxic activities against mammalian cells and protozoa. The effect of ISP has been investigated on the growth and viability of HCT-116 colon cancer cells during their exponentially growing phase. ISP induced apoptotic cell death as shown by the translocation of phosphatidylserine from the inner layer to the outer layer of the plasma membrane, chromatin condensation, DNA fragmentation, and caspase-3 and -9 activation. ISP provoked also cell cycle arrest in the G(2)-M phase. We also showed that the expression of p53 was not modified in ISP-treated cells, but that p21 was induced in a p53-independent manner. Finally, we demonstrated that ISP did not affect the catalytic activity of human topoisomerases I and II. In conclusion, ISP, which promotes cell death by a p53-independent apoptotic pathway, could be an interesting lead for cancer chemotherapy.</Abstract>
    <JournalRelease>0022-3565</JournalRelease>
    <Pages>1103-10</Pages>
    <Affiliation>Natural and Synthetic Drug Research Center, Laboratory of Pharmacognosy and Structural Chemistry, University of Li챔ge, Li챔ge, Belgium. m.frederich@ulg.ac.be</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12604687&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12578840</PMID>
    <AuthorListID>82</AuthorListID>
    <Title>BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome.</Title>
    <PubDate>20030210</PubDate>
    <Language>eng</Language>
    <doi>10.1074/jbc.M210756200</doi>
    <Abstract>In this study, we describe an ordered formation of long- and very long-chain ceramide species in relation to the progression of B-cell receptor (BcR) triggering induced apoptosis. An early and caspase-independent increase in long-chain ceramide species, in which C(16)- ceramide predominated, was observed 6 h after BcR triggering. In contrast, very long-chain ceramide species were generated later, 12-24 h after BcR triggering. The formation of these very long-chain ceramide species, in which C(24)-ceramide predominated, required the activation of effector caspases. BcR-induced formation of long-chain ceramide species resulted in proteasomal activation and degradation of XIAP and subsequent activation of effector caspases, demonstrating an important cell-biological mechanism through which long-chain ceramides may be involved in the progression of BcR triggering induced apoptosis and subsequent formation of very long-chain ceramide species. BcR-induced activation of the proteasome was blocked with ISP-1/myriocin, a potent and selective inhibitor of serine palmitoyl transferase that catalyzes the first and rate-limiting step in the de novo formation of ceramide. Both ISP-1 and clasto-lactacystin beta-lactone, an irreversible inhibitor of the proteasome, prevented BcR cross-linking-induced XIAP degradation. Also, a mutant XIAP lacking the ubiquitin-ligating ring finger motif was completely resistant to proteasome-mediated degradation, and Ramos cells overexpressing XIAP became highly resistant to BcR cross-linking-induced activation of caspases. The formation of C(16)-ceramide in response to BcR cross-linking was found unaltered in XIAP overexpressing Ramos cells, whereas C(24)-ceramide formation was completely abolished. These results demonstrate how de novo generated long-chain ceramide species may be involved in the activation of downstream effector caspases and subsequent formation of very long-chain ceramide species. As such, these results provide novel and important insights into the significance of specific ceramide species in defined stages of apoptosis.</Abstract>
    <JournalRelease>0021-9258</JournalRelease>
    <Pages>14723-31</Pages>
    <Affiliation>Department of Pathology and Laboratory Medicine, Medical Biology branch, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. b.j.kroesen@thorax.azg.nl</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12578840&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12498721</PMID>
    <AuthorListID>83</AuthorListID>
    <Title>Linking Chinese medicine and G-protein-coupled receptors.</Title>
    <Language>eng</Language>
    <Abstract>Following the purification of the immunosuppressant ISP-1 from a Chinese medicine, Japanese scientists have developed a more potent immune modulator, FTY720, that induces T-cell homing. FTY720, a promising immunosuppressant for use in patients with tissue transplants and autoimmune diseases, is currently in clinical trials. Two recent studies have elucidated that the mechanism of action of FTY720 is via a subset of G-protein-coupled receptors for the lysophospholipid mediator sphingosine-1-phosphate.</Abstract>
    <JournalRelease>0165-6147</JournalRelease>
    <Pages>2-4</Pages>
    <Affiliation>Laboratory of Pharmacology, College of Pharmacy, Pusan National University, San 30, Chang-Jun-dong, Keum-Jung-gu, 609-735, Busan, South Korea. imds@pusan.ac.kr</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12498721&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12213223</PMID>
    <AuthorListID>84</AuthorListID>
    <Title>A role for the de novo sphingolipids in apoptosis of photosensitized cells.</Title>
    <Language>eng</Language>
    <Abstract>Sphingolipids have been implicated in apoptosis after various stress inducers. To assess the involvement of the de novo sphingolipid pathway in apoptosis, photodynamic therapy (PDT) with the photosensitizer Pc 4 was used as a novel stress inducer. Here we provide biochemical and genetic evidence of the role of the de novo sphingolipids in apoptosis post-Pc 4-PDT. In Jurkat cells PDT-induced intracellular sphinganine accumulation, DEVDase activation, PARP cleavage, and apoptosis were suppressed by the de novo sphingolipid synthesis inhibitor ISP-1 (Myriocin). Coincubation with sphinganine, sphingosine, or C16-ceramide specifically reversed the antiapoptotic actions of ISP-1 or the singlet oxygen scavenger L-histidine. PDT-induced cytochrome c release from mitochondria into the cytosol was inhibited by L-histidine, but not by ISP-1. Cotreatment with sphinganine did not reverse the inhibitory effect of L-histidine. In addition, PDT-induced sphinganine accumulation and apoptosis were ISP-1-sensitive in A431 human epidermoid and HT29 human carcinoma cells. Furthermore, in LY-B cells, CHO-derived mutants deficient in the de novo sphingolipid synthesis enzyme serine palmitoyltransferase (SPT) activity, DEVDase activation and apoptosis were delayed and suppressed post-PDT. Hence, the data are consistent with the partial involvement of the de novo sphingolipid pathway in apoptosis via DEVDase activation downstream of mitochondrial cytochrome c release post-Pc 4-PDT.</Abstract>
    <JournalRelease>0014-4827</JournalRelease>
    <Pages>153-65</Pages>
    <Affiliation>Department of Occupational and Environmental Health Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit Michigan 48201, USA.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12213223&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>12069821</PMID>
    <AuthorListID>85</AuthorListID>
    <Title>Sphingolipids involved in the induction of multinuclear cell formation.</Title>
    <Language>eng</Language>
    <Abstract>In this review, we focus on sphingolipids as potential regulators of the induction of multinuclear cell formation through the inhibition of cytokinesis. A sphingolipid, psychosine (Psy) (galactosylsphingosine), was demonstrated to be a trigger lipid for the inhibition of cytokinesis and the induction of multinuclear giant cells associated with a sphingolipid metabolic disease, globoid cell leukodystrophy (GLD). Indeed, Psy is known to accumulate in the patients' brains. Interestingly, inhibition of sphingolipid biosynthesis also induced multinuclear cells. When cells were treated with a new immunosuppressant, ISP-1/myriocin, which inhibits serine palmitoyltransferase, the first step enzyme of sphingolipid biosynthesis, the cells underwent multinucleation and apoptosis. At present, a definitive model of the function of sphingolipids as to the induction of multinuclear cell formation is not available due to the rudimentary information but possible mechanisms are discussed.</Abstract>
    <JournalRelease>0006-3002</JournalRelease>
    <Pages>138-43</Pages>
    <Affiliation>Laboratory of Membrane Biochemistry and Biophysics, Graduate School of Biostudies, Kyoto University, Kyoto, Japan. yasu@pharm.kyoto-u.ac.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=12069821&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>11942050</PMID>
    <AuthorListID>86</AuthorListID>
    <Title>"In situ preparation": new surgical procedure indicated for soft-tissue sarcoma of a lower limb in close proximity to major neurovascular structures.</Title>
    <Language>eng</Language>
    <doi>10.1007/s101470200006</doi>
    <Abstract>When soft-tissue sarcomas occur near neurovascular structures, preoperative images cannot always reveal the accurate relationship between the tumor and these structures. Therefore, in some patients, neurovascular structures are sacrificed unnecessarily. In other patients, neurovascular structures are preserved with an inappropriate margin, followed by local recurrence. The objective of this study was to evaluate a new surgical method, "in situ preparation" (ISP), which enables the preparation of neurovascular bundles and the intraoperative evaluation of the surgical margin without contamination by tumor cells. With this method, additional procedures, including pasteurization, alcohol soaking, and distilled water soaking of the preserved neurovascular bundle can also be performed to preserve the continuity of vessels.Between April 1992 and December 1998, 18 patients with soft-tissue sarcoma were operated on using ISP. The tumor and neurovascular structure were lifted en bloc from the surgical bed and separated from the field by the use of a vinyl sheet. The consistency of the neurovascular structures was preserved. The tissue block could be freely turned around and the neurovascular structure was separated from the block through the nearest approach. The margin between the tumor and neurovascular structure was evaluated, and an additional procedure, such as pasteurization, alcohol soaking or distilled water soaking, was performed, according to the safety of the surgical margin.Only one patient showed recurrence after ISP. Complications after ISP were arterial occlusion in two patients and nerve palsy in three patients. The main cause of these complications was the long period of pasteurization; modified additional procedures could prevent such complications.ISP is a useful method with which to ensure a safe surgical margin and good functional results.</Abstract>
    <JournalRelease>1341-9625</JournalRelease>
    <Pages>51-6</Pages>
    <Affiliation>Cancer Institute Hospital, Department of Orthopedic Surgery, 1-37-1 Kami-ikebukuro, Toshima-ku, Tokyo 170-0012, Japan. smatsumoto@jfcr.or.jp</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=11942050&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>11856628</PMID>
    <AuthorListID>87</AuthorListID>
    <Title>Human masseter inhibitory reflexes evoked by repetitive electrical stimulation.</Title>
    <Language>eng</Language>
    <Abstract>The relationship between the masseter inhibitory reflex (MIR) and nociceptive processing in the trigeminal region was studied in 10 healthy subjects. Based on the known increase in perceived sensory intensity following repetitive stimulation of the nociceptive system, we examined the hypothesis that the MIR reflects noxious activity in the trigeminal system by determining the possible relation between changes in MIR and perceived sensory intensity.The MIR was quantitated and compared with psychophysical measures following repetitive peri-oral electrical stimulation (5 square wave pulses of 0.5ms repeated at 2Hz). In addition to the early (ES1) and late (ES2) periods of exteroceptive suppression, two periods with apparent excitation could be distinguished from the background electromyografical activity: (a) the inter-suppression period (ISP) between the ES1 and the ES2, and (b) the post-suppression period (PSP) after the ES2. A computer algorithm was used to detect and quantitate ES1, ES2, ISP, and PSP. The response variables were (a) onset latencies and (b) magnitudes of suppression (ES1 and ES2) and excitation (ISP and PSP).Consistent reduction of the magnitude of ES2 suppression in response to repetitive stimuli was observed below as well as above the pain detection threshold.The observed reduction of the magnitude of ES2 suppression is not specifically related to nociceptive processing. Habituation or net inhibitory effects on inhibitory pre-motor neurones (i.e. disinhibition) are possible mechanisms for the observed reduction of the magnitude of ES2 suppression after repetitive stimulation.</Abstract>
    <JournalRelease>1388-2457</JournalRelease>
    <Pages>236-42</Pages>
    <Affiliation>Danish Pain Research Center and Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. orm@dadlnet.dk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=11856628&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>11709184</PMID>
    <AuthorListID>88</AuthorListID>
    <Title>Mitochondrial electron transport is a key determinant of life span in Caenorhabditis elegans.</Title>
    <Language>eng</Language>
    <Abstract>Increased protection from reactive oxygen species (ROS) is believed to increase life span. However, it has not been clearly demonstrated that endogenous ROS production actually limits normal life span. We have identified a mutation in the Caenorhabditis elegans iron sulfur protein (isp-1) of mitochondrial complex III, which results in low oxygen consumption, decreased sensitivity to ROS, and increased life span. Furthermore, combining isp-1(qm150) with a mutation (daf-2) that increases resistance to ROS does not result in any significant further increase in adult life span. These findings indicate that both isp-1 and daf-2 mutations increase life span by lowering oxidative stress and result in the maximum life span increase that can be produced in this way.</Abstract>
    <JournalRelease>1534-5807</JournalRelease>
    <Pages>633-44</Pages>
    <Affiliation>Department of Biology, McGill University, 1205 Avenue Dr Penfield, H3A 1B1, Montr챕al, Qu챕bec, Canada.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=11709184&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>11440778</PMID>
    <AuthorListID>89</AuthorListID>
    <Title>Lectins in fruits having gastrointestinal activity: their participation in the hemagglutinating property of Escherichia coli O157:H7.</Title>
    <Language>eng</Language>
    <Abstract>In fruits with therapeutic properties for antidiarrheal and laxative uses, the presence of lectins may be the bioactive properties that interfere with bacterial adhesion, thought to be competition for glycoside signal sites in the attachment.This study identifies lectins in crude extracts from fruits such as Tamarindus indica (tamarind), Spontia vulgaris (plum), Psidium guava (guava), Mangifera indica (mango), Cydonia vulgaris (quince), and Crataegus mexicanus (tejocote). To verify the procedures, extracts from Ricinus communis (castor bean), Glycine max (soybean), Phaseolus vulgaris (beans), Vicia fava (fava bean), and Solanum tuberosum (potato) were used as controls for lectin activity. Both sources of lectins were analyzed to determine their participation in the host-parasite interaction, using as a model the hemagglutinating properties of Escherichia coli O157:H7 (EHA).All extracts showed hemagglutination to group O erythrocytes test (HA) with the exception of mango. Two new galactose-specific lectins were identified from tamarind and guava. When analyzed for participation in EHA, only guava lectins inhibited this, while soybean lectin induced hemolysis; as both lectins bind to galactose, it is probable that their recognition occurs in different domains. Sugars involved in the attachment between Escherichia coli O157:H7 and red cells were identified and again, galactose in addition to mannose was found to be related in EHA. On the other hand, guava lectins also agglutinated E. coli O157:H7, perhaps due to the same galactose-specific lectin or to another type of lectin.In summary, guava has a galactose-specific lectin that prevents adhesion of E. coli O157:H7 to red cells; this lectin is mediated by galactose. Prevention could also be due to their capacity of agglutinating E. coli by guava lectins. Soybean lectin induced hemolysis only when bacteria was present, but not with floating secretions. This finding showed that guava is a source of lectin that can be explored to prevent adhesion of E. coli to epithelial intestinal cells; contrariwise, soya must be studied to see its participation in the uremia caused during E. coli O157:H7 pathogenesis.</Abstract>
    <JournalRelease>0188-4409</JournalRelease>
    <Pages>251-7</Pages>
    <Affiliation>Laboratorio de Salud y Ecolog챠a, Instituto de Salud P첬blica, Universidad Veracruzana, Xalapa, Veracruz, Mexico. rocio@aladino.isp.uv.mx</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=11440778&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>11208198</PMID>
    <AuthorListID>90</AuthorListID>
    <Title>An endosseous, implant-retained obturator for the rehabilitation of a recurrent central giant cell granuloma: a clinical report.</Title>
    <Language>eng</Language>
    <doi>10.1067/mpr.2001.113213</doi>
    <Abstract>The prosthodontic rehabilitation of a patient with a recurrent maxillary CGCG has been described. The patient's immense defect originally was rehabilitated with a scapular microvascular free flap, endosseous dental implants, and an ISP that became obsolete by virtue of the resection of recurrent disease and the subsequent need for velopharyngeal obturation. The patient was provided with a surgical obturator at the time of the resection of the recurrent CGCG. The surgical obturator thereafter was modified into an interim obturator to provide velopharyngeal competence while the soft tissues around the palatal defect healed. Finally, the construction of a bar-retained definitive obturator markedly improved the patient's speech, mastication, and deglutition.</Abstract>
    <JournalRelease>0022-3913</JournalRelease>
    <Pages>116-20</Pages>
    <Affiliation>Department of Hospitl Dentistry, Division of Maxillofacial Prosthetics, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242-1049, USA. jeffery-markt@uiowa.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=11208198&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>10924327</PMID>
    <AuthorListID>91</AuthorListID>
    <Title>Imipramine inhibits Cl(-) secretion by desensitization of beta-adrenergic receptors in calu-3 human airway cells.</Title>
    <Language>eng</Language>
    <doi>10.1006/bbrc.2000.3202</doi>
    <Abstract>Recent investigations have found that tetracyclic antidepressants like imipramine (IMP) have high-affinity sites not only in brain but also in mammalian lung. In the present study, we examined the effects of IMP on the Cl(-) secretion produced by isoproterenol (ISP), a beta-adrenergic receptor (beta-AR) agonist, in Calu-3 human airway cells. ISP applied in the basolateral solution generated a sustained short-circuit current that was abolished by diphenylamine-2-carboxylate, a Cl(-) channel blocker. IMP (0.01-1 mM) applied in the apical or basolateral solution for 30 min significantly inhibited the ISP-induced responses in a concentration-dependent manner, and the inhibitory effects of this drug were remarkable when applied from the apical rather than the basolateral side. ISP-induced responses were mimicked by forskolin- and 8-bromo-cyclic AMP-induced ones, but which were insensitive to IMP. These results indicate that IMP desensitizes the beta-AR on the basolateral membrane from the cytosolic side in Calu-3 cells.Copyright 2000 Academic Press.</Abstract>
    <JournalRelease>0006-291X</JournalRelease>
    <Pages>620-5</Pages>
    <Affiliation>Second Division (Respiratory Division), First Department of Physiology, School of Medicine, Nagoya University, Tsurumai-cho, Showa-ku, Nagoya, 466, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=10924327&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>10886724</PMID>
    <AuthorListID>92</AuthorListID>
    <Title>Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat.</Title>
    <Language>eng</Language>
    <Abstract>S-100 proteins (S100) are characterized by calcium-binding ability with two structural EF hands. Several S100 are expressed in cardiomyocytes and thought to play a crucial role in calcium signaling. To examine whether the expression of S100 is a response to detectable myocardial damage or regeneration, we investigated, immunohistochemically, the expression of S100A4 and S100A11 in the isoproterenol (ISP)-treated rat heart. Definite expression of S100A4 and S100A11 was demonstrated in normal cardiomyocytes, and their staining patterns were enhanced in the ISP-treated rat heart, suggesting the possible involvement of S1-A4 and S100A11 in ISP-induced myocardial damage.</Abstract>
    <JournalRelease>1320-5463</JournalRelease>
    <Pages>480-5</Pages>
    <Affiliation>The Second Department of Pathology, andThe First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=10886724&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <Title>Mucosal projections of enteric neurons in the porcine small intestine.</Title>
    <Language>eng</Language>
    <Abstract>In the present study, a combination of immunohistochemistry and retrograde 1,1;-didodecyl-3,3,3;,3;-tetramethylindocarbocyanine perchlorate (DiI) tracing was used to unravel the morphology, distribution, and neurochemical coding of submucous and myenteric neurons with axonal projections to the mucosa of the porcine small intestine. The majority of traced neurons was located in the inner submucous plexus (ISP; 78%), whereas the remaining part was distributed between the outer submucous plexus (OSP; 10%) and myenteric plexus (MP; 12%). Among these traced neurons, some distinct neuronal populations could be distinguished according to their morphologic and neurochemical properties. In the ISP, several types of traced neurons were detected: 1) morphologic type II neurons expressing choline acetyltransferase (ChAT) immunoreactivity, calcitonin gene-related peptide (CGRP) immunoreactivity, and substance P (SP) immunoreactivity; 2) ChAT/SP-immunoreactive (-IR) small neurons; 3) vasoactive intestinal polypeptide (VIP) -IR small neurons; and 4) multidendritic ChAT/somatostatin (SOM) -IR neurons. The traced neuronal populations of the OSP and MP were similar to each other. In both plexuses, the following DiI-labelled neurons were found: 1) ChAT/CGRP/(SP)-IR type II neurons; 2) multidendritic ChAT/SP-IR neurons; and 3) multidendritic ChAT/SOM-IR neurons. Comparison of the present findings with previously obtained data concerning the mucosal innervation pattern of the intestine of small mammals, revealed significant species differences with respect to the morphologic and neurochemical features of the involved enteric neuronal classes. Although not identical, a closer resemblance between pig and human enteric nervous system seems to be at hand, as far as the anatomic organization and the presence of neurochemically identified neuronal subtypes within the enteric nervous system are concerned.Copyright 2000 Wiley-Liss, Inc.</Abstract>
    <JournalRelease>0021-9967</JournalRelease>
    <Pages>429-36</Pages>
    <Affiliation>Laboratory of Cell Biology and Histology, University of Antwerp, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=10813797&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>10461730</PMID>
    <AuthorListID>94</AuthorListID>
    <Title>Transient poration and cell surface receptor removal from human lymphocytes in vitro by 1 MHz ultrasound.</Title>
    <Language>eng</Language>
    <Abstract>The study objective was to gain insight into ultrasound-induced, sub-lytic cell surface modifications. Two primary hypotheses were tested by flow cytometric methods; viz., sonication will: 1. remove all or part of a specific cell surface marker in lymphocytes surviving insonation, and 2. induce transient pores in the cell membranes of some surviving cells. RPMI 1788 human lymphocytes were exposed in vitro to 1-MHz, continuous-wave ultrasound (approximately 8 W/cm2 ISP) for 30 s, which lysed approximately 50% of the cells. Insonation: 1. altered cell morphology, increasing the population of cells of reduced size but high structure (designated as population R2), many of which were nonviable, and diminishing the population of cells of large size and high structure (designated as population R1), most of which were viable, 2. diminished the fluorescence signal from the pan B lymphocyte marker CD19 in populations R1 and R2 to equivalent extents, and 3. increased by approximately 7-fold the number of transiently permeabilized cells in R1, as evidenced by simultaneous uptake of propidium iodide and fluorescein diacetate. The results indicate that ultrasound-induced CD19 removal from R1 cells can occur without accompanying gross membrane loss. The cell morphology/mortality shifts indicate that the ultrasound-induced morphological change is associated with lethal membrane poration, suggesting that the diminished CD19 fluorescence signal from insonated R2 cells arises partly by simultaneous loss of membrane fragments, CD19 and cytoplasm.</Abstract>
    <JournalRelease>0301-5629</JournalRelease>
    <Pages>999-1008</Pages>
    <Affiliation>Department of Obstetrics and Gynecology, School of Medicine and Dentistry, University of Rochester, NY 14642, USA. andrew_brayman@urmc.rochester.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=10461730&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <Title>Preliminary results of a phase I dose escalation clinical trial using focused ultrasound in the treatment of localised tumours.</Title>
    <Language>eng</Language>
    <Abstract>The primary aim of this phase I trial was to assess the tolerance of cancer patients to focused ultrasound (FUS) treatment in a variety of different sites and to document any associated acute or delayed toxicity. This would appear to be the first time that treatment has been given without sedation or anaesthesia.Patients with advanced and/or metastatic disease were eligible for entry into this study. Previous work has established that an in situ ablative intensity (AI) of 1500 W/cm2 Isp for 1 s achieves coagulative necrosis at the focal spot. Ultrasonic exposures of 25-100% of AI for 1 s were delivered to preselected tissue volumes. Pain questionnaires recording any side effects were completed by the patient and the investigator separately. Ultrasound images of the target volume were taken before, immediately after, and 1 week after treatment.A total of 14 patients have been entered into this study to date. Seven patients were treated at their primary site and seven received treatment to one of their metastases. No treatment needed to be stopped because of pain. Eight of the 14 patients did not complain of any side effect during or after the treatment. One patient complained of mild, and two of moderate pain during the week following treatment. One patient developed an asymptomatic blister on the skin.Focused ultrasound is a safe, well-tolerated and non-invasive method of delivering ablative thermal energy to selected tumours. More clinical trials are needed to assess the role of this modality in the treatment of cancer.</Abstract>
    <JournalRelease>0929-8266</JournalRelease>
    <Pages>11-8</Pages>
    <Affiliation>Joint Department of Physics, Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK. a.visioli@icr.ac.uk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=10099162&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>9782161</PMID>
    <AuthorListID>96</AuthorListID>
    <Title>Differential modulation of the phases of a Ca2+ spike by the store Ca2+-ATPase in human umbilical vein endothelial cells.</Title>
    <Language>eng</Language>
    <Abstract>1. Histamine-stimulated cytosolic free Ca2+ ([Ca2+]i) oscillations in human umbilical vein endothelial cells (HUVECs) comprise repetitive spikes generated by pulsatile release from stores. We have investigated the roles of the store Ca2+-ATPases in regulating both the upstroke and downstroke of a Ca2+ spike. 2. The sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor cyclopiazonic acid (CPA) dramatically affected oscillations whereas inhibition of the plasma membrane Ca2+-ATPase (PMCA) with La3+ had little effect. This and other evidence suggested that the downstroke of a spike is predominantly mediated by SERCA. 3. Artificial [Ca2+]i spiking generated by repetitive pulsatile application of 0.3 microM histamine in Ca2+-free medium did not cause net loss of Ca2+ from the cell whereas repetitive pulsatile application of 1 and 10 microM histamine did, with the higher concentration being more effective. We conclude that there is an inverse relationship between stimulus intensity and relative SERCA activity. 4. For a Ca2+ transient, the initiation of release was suppressed by SERCA during either the lag phase or the interspike period (ISP) since: (i) the ISP was shortened by low CPA concentrations, (ii) higher concentrations of CPA stimulated an explosive Ca2+ release when applied during the ISP but not when applied in the absence of agonist, and (iii) CPA synchronized the initial Ca2+ response to a low histamine dose (even recruiting silent, histamine-unresponsive cells). 5. Two aspects of the regenerative upstroke of a spike were differently affected by SERCA inhibition: Ca2+ wave velocity was entirely unaffected by CPA whereas the local rate of rise was increased. 6. The [Ca2+]i at which a Ca2+ spike terminated depended on SERCA since CPA dose dependently enhanced the peak [Ca2+]i. 7. We conclude that SERCA plays a powerful and dynamic role in regulating [Ca2+]i oscillations in HUVECs. SERCA differentially modulates the phases of Ca2+ release in addition to bringing about the falling phase of a Ca2+ spike.</Abstract>
    <JournalRelease>0022-3751</JournalRelease>
    <Pages>83-101</Pages>
    <Affiliation>Vascular Biology Research Centre, Physiology Group, Biomedical Sciences Division, King's College London, London W8 7AH, UK. anthony.morgan@kcl.ac.uk</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=9782161&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>9698100</PMID>
    <AuthorListID>97</AuthorListID>
    <Title>Down modulation of MHC surface molecules on B cells by suppressive immune complexes obtained from chronic intestinal schistosomiasis patients.</Title>
    <Language>eng</Language>
    <Abstract>Granulomatous inflammation around parasite eggs is the prominent lesion in human schistosomiasis. Studies have suggested the involvement of a series of suppressive mechanisms in the control of this reaction, such as macrophages, cytokines, idiotypic interactions and immune complexes (IC). The studies examine the role of IC obtained from chronic intestinal schistosomiasis patients (ISP) in the reactivity of peripheral blood mononuclear cells (PBMC). The results have shown that these immune complexes are able to suppress cell reactivity by inducing an increase in the production of soluble mediators such as prostaglandins and IL-10. To gain a better understanding of how this suppression occurs the present study examines the phenotypic pattern of PBMC after immune complex treatment in cell proliferation assays. These data show that cultures including immune complex present a higher percentage of B lymphocytes in which a lower expression of a MHC-class II gene product, HLA-DR was detected. This altered expression of the HLA-DR molecule on B lymphocytes after IC treatment suggests a novel mechanism for the suppression observed, that is, IC might decrease the antigen-presenting function of B lymphocytes.</Abstract>
    <JournalRelease>0165-2478</JournalRelease>
    <Pages>67-73</Pages>
    <Affiliation>Departamento de Bioqu챠mica-Immunologia, Instituto de Ci챗ncias Biol처gicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=9698100&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>9562860</PMID>
    <AuthorListID>98</AuthorListID>
    <Title>A common immunological epitope existing between HIV-1 gp41 and human interferon-alpha and -beta.</Title>
    <Language>eng</Language>
    <Abstract>Based on the similar effects that HIV-1 gp41 like human type I interferons (IFN-alpha and -beta) upregulated MHC expression and inhibited lymphocyte proliferation, we compared amino acid sequences of gp41 and human type I interferons (IFN-alpha and -beta), and found sequence-similarity existing between the immunosuppressive domain (aa583-599, LQARILAVERYLKDQQL) of HIV-1 gp41 and human IFN-alpha (region aa117-129) and IFN-beta (region aa128-134); besides, the immunosuppressive domain of HIV-1 gp41 shows sequence-homology with bovine and murine IFN-alpha and IFN-beta in the same region. We examined polyclonal antibodies to human IFN-alpha and IFN-beta respectively and found that both antibodies could recognize rsgp41 from two different sources. The polyclonal antibody to IFN-beta could bind to the immunosuppressive peptide (ISP, aa583-599, LQARILAVERYLKDQQL) of HIV-1 gp41, only when the ISP was coupled with carrier-protein, and inhibit, if preincubated with rsgp41, binding of rsgp41 to human H9 (T cells), Raji (B cells), and U937 (monocyte cells) completely. The polyclonal antibody to IFN-alpha could partially inhibit the binding of rsgp41 to U937 and Raji. These results indicate that a common immunological epitope exists between HIV-1 gp41 and human type I interferons.</Abstract>
    <JournalRelease>0171-2985</JournalRelease>
    <Pages>333-42</Pages>
    <Affiliation>Department of Biological Science and Biotechnology, Tsinghua University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=9562860&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>9473533</PMID>
    <AuthorListID>99</AuthorListID>
    <Title>Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases.</Title>
    <Language>eng</Language>
    <doi>10.1006/taap.1997.8356</doi>
    <Abstract>Fumonisin B1 (FB1) and aminopentol (AP1) (which is formed by hydrolysis of FB1) are found in corn contaminated with some strains of Fusarium moniliforme. Incubation of HT29 cells (a human colonic cell line) with FB1 or AP1 caused a significant reduction in cell number; AP1 was less potent, with 50 microM AP1 causing the same reduction (ca. 30% after 24 h) as 10 microM FB1. The reduction in cell number reflected increases in DNA fragmentation and the percentage of apoptotic cells. Both FB1 and AP1 caused the accumulation of sphinganine (25- and 35-fold by 10 microM FB1 and 50 microM AP1, respectively); thus, concentrations of FB1 and AP1 that caused comparable reductions in cell number were also similar with respect to elevation of sphinganine, a compound that is growth inhibitory and cytotoxic. Inhibition of the first step of sphingolipid biosynthesis with ISP-1 prevented the elevation in sphinganine, DNA fragmentation, and apoptosis induced by FB1. Therefore, these effects of FB1 on HT29 cells can be attributed to the accumulation of sphinganine. Since consumption of food contaminated with Fusarium moniliforme (Sheldon) exposes colonic cells to these mycotoxins, the possibility that FB1 and AP1 are toxic for intestinal cells in vivo should be evaluated, especially in the light of the recent report (Bhat et al., Clin. Toxicol. 35, 249, 1997) describing intestinal disturbances in humans after consumption of moldy corn and sorghum containing fumonisins.Copyright 1998 Academic Press.</Abstract>
    <JournalRelease>0041-008X</JournalRelease>
    <Pages>252-60</Pages>
    <Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322-3050, USA. eschmel@emory.edu</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=9473533&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>9373217</PMID>
    <AuthorListID>100</AuthorListID>
    <Title>The immunosuppressive peptide of HIV-1 gp41 like human type I interferons up-regulates MHC class I expression on H9 and U937 cells.</Title>
    <Language>eng</Language>
    <Abstract>Based on our findings that the immunosuppressive peptide (ISP, amino acids (aa) 583-599) of human immunodeficiency virus type 1 (HIV-1) gp41 shows sequence-similarity with human type I interferons (IFN-alpha and IFN-beta) and HIV-1 soluble gp41 (sgp41, aa 539-684) enhanced cell surface expression of major histocompatibility complex (MHC) class I molecule on human H9 (T cells), Raji (B cells) and U937 (monocytic cells) cells, we examined the effect of HIV-1 immunosuppressive peptide on the surface expression of MHC class I molecules on H9 and U937 cells. Flow cytometry analysis demonstrated that ISP-BSA (conjugate) could enhance MHC class I expression by about 40% on H9 cells and by about 45% on U937 cells, while monomer ISP (not conjugated) and EDCI-treated carrier protein (BSA-EDCI) did not increase the expression. By comparison, human type I interferons, IFN-alpha and IFN-beta, showed similar effects (enhanced the expression by about 40-60%) to ISP-BSA on the MHC class I expression on H9 and U937 cells. The results suggest that HIV-1 gp41 in a polymerized form by its immunosuppressive domain upregulates human MHC class I expression. The basis for this similar effect of HIV-1 gp41 and IFN-alpha and -beta, i.e. upregulation of MHC class I molecule expression, may be based on the sequence-similarity between these otherwise different molecules.</Abstract>
    <JournalRelease>0165-2478</JournalRelease>
    <Pages>93-7</Pages>
    <Affiliation>Department of Biological Science and Biotechnology, Tsinghua University, Beijing, China.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=9373217&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>7844457</PMID>
    <AuthorListID>101</AuthorListID>
    <Title>[The mechanism of beta-receptor desensitization in human myometrial culture cell].</Title>
    <Language>jpn</Language>
    <Abstract>Beta-adrenoceptor desensitization is considered to be primarily due to phosphorylation of receptors by protein kinase A (PKA) and beta-adrenaline receptor kinase (beta-ARK) and sequestration of receptors themselves. But in the human uterine muscle, the desensitization mechanism has been evaluated only as a phenomenon, and there are few studies on its mechanism. We evaluated cAMP production by beta-agonist and changes in the number of beta-receptors in cultured human myometrial cells. Uterine muscle cell were obtained from patients with benign disease before menopause and cultured. 1) At the confluent stage, dl-Isoproterenol Hydrochloride (ISP) was added under various conditions, and the intracellular cAMP concentration was determined by EIA. 2) After the addition of ISP (10(-6) M), plates were incubated at 37 degrees C, and beta-AR on the cell membrane surface (S beta-AR) and total beta-AR (T beta-AR) was measured in a binding assay with 125I-pindolol. The production of cAMP dose-dependently increased 30 minutes after the addition of ISP at 10(-6) M or higher, but rapidly decreased thereafter. T beta-AR was similar in the cells treated with ISP (10(-6) M) and the untreated cells. On the other hand, S beta-AR decreased by about 50% in the ISP treated cells. These result suggest the desensitization of beta-AR in human uterine muscle, and the involvement of the sequestration mechanism as its cause.</Abstract>
    <JournalRelease>0300-9165</JournalRelease>
    <Pages>7-13</Pages>
    <Affiliation>Department of Obstetrics and Gynecology, Nara Medical University.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=7844457&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>7752809</PMID>
    <AuthorListID>102</AuthorListID>
    <Title>Beta-adrenergic receptor-mediated calcium mobilization in the human Jurkat T cell line.</Title>
    <Language>eng</Language>
    <Abstract>The regulation of Ca2+ mobilization by beta-adrenergic receptor in the human Jurkat T cell line was investigated. Jurkat cells had a single class of beta-adrenergic receptor binding sites. Isoproterenol (ISP) caused the increase in cytosolic free Ca2+ concentration ([Ca2+]i) in a dose-dependent manner. In the absence of extracellular Ca2+, the pretreatment with OKT3, an anti-CD3 antibody, did not affect a transient increase in [Ca2+]i induced by the subsequent addition of ISP, and vice versa. On the other hand, the pretreatment with thapsigargin abolished the response of [Ca2+]i to the subsequent additions of ISP and OKT3. In permeabilized Jurkat cells, the addition of cAMP released Ca2+ from the intracellular Ca2+ pool. Neither nimodipine nor H8, a protein kinase A inhibitor, affected the increase in [Ca2+]i induced by ISP. The results suggest that cAMP accumulated by the activation of beta-adrenergic receptor may directly release Ca2+ from the inositol trisphosphate-insensitive intracellular Ca2+ pool in Jurkat T cells.</Abstract>
    <JournalRelease>0024-3205</JournalRelease>
    <Pages>1443-54</Pages>
    <Affiliation>Department of Pharmacology, School of Medicine, Sapporo Medical University, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=7752809&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>7933530</PMID>
    <AuthorListID>103</AuthorListID>
    <Title>[Bactericidal activities of isepamicin and ofloxacin against Pseudomonas aeruginosa evaluated using an in vitro pharmacokinetic simulation system].</Title>
    <Language>jpn</Language>
    <Abstract>Bactericidal activities of isepamicin and ofloxacin against Pseudomonas aeruginosa E7 were examined using an in vitro computer programmed pharmacokinetic simulation system. Concentration of the drugs simulated the pharmacokinetic data obtained in healthy human adult subjects after 200 mg or 400 mg I.M. administration of isepamicin (ISP), and 300 mg P.O. administration of ofloxacin (OFLX). P. aeruginosa cell counts were depressed by ISP or OFLX to -4 log -(-)5 log levels of magnitude below the initial cell counts. The time required in recovery of cell counts to the initial level after treatment with ISP (200 mg) was longer than that after OFLX (300 mg) treatment. An excellent synergistic effect was observed between ISP and OFLX.</Abstract>
    <JournalRelease>0368-2781</JournalRelease>
    <Pages>1006-12</Pages>
    <Affiliation>Department of Microbiology, Toho University School of Medicine.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=7933530&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <Title>Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite.</Title>
    <Language>eng</Language>
    <Abstract>A potent immunosuppressive activity was found in the culture broth of the fungus Isaria sinclairii (ATCC 24400). The metabolite, ISP-I ((2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2- hydroxymethyl-14-oxoeicos-6-enoic acid, myriocin = thermozymocidin) suppressed the proliferation of lymphocytes in mouse allogeneic mixed lymphocyte reaction, but had no effect on the growth of human tumor cell lines. It also suppressed the appearance of plaque-forming cells in response to sheep red blood cells and the generation of allo-reactive cytotoxic T lymphocytes in mice after intraperitoneal or oral administration. The metabolite was 10- to 100-fold more potent than cyclosporin A as an immunosuppressive agent of the immune response in vitro and in vivo, and appears to be a candidate for clinical application as a powerful immunosuppressant.</Abstract>
    <JournalRelease>0021-8820</JournalRelease>
    <Pages>208-15</Pages>
    <Affiliation>Faculty of Pharmaceutical Sciences, Kyoto University, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=8150717&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <Title>Surfactant apoprotein A secretion by human tracheobronchial epithelial cells.</Title>
    <Language>eng</Language>
    <Abstract>To determine whether surfactant apoproteins are produced locally by the airway walls, we used a two-site simultaneous immunoassay with monoclonal antibodies and measured the surfactant apoprotein-A (SP-A) content in media cultured with human airway explants or cultured epithelial cells. Tracheobronchial explants were cultured for 2 successive periods (periods I and II). Significant SP-A concentrations were detected in both periods. Methacholine (MCh) or isoproterenol (ISP), added to the medium at the beginning of period II, reduced the ratio of SP-A concentration in period II to that in period I, compared to samples without treatment. The SP-A concentration in the medium at the confluent period of cultured epithelial cells was significantly higher than at the mid-period, indicating that SP-A secretion is dependent on the cell number. The supernatant from explants stimulated by MCh was capable of reducing SP-A secretion from cultured epithelial cells. Immunohistochemical study of SP-A using monoclonal antibody demonstrated positive immunoperoxidase staining in the cytoplasm of epithelial cells. Further, Western blots of electrophoresed proteins from epithelial cells showed the characteristic properties of SP-A. These findings indicate that tracheobronchial epithelium can secrete SP-A.</Abstract>
    <JournalRelease>0034-5687</JournalRelease>
    <Pages>239-51</Pages>
    <Affiliation>First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=8351444&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>8097745</PMID>
    <AuthorListID>106</AuthorListID>
    <Title>Secretion of alpha-amylase in human parotid gland epithelial cell culture.</Title>
    <Language>eng</Language>
    <doi>10.1002/jcp.1041550202</doi>
    <Abstract>The secretions of the salivary gland system are essential for the maintenance of oral health. The nature of cell-specific secretions of the various glands and their regulation is not completely understood. The objective of this study was to establish epithelial cell cultures from the human parotid gland that exhibit the tissue-specific function of alpha-amylase secretion. A specimen of normal human parotid gland was obtained at surgery and used to obtain primary cultures by the explant/outgrowth procedure. The cultures were maintained in keratinocyte basal medium, supplemented with insulin (5 micrograms/ml), EGF (10 ng/ml), hydrocortisone (0.5 micrograms/ml), bovine pituitary extract (25 micrograms/ml), and antibiotics. The cultures were passaged using 0.125% trypsin to dissociate the cells. Phase contrast and ultrastructural observations showed that the cells were polygonal and exhibited desmosomes. Their cytoplasm contained tonofilament bundles and abundant rough endoplasmic reticulum and Golgi complexes. Immunofluorescence studies showed that all cells were positive for cytokeratins. Immunoblot analysis revealed keratins with molecular weights of 58, 56, 52, 50, 48, 46, and 40 KD, which are characteristic of secretory epithelia. The cells have been passaged 35 times so far, undergoing a cumulative 120-140 population doublings. The serially passaged epithelial cell cultures produced and secreted alpha-amylase, a major component of parotid gland acinar cell secretion. The beta-adrenergic agonist, isoproterenol (ISP), stimulated alpha-amylase secretion, which was accompanied by increased intracellular concentrations of cAMP. ISP-induced stimulation of amylase and cAMP was blocked by the beta-adrenergic antagonist, propranolol. Further, dibutyryl cAMP also enhanced the secretion of amylase. Thus we have established a long-term epithelial cell culture model of human parotid gland epithelial cells that exhibits differentiated function and retains the intact beta-adrenergic receptor system.</Abstract>
    <JournalRelease>0021-9541</JournalRelease>
    <Pages>223-33</Pages>
    <Affiliation>Institute of Chemical Toxicology, Wayne State University, Detroit, Michigan 48201.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=8097745&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>1316462</PMID>
    <AuthorListID>107</AuthorListID>
    <Title>Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association.</Title>
    <Language>eng</Language>
    <Abstract>By deletion mutagenesis analyses, we have examined the contribution of the immunosuppressive peptide (ISP) region within the transmembrane (TM) protein of Mason-Pfizer monkey virus to viral maturation and infectivity. Deletion of the entire region (mutant D105) results in the production of an Env precursor that is transport defective and therefore unable to be processed to mature glycoproteins. This mutation results in the release of noninfectious virions devoid of surface glycoproteins. A second deletion that removes the most highly conserved 11 amino acids of the ISP (mutant D33) does not affect the production, transport, or processing of the Env precursor yet produces virions that are noninfectious. The mutation was shown to cause the loss of interaction between the surface (SU) and TM proteins and result in the efficient shedding of gp70 into the culture medium. The released gp70 protein was biologically active and could still bind with high specificity to susceptible target cells. Since the ISP domain may represent an area of contact between SU and TM, it could provide an additional explanation for the amino acid sequence homology observed within this region of a variety of retroviruses.</Abstract>
    <JournalRelease>0022-538X</JournalRelease>
    <Pages>3466-75</Pages>
    <Affiliation>Department of Microbiology, University of Alabama, Birmingham 35294.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=1316462&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>1402073</PMID>
    <AuthorListID>108</AuthorListID>
    <Title>[A clinical study on postantibiotic effect (PAE) and its application to chemotherapy for complicated cystitis with an automatic simulator of urinary drug concentration].</Title>
    <Language>jpn</Language>
    <Abstract>In an in vitro complicated cystitis model, the concentrations of the urinary antimicrobial agents were determined using a computer-controlled automatic urine concentration simulator. The effects on the bacterial count curves showing the presence or absence of PAE in antimicrobial agents were studied by comparing the times required for regrowth to the concentration at the initial inoculation, i.e., effective regrowth time (ERT). The following results were obtained. 1. When beta-lactam antimicrobial agents (such as AMPC and CFIX) with no PAE against the gram-negative rods were tested, the ERT of the gram-negative rods were about two hours shorter than that of the gram-positive coccus. 2. When new quinolone antimicrobial agents (such as OFLX) and aminoglycosides (such as ISP) that possess PAE against both the gram-positive and negative organisms were used there was no difference between ERT of the gram-negative rods and gram-positive coccus. Therefore, it was demonstrated that the presence or absence of PAE is also reflected in the cell number curve in the case of this in vitro model, more closely related to clinical cases, when the antibiotics is simulated in urinary concentration shifting.</Abstract>
    <JournalRelease>0387-5911</JournalRelease>
    <Pages>135-43</Pages>
    <Affiliation>Department of Urology, Sapporo Medical College.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=1402073&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>1999314</PMID>
    <AuthorListID>109</AuthorListID>
    <Title>Increased lysophosphatidylcholine and pancreatic enzyme content in bile of patients with anomalous pancreaticobiliary ductal junction.</Title>
    <Language>eng</Language>
    <Abstract>A high incidence of inflammation and carcinoma of the biliary tract in patients with anomalous pancreaticobiliary ductal junction has been well documented. The change in biliary phospholipids as a result of the reflux of pancreatic juice into the biliary tract through anomalous pancreaticobiliary ductal junction may be responsible for it. We developed a new method of analysis of phospholipid classes using aminopropyl Bond Elut cartridge for extraction and high-performance liquid chromatography for separation. Satisfactory recovery was achieved (i.e., more than 95% for both phosphatidylcholine and lysophosphatidylcholine). With this method, the bile of 11 patients with anomalous pancreaticobiliary ductal junction was examined. The concentration and proportion of lysophosphatidylcholine in bile were much higher in the presence of anomalous pancreaticobiliary ductal junction than in controls (3.44 +/- 1.50 mmol/L vs. 0.52 +/- 0.25 mmol/L, 60.0% +/- 31.0% vs. 2.3% +/- 1.4% in gallbladder bile; p less than 0.001). In contrast, the concentration of phosphatidylcholine and the sum of phosphatidylcholine and lysophosphatidylcholine in gallbladder bile significantly decreased (p less than 0.001), but in hepatic bile they did not. An inverse correlation was found between the proportion of lysophosphatidylcholine and phospholipid concentration in gallbladder bile. Phospholipase A2 and amylase activities in bile were markedly high. Increased total fatty acid concentration and proportion of unsaturated fatty acid in bile were found. Total bile acid concentration in gallbladder bile was significantly lower than in controls. These results suggest that a considerable amount of lysophosphatidylcholine, which is known to have a cytotoxic effect, isp reduced by phospholipase A2 in refluxing pancreatic juice, and an increased concentration of lysophosphatidylcholine gives rise to cell damage causing mucosal hyperplasia and metaplasia.(ABSTRACT TRUNCATED AT 250 WORDS)</Abstract>
    <JournalRelease>0270-9139</JournalRelease>
    <Pages>438-44</Pages>
    <Affiliation>Department of Surgery I, Kyushu University Faculty of Medicine, Japan.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=1999314&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>1695103</PMID>
    <AuthorListID>110</AuthorListID>
    <Title>Vitronectin and type-I collagen binding by Staphylococcus aureus and coagulase-negative staphylococci.</Title>
    <Language>eng</Language>
    <Abstract>Binding of 125I-labelled type-I collagen and 125I-labelled vitronectin (human serum spreading factor or S-protein) was studied using Staphylococcus aureus and coagulase-negative staphylococci of different species. Binding of collagen and vitronectin was time dependent for S. aureus ISP 546, and S. haemolyticus E 2498/86. Co-operative binding of vitronectin and collagen by staphylococcal cells was demonstrated. Binding to S. haemolyticus E 2498/86 was more rapid and was enhanced in vitronectin/collagen mixtures than for either protein separately. Furthermore, pre-incubation of staphylococcal cells with unlabelled collagen enhanced vitronectin binding. When cells of S. haemolyticus E 2498/86 were treated with pronase E, proteinase K, subtilopeptidase A or trypsin, vitronectin-binding was decreased by 50% or more, whereas collagen-binding was protease resistant. For the strains of S. aureus tested, both vitronectin and collagen binding were found to be protease sensitive. Type-I collagen peptides inhibited collagen-binding to S. haemolyticus E 2498/86, whereas vitronectin-binding was not affected perhaps indicating different receptors for these proteins. The binding of both collagen and vitronectin was shown to be reversible, since bound 125I-collagen and 125I-vitronectin were displaced after adding excess of the homologous protein.</Abstract>
    <JournalRelease>0920-8534</JournalRelease>
    <Pages>55-62</Pages>
    <Affiliation>Department of Medical Microbiology, University of Lund, Sweden.</Affiliation>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=1695103&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <Title>Toxicological studies on the organophosphorous insecticide methyl-ISP.</Title>
    <Language>eng</Language>
    <Abstract>Methyl-ISP, a newly developed organophosphorous insecticide, is used in China to treat and protect plants from pest infestation. Our studies demonstrated that methyl-ISP is metabolized rapidly in rat and mouse. Its toxicity was low, no obvious accumulative toxicity, chronic toxicity, teratogenicity, mutagenicity, reproductive toxicity or delayed neurotoxicity could be observed. It is therefore concluded that methyl-ISP is relatively safe to animals and human subjects. methyl-ISP is now employed to replace the other commonly used insecticide hexachlorobenzene (666) in agriculture. A preliminary study was performed to elucidate the mechanism of intoxication at subcellular levels.</Abstract>
    <JournalRelease>0257-716X</JournalRelease>
    <Pages>58-64</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=2760965&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>2428988</PMID>
    <AuthorListID>112</AuthorListID>
    <Title>Early myocardial infarction. A feasible histologic diagnostic procedure.</Title>
    <Language>eng</Language>
    <Abstract>The Barbeito-L처pez trichrome stain (BLTS) was compared with hematoxylin and eosin (HE), the basic fuchsin picric acid (BFP) and nitro-blue tetrazolium (NBT) dye tests. Two types of hearts were studied: myocardial necrosis induced by isoproterenol (ISP) in rats and human hearts with early coagulation necrosis (Early CN). The BLTS was much more sensitive than HE for diagnosis of Early CN in rats. By 24 hours, both BLTS and HE showed established coagulation necrosis (Established CN) although BLTS did so more clearly. In human material BLTS was a useful indicator of Early CN. It showed patchy areas of coagulation necrosis in the cytoplasm of damaged myocardial cells which were not visualized with HE. Normal myocardium remained green or pale blue. Early CN appears as patchy yellow areas while the remainder of the cytoplasm stains green. Established CN appears "golden yellow" or "orange yellow".</Abstract>
    <JournalRelease>0021-4868</JournalRelease>
    <Pages>307-19</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=2428988&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>2433235</PMID>
    <AuthorListID>113</AuthorListID>
    <Title>Differential effect of isoprinosine on lymphocyte proliferation: comparison of two tissue culture media.</Title>
    <Language>eng</Language>
    <Abstract>Isoprinosine (ISP) has been reported to stimulate a variety of immunological responses. This study showed a differential effect of this drug on the proliferative response of human peripheral blood mononuclear cells to phytohemagglutinin (PHA). ISP was found to increase this proliferative response when Eagle's Minimum Essential Medium (MEM) was used. When Medium-199 (M-199) was used to culture the cells, no increase in the proliferative response was observed. This inhibition by M-199 of the ISP effect on PHA-stimulated cells has been traced to the presence of the purines adenine and hypoxanthine in M-199.</Abstract>
    <JournalRelease>0192-0561</JournalRelease>
    <Pages>893-6</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=2433235&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>3002305</PMID>
    <AuthorListID>114</AuthorListID>
    <Title>The role of presynaptic beta-receptors in Raynaud's disease.</Title>
    <Language>eng</Language>
    <Abstract>This report concerns the results of a study carried out to show the presence of presynaptic Beta adrenergic receptor supersensitivity in RD patients and the possibility to prevent or at least decrease this supersensitivity with Beta-blocker treatment. It is shown that the paradoxical vasoconstriction response to ISP infusion can be prevented in RD patients by the acute administration of Beta-blocker, such as Atenolol or DL Propranolol. Moreover, chronic treatment with the correct Beta-blocker was seen to prevent angiospastic crisis in these patients.</Abstract>
    <JournalRelease>0098-6127</JournalRelease>
    <Pages>77-86</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=3002305&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>6356989</PMID>
    <AuthorListID>115</AuthorListID>
    <Title>Insulin- and glucagonlike peptides in the brain.</Title>
    <Language>eng</Language>
    <doi>10.1002/ar.1092070108</doi>
    <Abstract>The cellular localization and regional distribution of insulin- and glucagonlike substance, C-peptide-like immunoreactivity, thiol:protein disulphide oxidoreductase, TPO (E.C.1.8.4.2.), and insulin/glucagon-specific proteinase, ISP (E.C.3.4.22.-), are studied in the CNS of man, adult and juvenile rats, mice, tortoises, and frogs by use of immunohistochemistry. Furthermore, the content of immunoreactive insulin, glucagon, and C-peptide was estimated in human cadaver brains by radioimmunoassay. It could be shown that insulinlike immunoreactive material is widely distributed in the human brain and the CNS of juvenile rats as well as in mice, whereas in the CNS of adult rats and nonmammalian animals (frogs, tortoises) the polypeptide is restricted to a few nerve cell populations. C-peptide immunoreactivity was demonstrated in human CNS in the same nerve cells as insulin. By use of two different glucagon-antisera it was revealed that gut-type glucagon occurs in many nerve cells of human and mouse brains, as well as in the CNS of juvenile rats. On the other hand, pancreas-type glucagon was less widely distributed in the human brain and nearly not detectable in the CNS of mice and rats. With the exception of neurosecretory nerve cells, there was a high degree of coincidence between the localization of insulin and TPO. The immunoreaction against the ISP antiserum was weak, but correlated well with the distribution of insulin-immunoreactivity. The occurrence of TPO and ISP in the brain demonstrates the ability of nervous tissue to degrade insulin and glucagon. By radioimmunoassay it was established that human brain contains insulin, glucagon and C-peptide at concentrations that exceed blood levels. We conclude from our data that, at least in part, cerebral insulin and glucagon are products of the brain itself.</Abstract>
    <JournalRelease>0003-276X</JournalRelease>
    <Pages>69-77</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=6356989&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>639073</PMID>
    <AuthorListID>116</AuthorListID>
    <Title>Pathogenesis of isoproterenol-induced myocardial lesions: its reation to human 'coagulative myocytolysis'.</Title>
    <Language>eng</Language>
    <Abstract>Animals develop 'infarct-like' lesions when injected with isoproterenol (ISP), a potent synthetic catecholamine. These lesions are morphologically similar to those of 'coagulative myocytolysis' (COAM) or myofibrillar degeneration, one of the findings described in acute myocardial infarction and sudden death in man. Wistar rats were divided into 8 groups: some were injected with 10 mg/kg ISP i.p. plus 5 muCi of tritiated ISP, while others served as control. Animals were sacrified at 5 and 30 min and 24 and 72 h. The ISP-induced lesions were studied by means of light microscopy, histochemistry, autoradiography and electron microscopy. Myofibrillar degeneration, positive tests for ischemia, increase of succinic dehydrogenase enzymes, hypercontraction and widening of Z bands of sarcomers were correlated with the rapid distribution of ISP. These lesions were minimized by prenylamine, a drug which inhibits catecholamine effects by slowing down Ca transport. It is concluded that myocardial necrosis induced by ISP is probably due to a primary act on the sarcolemmal membrane, followed by stimulation of adenylate cyclase, activation of Ca and Na channels, exaggreated Ca inflow, excess of excitation-contraction coupling mechanism, energy consumption and cellular death. The close resemblance of human COAM to ISP-induced lesions suggests that similar mechanisms may be involved.</Abstract>
    <JournalRelease>0008-6312</JournalRelease>
    <Pages>139-51</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=639073&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>949029</PMID>
    <AuthorListID>117</AuthorListID>
    <Title>Localization by autoradiography of tritiated isoproterenol in "infarct-like" lesions of rat myocardium.</Title>
    <Language>eng</Language>
    <Abstract>A number of physiopathogenic mechanisms have been outlined to explain the "infarct-like" lesions produced by isoproterenol (ISP) in the hearts of various animals: Excess of oxygen consumption and inotropic effect, coronary vasoconstriction, deleterious action on glucose and lipid metabolism, direct cardiotoxic effect, platelet aggregation in the small cardiac vessels and formation of microclots, excessive mobilization of fatty acids, fluid and electrolytic imbalances, loss of high-energy intracellular coupling, and inadequate activation of the "calcium pump." For this reason, localization of the tritiated ISP in the normal myocardial fibers and in the induced lesions was studied. The first control group (G-1), consisted of 40 Wistar rats, weighing from 180 to 200 grams; they were injected intraperitoneally with ISP sulfate (10 mg. per kilogram) and were killed under ether anesthesia after periods of 5, 30, and 120 minutes, and 12 and 24 hours. A similar group (G-2) was injected intraperitoneally with an equal dose of ISP plus 5 muCi of tritiated ISP sulfate (3H). In this group animals were killed at the same periods as above. In rats treated with ISP-3H an abundant amount of the labeled drug was observed on the sarcolemma surface and a smaller quantity was noted inside the myocardial fibers. This observation was noted in the autoradiographs obtained 5 minutes after the injection and persisted in all subsequent observation times. In those animals which were killed 5 and 30 minutes after injection, the deposit was noted in "grooves" along the edge of the sarcolemma, strongly suggesting a primary action on the cellular membrane. These findings and the peculiar topography suggest that (1) myocardial necrosis induced by ISP is probably due to an increased activation of the "calcium pump"; the early presence of contracture bands and the positivity of the ischemia test further emphasize this statement; (2) the ISP effect is rapid; (3) the morphologic alterations are similar to those recently described as "coagulation myocytolysis" and present in human infarctions or following sudden death.</Abstract>
    <JournalRelease>0002-8703</JournalRelease>
    <Pages>351-5</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=949029&amp;retmode=xml</URL>
  </T_Article>
  <T_Article>
    <PMID>4327576</PMID>
    <AuthorListID>118</AuthorListID>
    <Title>Direct measurement of proinsulin in human plasma by the use of an insulin-degrading enzyme.</Title>
    <Language>eng</Language>
    <doi>10.1172/JCI106669</doi>
    <Abstract>A method has been described for the direct measurement of proinsulin in human plasma. The method makes use of an insulin-degrading enzyme designated "insulin-specific protease (ISP)", which is obtained from rat skeletal muscle. Under the conditions used, this enzyme rapidly degrades insulin and insulin-like polypeptides to nonimmunoassayable components, whereas proinsulin and proinsulin cleaved at position B(54,55) are not appreciably affected. The incubation of plasma with ISP results in the disappearance of insulin, but not proinsulin, as demonstrated by column chromatography. Immunoassay of the plasma, therefore, before and after incubation, determines the values for the total immunoreactive substance (TIR) and for immunoreactive proinsulin (IRP), respectively. The values obtained for proinsulin levels are reproducible and compare closely with the more complicated column fractionation methods. Proinsulin responses were studied in four normal subjects and one patient with an insulinoma after a glucose load. Fasting proinsulin levels varied widely in the normal subjects, and the levels rose more slowly than TIR levels after glucose. IRP levels in the patient with an insulinoma were very high and fell to normal after removal of the tumor. The ISP method, therefore, appears to be suitable for the direct, accurate, and rapid determination of proinsulin and proinsulin-like materials in human plasma.</Abstract>
    <JournalRelease>0021-9738</JournalRelease>
    <Pages>1792-9</Pages>
    <URL>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;id=4327576&amp;retmode=xml</URL>
  </T_Article>
  <T_AuthorList>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>1</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>2</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>3</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>4</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>5</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>6</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23543559</PMID>
    <AuthorListID>1</AuthorListID>
    <AuthorID>7</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>8</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>9</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>10</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>11</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>12</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>13</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23372719</PMID>
    <AuthorListID>2</AuthorListID>
    <AuthorID>14</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23352090</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>15</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23352090</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>16</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23352090</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>17</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23352090</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>18</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23352090</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>19</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23352090</PMID>
    <AuthorListID>3</AuthorListID>
    <AuthorID>20</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>21</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>22</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>23</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>24</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>25</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>26</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>27</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>28</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23199969</PMID>
    <AuthorListID>4</AuthorListID>
    <AuthorID>29</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23189540</PMID>
    <AuthorListID>5</AuthorListID>
    <AuthorID>30</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23189540</PMID>
    <AuthorListID>5</AuthorListID>
    <AuthorID>31</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23189540</PMID>
    <AuthorListID>5</AuthorListID>
    <AuthorID>32</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23189540</PMID>
    <AuthorListID>5</AuthorListID>
    <AuthorID>33</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23189540</PMID>
    <AuthorListID>5</AuthorListID>
    <AuthorID>34</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23189540</PMID>
    <AuthorListID>5</AuthorListID>
    <AuthorID>35</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23024152</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>36</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23024152</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>37</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23024152</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>38</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23024152</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>39</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23024152</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>40</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>23024152</PMID>
    <AuthorListID>6</AuthorListID>
    <AuthorID>41</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>42</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>43</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>44</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>45</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>46</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>47</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>48</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22672275</PMID>
    <AuthorListID>7</AuthorListID>
    <AuthorID>49</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22659420</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>50</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22659420</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>51</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22659420</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>52</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22659420</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>53</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22659420</PMID>
    <AuthorListID>8</AuthorListID>
    <AuthorID>54</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>55</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>56</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>57</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>58</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>59</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>60</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>61</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22610699</PMID>
    <AuthorListID>9</AuthorListID>
    <AuthorID>62</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22592975</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>63</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22592975</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>64</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22592975</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>65</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22592975</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>66</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22592975</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>67</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22592975</PMID>
    <AuthorListID>10</AuthorListID>
    <AuthorID>68</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22448717</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>69</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22448717</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>70</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22448717</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>71</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22448717</PMID>
    <AuthorListID>11</AuthorListID>
    <AuthorID>72</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22337793</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>73</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22337793</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>74</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22337793</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>75</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22337793</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>76</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22337793</PMID>
    <AuthorListID>12</AuthorListID>
    <AuthorID>77</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22284237</PMID>
    <AuthorListID>13</AuthorListID>
    <AuthorID>78</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>79</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>80</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>81</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>82</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>83</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>84</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>85</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>86</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22274813</PMID>
    <AuthorListID>14</AuthorListID>
    <AuthorID>87</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>88</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>89</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>90</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>91</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>92</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>93</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>94</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>95</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22132161</PMID>
    <AuthorListID>15</AuthorListID>
    <AuthorID>96</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22042512</PMID>
    <AuthorListID>16</AuthorListID>
    <AuthorID>97</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22042512</PMID>
    <AuthorListID>16</AuthorListID>
    <AuthorID>98</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>22042512</PMID>
    <AuthorListID>16</AuthorListID>
    <AuthorID>99</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>100</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>101</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>102</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>103</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>104</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>105</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21920450</PMID>
    <AuthorListID>17</AuthorListID>
    <AuthorID>106</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21819665</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>107</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21819665</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>108</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21819665</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>109</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21819665</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>110</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21819665</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>111</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21819665</PMID>
    <AuthorListID>18</AuthorListID>
    <AuthorID>112</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21480416</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>113</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21480416</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>114</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21480416</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>115</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21480416</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>116</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21480416</PMID>
    <AuthorListID>19</AuthorListID>
    <AuthorID>117</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21416629</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>118</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21416629</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>119</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21416629</PMID>
    <AuthorListID>20</AuthorListID>
    <AuthorID>120</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>121</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>122</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>123</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>124</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>125</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>126</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>127</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21401652</PMID>
    <AuthorListID>21</AuthorListID>
    <AuthorID>128</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>129</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>130</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>131</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>132</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>133</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>134</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>135</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>136</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>137</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21394107</PMID>
    <AuthorListID>22</AuthorListID>
    <AuthorID>138</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21382056</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>139</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21382056</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>140</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21382056</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>141</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21382056</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>142</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>21382056</PMID>
    <AuthorListID>23</AuthorListID>
    <AuthorID>143</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20849980</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>144</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20849980</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>145</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20849980</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>146</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20849980</PMID>
    <AuthorListID>24</AuthorListID>
    <AuthorID>147</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20844581</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>148</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20844581</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>149</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20844581</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>150</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20844581</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>151</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20844581</PMID>
    <AuthorListID>25</AuthorListID>
    <AuthorID>152</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20805755</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>153</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20805755</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>154</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20805755</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>155</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20805755</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>156</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20805755</PMID>
    <AuthorListID>26</AuthorListID>
    <AuthorID>157</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20618558</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>158</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20618558</PMID>
    <AuthorListID>27</AuthorListID>
    <AuthorID>159</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>160</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>161</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>162</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>163</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>164</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>165</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>166</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>167</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>168</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20506484</PMID>
    <AuthorListID>28</AuthorListID>
    <AuthorID>169</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20407012</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>170</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20407012</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>171</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20407012</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>172</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20407012</PMID>
    <AuthorListID>29</AuthorListID>
    <AuthorID>173</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>174</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>175</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>176</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>177</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>178</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>179</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20198341</PMID>
    <AuthorListID>30</AuthorListID>
    <AuthorID>180</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20097674</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>181</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20097674</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>182</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20097674</PMID>
    <AuthorListID>31</AuthorListID>
    <AuthorID>183</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20089839</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>184</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20089839</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>185</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>20089839</PMID>
    <AuthorListID>32</AuthorListID>
    <AuthorID>186</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>187</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>188</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>189</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>190</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>191</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>192</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>193</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>194</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>195</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>196</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19937735</PMID>
    <AuthorListID>33</AuthorListID>
    <AuthorID>197</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19916082</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>198</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19916082</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>199</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19916082</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>200</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19916082</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>201</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19916082</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>202</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19916082</PMID>
    <AuthorListID>34</AuthorListID>
    <AuthorID>203</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>204</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>205</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>206</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>207</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>208</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>209</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19906097</PMID>
    <AuthorListID>35</AuthorListID>
    <AuthorID>210</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>211</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>212</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>213</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>214</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>215</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>216</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>217</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19900588</PMID>
    <AuthorListID>36</AuthorListID>
    <AuthorID>218</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>219</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>220</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>221</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>222</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>223</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>224</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>225</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>226</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>227</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19350552</PMID>
    <AuthorListID>37</AuthorListID>
    <AuthorID>228</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>229</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>230</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>231</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>232</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>233</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>234</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19268713</PMID>
    <AuthorListID>38</AuthorListID>
    <AuthorID>235</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>236</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>237</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>238</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>239</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>240</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>241</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19259249</PMID>
    <AuthorListID>39</AuthorListID>
    <AuthorID>242</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>243</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>244</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>245</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>246</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>247</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>248</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19158945</PMID>
    <AuthorListID>40</AuthorListID>
    <AuthorID>249</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>250</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>251</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>252</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>253</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>254</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>255</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>19088704</PMID>
    <AuthorListID>41</AuthorListID>
    <AuthorID>256</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18952783</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>257</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18952783</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>258</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18952783</PMID>
    <AuthorListID>42</AuthorListID>
    <AuthorID>259</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18662621</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>260</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18662621</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>261</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18662621</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>262</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18662621</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>263</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18662621</PMID>
    <AuthorListID>43</AuthorListID>
    <AuthorID>264</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>265</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>266</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>267</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>268</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>269</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>270</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>271</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>272</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>273</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18652866</PMID>
    <AuthorListID>44</AuthorListID>
    <AuthorID>274</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>275</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>276</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>277</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>278</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>279</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>280</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>281</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>282</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18555888</PMID>
    <AuthorListID>45</AuthorListID>
    <AuthorID>283</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18520051</PMID>
    <AuthorListID>46</AuthorListID>
    <AuthorID>284</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18520051</PMID>
    <AuthorListID>46</AuthorListID>
    <AuthorID>285</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18520051</PMID>
    <AuthorListID>46</AuthorListID>
    <AuthorID>286</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18520051</PMID>
    <AuthorListID>46</AuthorListID>
    <AuthorID>287</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18416311</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>288</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18416311</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>289</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18416311</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>290</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18416311</PMID>
    <AuthorListID>47</AuthorListID>
    <AuthorID>291</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>292</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>293</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>294</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>295</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>296</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>297</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>298</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>299</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>300</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18400537</PMID>
    <AuthorListID>48</AuthorListID>
    <AuthorID>301</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>302</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>303</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>304</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>305</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>306</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>307</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18287049</PMID>
    <AuthorListID>49</AuthorListID>
    <AuthorID>308</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18279271</PMID>
    <AuthorListID>50</AuthorListID>
    <AuthorID>309</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18279271</PMID>
    <AuthorListID>50</AuthorListID>
    <AuthorID>310</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18279271</PMID>
    <AuthorListID>50</AuthorListID>
    <AuthorID>311</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18062244</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>312</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18062244</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>313</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18062244</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>314</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18062244</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>315</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18062244</PMID>
    <AuthorListID>51</AuthorListID>
    <AuthorID>316</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18061950</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>317</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18061950</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>318</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18061950</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>319</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18061950</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>320</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18061950</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>321</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>18061950</PMID>
    <AuthorListID>52</AuthorListID>
    <AuthorID>322</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17914900</PMID>
    <AuthorListID>53</AuthorListID>
    <AuthorID>323</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17914900</PMID>
    <AuthorListID>53</AuthorListID>
    <AuthorID>324</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17914900</PMID>
    <AuthorListID>53</AuthorListID>
    <AuthorID>325</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17900215</PMID>
    <AuthorListID>54</AuthorListID>
    <AuthorID>326</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17895250</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>327</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17895250</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>328</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17895250</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>329</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17895250</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>330</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17895250</PMID>
    <AuthorListID>55</AuthorListID>
    <AuthorID>331</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17556392</PMID>
    <AuthorListID>56</AuthorListID>
    <AuthorID>332</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17556392</PMID>
    <AuthorListID>56</AuthorListID>
    <AuthorID>333</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17530242</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>334</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17530242</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>335</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17530242</PMID>
    <AuthorListID>57</AuthorListID>
    <AuthorID>336</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>337</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>338</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>339</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>340</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>341</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>342</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>343</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17229855</PMID>
    <AuthorListID>58</AuthorListID>
    <AuthorID>344</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>345</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>346</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>347</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>348</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>349</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>350</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17027137</PMID>
    <AuthorListID>59</AuthorListID>
    <AuthorID>351</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17018115</PMID>
    <AuthorListID>60</AuthorListID>
    <AuthorID>352</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17018115</PMID>
    <AuthorListID>60</AuthorListID>
    <AuthorID>353</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17011585</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>354</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17011585</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>355</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17011585</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>356</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17011585</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>357</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17011585</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>358</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>17011585</PMID>
    <AuthorListID>61</AuthorListID>
    <AuthorID>359</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16549044</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>360</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16549044</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>361</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16549044</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>362</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16549044</PMID>
    <AuthorListID>62</AuthorListID>
    <AuthorID>363</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16527606</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>364</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16527606</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>365</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16527606</PMID>
    <AuthorListID>63</AuthorListID>
    <AuthorID>366</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>367</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>368</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>369</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>370</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>371</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>372</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16410634</PMID>
    <AuthorListID>64</AuthorListID>
    <AuthorID>373</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>374</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>375</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>376</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>377</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>378</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>379</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>380</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>381</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>382</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>383</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>384</AuthorID>
    <AuthorOrder>11</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>385</AuthorID>
    <AuthorOrder>12</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16278235</PMID>
    <AuthorListID>65</AuthorListID>
    <AuthorID>386</AuthorID>
    <AuthorOrder>13</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16257142</PMID>
    <AuthorListID>66</AuthorListID>
    <AuthorID>387</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>388</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>389</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>390</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>391</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>392</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>393</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>16172008</PMID>
    <AuthorListID>67</AuthorListID>
    <AuthorID>394</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <AuthorID>395</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <AuthorID>396</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <AuthorID>397</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <AuthorID>398</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <AuthorID>399</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <AuthorID>400</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15979402</PMID>
    <AuthorListID>68</AuthorListID>
    <AuthorID>401</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15966292</PMID>
    <AuthorListID>69</AuthorListID>
    <AuthorID>402</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15966292</PMID>
    <AuthorListID>69</AuthorListID>
    <AuthorID>403</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15966292</PMID>
    <AuthorListID>69</AuthorListID>
    <AuthorID>404</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15531524</PMID>
    <AuthorListID>71</AuthorListID>
    <AuthorID>405</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15531524</PMID>
    <AuthorListID>71</AuthorListID>
    <AuthorID>406</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15531524</PMID>
    <AuthorListID>71</AuthorListID>
    <AuthorID>407</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15339929</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>408</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15339929</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>409</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15339929</PMID>
    <AuthorListID>72</AuthorListID>
    <AuthorID>410</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>411</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>412</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>413</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>414</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>415</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>416</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15229803</PMID>
    <AuthorListID>73</AuthorListID>
    <AuthorID>417</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>418</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>419</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>420</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>421</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>422</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>423</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>15020599</PMID>
    <AuthorListID>74</AuthorListID>
    <AuthorID>424</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14986303</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>425</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14986303</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>426</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14986303</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>427</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14986303</PMID>
    <AuthorListID>75</AuthorListID>
    <AuthorID>428</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14573769</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>429</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14573769</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>430</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14573769</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>431</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14573769</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>432</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>14573769</PMID>
    <AuthorListID>76</AuthorListID>
    <AuthorID>433</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12915133</PMID>
    <AuthorListID>77</AuthorListID>
    <AuthorID>434</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>435</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>436</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>437</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>438</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>439</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>440</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>441</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>442</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>443</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12732183</PMID>
    <AuthorListID>78</AuthorListID>
    <AuthorID>444</AuthorID>
    <AuthorOrder>10</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12648232</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>445</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12648232</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>446</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12648232</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>447</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12648232</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>448</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12648232</PMID>
    <AuthorListID>80</AuthorListID>
    <AuthorID>449</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12604687</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>450</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12604687</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>451</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12604687</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>452</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12604687</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>453</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12604687</PMID>
    <AuthorListID>81</AuthorListID>
    <AuthorID>454</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12578840</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>455</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12578840</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>456</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12578840</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>457</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12578840</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>458</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12578840</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>459</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12578840</PMID>
    <AuthorListID>82</AuthorListID>
    <AuthorID>460</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12498721</PMID>
    <AuthorListID>83</AuthorListID>
    <AuthorID>461</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12213223</PMID>
    <AuthorListID>84</AuthorListID>
    <AuthorID>462</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12213223</PMID>
    <AuthorListID>84</AuthorListID>
    <AuthorID>463</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12213223</PMID>
    <AuthorListID>84</AuthorListID>
    <AuthorID>464</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12069821</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>465</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12069821</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>466</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12069821</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>467</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12069821</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>468</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12069821</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>469</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>12069821</PMID>
    <AuthorListID>85</AuthorListID>
    <AuthorID>470</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11942050</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>471</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11942050</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>472</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11942050</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>473</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11942050</PMID>
    <AuthorListID>86</AuthorListID>
    <AuthorID>474</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11856628</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>475</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11856628</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>476</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11856628</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>477</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11856628</PMID>
    <AuthorListID>87</AuthorListID>
    <AuthorID>478</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11709184</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>479</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11709184</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>480</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11709184</PMID>
    <AuthorListID>88</AuthorListID>
    <AuthorID>481</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11440778</PMID>
    <AuthorListID>89</AuthorListID>
    <AuthorID>482</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11440778</PMID>
    <AuthorListID>89</AuthorListID>
    <AuthorID>483</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11440778</PMID>
    <AuthorListID>89</AuthorListID>
    <AuthorID>484</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>11208198</PMID>
    <AuthorListID>90</AuthorListID>
    <AuthorID>485</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10924327</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>486</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10924327</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>487</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10924327</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>488</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10924327</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>489</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10924327</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>490</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10924327</PMID>
    <AuthorListID>91</AuthorListID>
    <AuthorID>491</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10886724</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>492</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10886724</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>493</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10886724</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>494</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10886724</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>495</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10886724</PMID>
    <AuthorListID>92</AuthorListID>
    <AuthorID>496</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>497</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>498</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>499</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>500</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>501</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>502</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>503</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10813797</PMID>
    <AuthorListID>93</AuthorListID>
    <AuthorID>504</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10461730</PMID>
    <AuthorListID>94</AuthorListID>
    <AuthorID>505</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10461730</PMID>
    <AuthorListID>94</AuthorListID>
    <AuthorID>506</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10461730</PMID>
    <AuthorListID>94</AuthorListID>
    <AuthorID>507</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10461730</PMID>
    <AuthorListID>94</AuthorListID>
    <AuthorID>508</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>509</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>510</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>511</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>512</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>513</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>514</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>515</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>10099162</PMID>
    <AuthorListID>95</AuthorListID>
    <AuthorID>516</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9782161</PMID>
    <AuthorListID>96</AuthorListID>
    <AuthorID>517</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9782161</PMID>
    <AuthorListID>96</AuthorListID>
    <AuthorID>518</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9698100</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>519</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9698100</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>520</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9698100</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>521</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9698100</PMID>
    <AuthorListID>97</AuthorListID>
    <AuthorID>522</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9562860</PMID>
    <AuthorListID>98</AuthorListID>
    <AuthorID>523</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9562860</PMID>
    <AuthorListID>98</AuthorListID>
    <AuthorID>524</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9473533</PMID>
    <AuthorListID>99</AuthorListID>
    <AuthorID>525</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9473533</PMID>
    <AuthorListID>99</AuthorListID>
    <AuthorID>526</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9473533</PMID>
    <AuthorListID>99</AuthorListID>
    <AuthorID>527</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9473533</PMID>
    <AuthorListID>99</AuthorListID>
    <AuthorID>528</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9473533</PMID>
    <AuthorListID>99</AuthorListID>
    <AuthorID>529</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9473533</PMID>
    <AuthorListID>99</AuthorListID>
    <AuthorID>530</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9373217</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>531</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9373217</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>532</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9373217</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>533</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>9373217</PMID>
    <AuthorListID>100</AuthorListID>
    <AuthorID>534</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7844457</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>535</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7844457</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>536</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7844457</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>537</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7844457</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>538</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7844457</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>539</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7844457</PMID>
    <AuthorListID>101</AuthorListID>
    <AuthorID>540</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7752809</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>541</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7752809</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>542</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7752809</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>543</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7752809</PMID>
    <AuthorListID>102</AuthorListID>
    <AuthorID>544</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7933530</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>545</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7933530</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>546</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7933530</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>547</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>7933530</PMID>
    <AuthorListID>103</AuthorListID>
    <AuthorID>548</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>549</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>550</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>551</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>552</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>553</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>554</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>555</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>556</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8150717</PMID>
    <AuthorListID>104</AuthorListID>
    <AuthorID>557</AuthorID>
    <AuthorOrder>9</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>558</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>559</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>560</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>561</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>562</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>563</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>564</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8351444</PMID>
    <AuthorListID>105</AuthorListID>
    <AuthorID>565</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8097745</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>566</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>8097745</PMID>
    <AuthorListID>106</AuthorListID>
    <AuthorID>567</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1316462</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>568</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1316462</PMID>
    <AuthorListID>107</AuthorListID>
    <AuthorID>569</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1402073</PMID>
    <AuthorListID>108</AuthorListID>
    <AuthorID>570</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1402073</PMID>
    <AuthorListID>108</AuthorListID>
    <AuthorID>571</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1402073</PMID>
    <AuthorListID>108</AuthorListID>
    <AuthorID>572</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1402073</PMID>
    <AuthorListID>108</AuthorListID>
    <AuthorID>573</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1402073</PMID>
    <AuthorListID>108</AuthorListID>
    <AuthorID>574</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1402073</PMID>
    <AuthorListID>108</AuthorListID>
    <AuthorID>575</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1999314</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>576</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1999314</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>577</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1999314</PMID>
    <AuthorListID>109</AuthorListID>
    <AuthorID>578</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1695103</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>579</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>1695103</PMID>
    <AuthorListID>110</AuthorListID>
    <AuthorID>580</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>581</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>582</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>583</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>584</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>585</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>586</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>587</AuthorID>
    <AuthorOrder>7</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2760965</PMID>
    <AuthorListID>111</AuthorListID>
    <AuthorID>588</AuthorID>
    <AuthorOrder>8</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2428988</PMID>
    <AuthorListID>112</AuthorListID>
    <AuthorID>589</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2428988</PMID>
    <AuthorListID>112</AuthorListID>
    <AuthorID>590</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2433235</PMID>
    <AuthorListID>113</AuthorListID>
    <AuthorID>591</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>2433235</PMID>
    <AuthorListID>113</AuthorListID>
    <AuthorID>592</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>3002305</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>593</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>3002305</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>594</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>3002305</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>595</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>3002305</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>596</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>3002305</PMID>
    <AuthorListID>114</AuthorListID>
    <AuthorID>597</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6356989</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>598</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6356989</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>599</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6356989</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>600</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6356989</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>601</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6356989</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>602</AuthorID>
    <AuthorOrder>5</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>6356989</PMID>
    <AuthorListID>115</AuthorListID>
    <AuthorID>603</AuthorID>
    <AuthorOrder>6</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>639073</PMID>
    <AuthorListID>116</AuthorListID>
    <AuthorID>604</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>639073</PMID>
    <AuthorListID>116</AuthorListID>
    <AuthorID>605</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>4327576</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>606</AuthorID>
    <AuthorOrder>1</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>4327576</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>607</AuthorID>
    <AuthorOrder>2</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>4327576</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>608</AuthorID>
    <AuthorOrder>3</AuthorOrder>
  </T_AuthorList>
  <T_AuthorList>
    <PMID>4327576</PMID>
    <AuthorListID>118</AuthorListID>
    <AuthorID>609</AuthorID>
    <AuthorOrder>4</AuthorOrder>
  </T_AuthorList>
  <T_Authors>
    <AuthorID>1</AuthorID>
    <LastName>Arbyn</LastName>
    <ForeName>Marc</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>2</AuthorID>
    <LastName>Roelens</LastName>
    <ForeName>Jolien</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>3</AuthorID>
    <LastName>Simoens</LastName>
    <ForeName>Cindy</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>4</AuthorID>
    <LastName>Buntinx</LastName>
    <ForeName>Frank</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>5</AuthorID>
    <LastName>Paraskevaidis</LastName>
    <ForeName>Evangelos</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>6</AuthorID>
    <LastName>Martin-Hirsch</LastName>
    <ForeName>Pierre P L</ForeName>
    <Initials>PP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>7</AuthorID>
    <LastName>Prendiville</LastName>
    <ForeName>Walter J</ForeName>
    <Initials>WJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>8</AuthorID>
    <LastName>Lanotte</LastName>
    <ForeName>Philippe</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>9</AuthorID>
    <LastName>Perivier</LastName>
    <ForeName>Marylise</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>10</AuthorID>
    <LastName>Haguenoer</LastName>
    <ForeName>Eve</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>11</AuthorID>
    <LastName>Mereghetti</LastName>
    <ForeName>Laurent</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>12</AuthorID>
    <LastName>Burucoa</LastName>
    <ForeName>Christophe</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>13</AuthorID>
    <LastName>Claverol</LastName>
    <ForeName>St챕phane</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>14</AuthorID>
    <LastName>Atanassov</LastName>
    <ForeName>Christo</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>15</AuthorID>
    <LastName>Vandevijvere</LastName>
    <ForeName>Stefanie</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>16</AuthorID>
    <LastName>Amsalkhir</LastName>
    <ForeName>Sihame</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>17</AuthorID>
    <LastName>Van Oyen</LastName>
    <ForeName>Herman</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>18</AuthorID>
    <LastName>Egli</LastName>
    <ForeName>Ines</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>19</AuthorID>
    <LastName>Ines</LastName>
    <ForeName>Egli</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>20</AuthorID>
    <LastName>Moreno-Reyes</LastName>
    <ForeName>Rodrigo</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>21</AuthorID>
    <LastName>Ronco</LastName>
    <ForeName>Guglielmo</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>22</AuthorID>
    <LastName>Anttila</LastName>
    <ForeName>Ahti</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>23</AuthorID>
    <LastName>Meijer</LastName>
    <ForeName>Chris J L M</ForeName>
    <Initials>CJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>24</AuthorID>
    <LastName>Poljak</LastName>
    <ForeName>Mario</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>25</AuthorID>
    <LastName>Ogilvie</LastName>
    <ForeName>Gina</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>26</AuthorID>
    <LastName>Koliopoulos</LastName>
    <ForeName>George</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>27</AuthorID>
    <LastName>Naucler</LastName>
    <ForeName>Pontus</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>28</AuthorID>
    <LastName>Sankaranarayanan</LastName>
    <ForeName>Rengaswamy</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>29</AuthorID>
    <LastName>Peto</LastName>
    <ForeName>Julian</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>30</AuthorID>
    <LastName>Van Beckhoven</LastName>
    <ForeName>D</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>31</AuthorID>
    <LastName>Buv챕</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>32</AuthorID>
    <LastName>Ruelle</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>33</AuthorID>
    <LastName>Seyler</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>34</AuthorID>
    <LastName>Sasse</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>35</AuthorID>
    <CollectiveName>Belgian HIV Cohort Study Group</CollectiveName>
  </T_Authors>
  <T_Authors>
    <AuthorID>36</AuthorID>
    <LastName>Gerber</LastName>
    <ForeName>Christian</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>37</AuthorID>
    <LastName>Meyer</LastName>
    <ForeName>Dominik C</ForeName>
    <Initials>DC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>38</AuthorID>
    <LastName>Von Rechenberg</LastName>
    <ForeName>Brigitte</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>39</AuthorID>
    <LastName>Hoppeler</LastName>
    <ForeName>Hans</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>40</AuthorID>
    <LastName>Frigg</LastName>
    <ForeName>Robert</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>41</AuthorID>
    <LastName>Farshad</LastName>
    <ForeName>Mazda</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>42</AuthorID>
    <LastName>Bergeron</LastName>
    <ForeName>Laurine</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>43</AuthorID>
    <LastName>Gondran</LastName>
    <ForeName>Catherine</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>44</AuthorID>
    <LastName>Oberto</LastName>
    <ForeName>Gilles</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>45</AuthorID>
    <LastName>Garcia</LastName>
    <ForeName>Noelle</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>46</AuthorID>
    <LastName>Botto</LastName>
    <ForeName>Jean Marie</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>47</AuthorID>
    <LastName>Cucumel</LastName>
    <ForeName>Karine</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>48</AuthorID>
    <LastName>Dal Farra</LastName>
    <ForeName>Claude</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>49</AuthorID>
    <LastName>Domloge</LastName>
    <ForeName>Nouha</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>50</AuthorID>
    <LastName>Fung</LastName>
    <ForeName>Connie</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>51</AuthorID>
    <LastName>Beck</LastName>
    <ForeName>Josh R</ForeName>
    <Initials>JR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>52</AuthorID>
    <LastName>Robertson</LastName>
    <ForeName>Seth D</ForeName>
    <Initials>SD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>53</AuthorID>
    <LastName>Gubbels</LastName>
    <ForeName>Marc-Jan</ForeName>
    <Initials>MJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>54</AuthorID>
    <LastName>Bradley</LastName>
    <ForeName>Peter J</ForeName>
    <Initials>PJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>55</AuthorID>
    <LastName>Cuschieri</LastName>
    <ForeName>Kate</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>56</AuthorID>
    <LastName>Cuzick</LastName>
    <ForeName>Jack</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>57</AuthorID>
    <LastName>Szarewski</LastName>
    <ForeName>Ann</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>58</AuthorID>
    <LastName>Ratnam</LastName>
    <ForeName>Sam</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>59</AuthorID>
    <LastName>Reuschenbach</LastName>
    <ForeName>Miriam</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>60</AuthorID>
    <LastName>Belinson</LastName>
    <ForeName>Suzanne</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>61</AuthorID>
    <LastName>Belinson</LastName>
    <ForeName>Jerome L</ForeName>
    <Initials>JL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>62</AuthorID>
    <LastName>Monsonego</LastName>
    <ForeName>Joseph</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>63</AuthorID>
    <LastName>Verschaeve</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>64</AuthorID>
    <LastName>Mertens</LastName>
    <ForeName>B</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>65</AuthorID>
    <LastName>Ndhlala</LastName>
    <ForeName>A R</ForeName>
    <Initials>AR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>66</AuthorID>
    <LastName>Anthonissen</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>67</AuthorID>
    <LastName>Gorissen</LastName>
    <ForeName>B</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>68</AuthorID>
    <LastName>Van Staden</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>69</AuthorID>
    <LastName>Pedersen</LastName>
    <ForeName>Inge S첩kilde</ForeName>
    <Initials>IS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>70</AuthorID>
    <LastName>Krarup</LastName>
    <ForeName>Henrik Bygum</ForeName>
    <Initials>HB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>71</AuthorID>
    <LastName>Thorlacius-Ussing</LastName>
    <ForeName>Ole</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>72</AuthorID>
    <LastName>Madsen</LastName>
    <ForeName>Poul Henning</ForeName>
    <Initials>PH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>73</AuthorID>
    <LastName>Deconinck</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>74</AuthorID>
    <LastName>Verstraete</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>75</AuthorID>
    <LastName>Van Gyseghem</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>76</AuthorID>
    <LastName>Vander Heyden</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>77</AuthorID>
    <LastName>Coomans</LastName>
    <ForeName>D</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>78</AuthorID>
    <LastName>Reich</LastName>
    <ForeName>Jerome M</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>79</AuthorID>
    <LastName>Shin</LastName>
    <ForeName>Kyong-Oh</ForeName>
    <Initials>KO</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>80</AuthorID>
    <LastName>Park</LastName>
    <ForeName>Myong-Yong</ForeName>
    <Initials>MY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>81</AuthorID>
    <LastName>Seo</LastName>
    <ForeName>Cho-Hee</ForeName>
    <Initials>CH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>82</AuthorID>
    <LastName>Lee</LastName>
    <ForeName>Yong-Ill</ForeName>
    <Initials>YI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>83</AuthorID>
    <LastName>Kim</LastName>
    <ForeName>Hyun Sik</ForeName>
    <Initials>HS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>84</AuthorID>
    <LastName>Yoo</LastName>
    <ForeName>Hwan-Soo</ForeName>
    <Initials>HS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>85</AuthorID>
    <LastName>Hong</LastName>
    <ForeName>Jin Tae</ForeName>
    <Initials>JT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>86</AuthorID>
    <LastName>Jung</LastName>
    <ForeName>Jae-Kyung</ForeName>
    <Initials>JK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>87</AuthorID>
    <LastName>Lee</LastName>
    <ForeName>Yong-Moon</ForeName>
    <Initials>YM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>88</AuthorID>
    <LastName>Sharma</LastName>
    <ForeName>Navneet</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>89</AuthorID>
    <LastName>Kumar</LastName>
    <ForeName>Rajeev</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>90</AuthorID>
    <LastName>Renaux</LastName>
    <ForeName>Bernard</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>91</AuthorID>
    <LastName>Saifeddine</LastName>
    <ForeName>Mahmoud</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>92</AuthorID>
    <LastName>Nishikawa</LastName>
    <ForeName>Sandra</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>93</AuthorID>
    <LastName>Mihara</LastName>
    <ForeName>Koichiro</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>94</AuthorID>
    <LastName>Ramachandran</LastName>
    <ForeName>Rithwik</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>95</AuthorID>
    <LastName>Hollenberg</LastName>
    <ForeName>Morley D</ForeName>
    <Initials>MD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>96</AuthorID>
    <LastName>Rancourt</LastName>
    <ForeName>Derrick E</ForeName>
    <Initials>DE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>97</AuthorID>
    <LastName>Fling</LastName>
    <ForeName>Brett W</ForeName>
    <Initials>BW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>98</AuthorID>
    <LastName>Benson</LastName>
    <ForeName>Bryan L</ForeName>
    <Initials>BL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>99</AuthorID>
    <LastName>Seidler</LastName>
    <ForeName>Rachael D</ForeName>
    <Initials>RD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>100</AuthorID>
    <LastName>Romano</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>101</AuthorID>
    <LastName>Aryan</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>102</AuthorID>
    <LastName>Korf</LastName>
    <ForeName>H</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>103</AuthorID>
    <LastName>Bruffaerts</LastName>
    <ForeName>N</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>104</AuthorID>
    <LastName>Franken</LastName>
    <ForeName>C L M C</ForeName>
    <Initials>CL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>105</AuthorID>
    <LastName>Ottenhoff</LastName>
    <ForeName>T H M</ForeName>
    <Initials>TH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>106</AuthorID>
    <LastName>Huygen</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>107</AuthorID>
    <LastName>Otto</LastName>
    <ForeName>R A</ForeName>
    <Initials>RA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>108</AuthorID>
    <LastName>Paker</LastName>
    <ForeName>I</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>109</AuthorID>
    <LastName>Bane</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>110</AuthorID>
    <LastName>Beamer</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>111</AuthorID>
    <LastName>Jaczynski</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>112</AuthorID>
    <LastName>Matak</LastName>
    <ForeName>K E</ForeName>
    <Initials>KE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>113</AuthorID>
    <LastName>Choi</LastName>
    <ForeName>Hye Duck</ForeName>
    <Initials>HD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>114</AuthorID>
    <LastName>Kim</LastName>
    <ForeName>Ji Hae</ForeName>
    <Initials>JH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>115</AuthorID>
    <LastName>Chang</LastName>
    <ForeName>Min Jung</ForeName>
    <Initials>MJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>116</AuthorID>
    <LastName>Kyu-Youn</LastName>
    <ForeName>Yeo</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>117</AuthorID>
    <LastName>Shin</LastName>
    <ForeName>Wan Gyoon</ForeName>
    <Initials>WG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>118</AuthorID>
    <LastName>Kustermann</LastName>
    <ForeName>Andreas</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>119</AuthorID>
    <LastName>Neuhuber</LastName>
    <ForeName>Winfried</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>120</AuthorID>
    <LastName>Brehmer</LastName>
    <ForeName>Axel</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>121</AuthorID>
    <LastName>Garcia</LastName>
    <ForeName>N</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>122</AuthorID>
    <LastName>Gondran</LastName>
    <ForeName>C</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>123</AuthorID>
    <LastName>Menon</LastName>
    <ForeName>G</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>124</AuthorID>
    <LastName>Mur</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>125</AuthorID>
    <LastName>Oberto</LastName>
    <ForeName>G</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>126</AuthorID>
    <LastName>Guerif</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>127</AuthorID>
    <LastName>Dal Farra</LastName>
    <ForeName>C</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>128</AuthorID>
    <LastName>Domloge</LastName>
    <ForeName>N</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>129</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>130</AuthorID>
    <LastName>Tuve</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>131</AuthorID>
    <LastName>Persson</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>132</AuthorID>
    <LastName>Beyer</LastName>
    <ForeName>I</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>133</AuthorID>
    <LastName>Yumul</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>134</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Z Y</ForeName>
    <Initials>ZY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>135</AuthorID>
    <LastName>Tragoolpua</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>136</AuthorID>
    <LastName>Hellstr철m</LastName>
    <ForeName>K-E</ForeName>
    <Initials>KE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>137</AuthorID>
    <LastName>Roffler</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>138</AuthorID>
    <LastName>Lieber</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>139</AuthorID>
    <LastName>Serre</LastName>
    <ForeName>C</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>140</AuthorID>
    <LastName>Lebleu</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>141</AuthorID>
    <LastName>Bergeron</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>142</AuthorID>
    <LastName>Plantivaux</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>143</AuthorID>
    <LastName>Botto</LastName>
    <ForeName>J M</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>144</AuthorID>
    <LastName>Vasta</LastName>
    <ForeName>V</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>145</AuthorID>
    <LastName>Sedensky</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>146</AuthorID>
    <LastName>Morgan</LastName>
    <ForeName>P</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>147</AuthorID>
    <LastName>Hahn</LastName>
    <ForeName>S H</ForeName>
    <Initials>SH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>148</AuthorID>
    <LastName>Rodriguez-Fernandez</LastName>
    <ForeName>Imilce A</ForeName>
    <Initials>IA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>149</AuthorID>
    <LastName>de Leon</LastName>
    <ForeName>Jessica Cruz</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>150</AuthorID>
    <LastName>Huynh</LastName>
    <ForeName>My-Hang</ForeName>
    <Initials>MH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>151</AuthorID>
    <LastName>Carruthers</LastName>
    <ForeName>Vern B</ForeName>
    <Initials>VB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>152</AuthorID>
    <LastName>Morrissette</LastName>
    <ForeName>Naomi S</ForeName>
    <Initials>NS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>153</AuthorID>
    <LastName>Van Nieuwenhuyse</LastName>
    <ForeName>An</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>154</AuthorID>
    <LastName>Bogers</LastName>
    <ForeName>Johannes</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>155</AuthorID>
    <LastName>De Jonge</LastName>
    <ForeName>Eric</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>156</AuthorID>
    <LastName>De Beeck</LastName>
    <ForeName>Lode Op</ForeName>
    <Initials>LO</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>157</AuthorID>
    <LastName>Mathe챦</LastName>
    <ForeName>Catharina</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>158</AuthorID>
    <LastName>Menon</LastName>
    <ForeName>Gopinathan K</ForeName>
    <Initials>GK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>159</AuthorID>
    <LastName>Botto</LastName>
    <ForeName>Jean-Marie</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>160</AuthorID>
    <LastName>Zheng</LastName>
    <ForeName>Tongsen</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>161</AuthorID>
    <LastName>Meng</LastName>
    <ForeName>Xianzhi</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>162</AuthorID>
    <LastName>Wang</LastName>
    <ForeName>Jiabei</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>163</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Xi</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>164</AuthorID>
    <LastName>Yin</LastName>
    <ForeName>Dalong</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>165</AuthorID>
    <LastName>Liang</LastName>
    <ForeName>Yingjian</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>166</AuthorID>
    <LastName>Song</LastName>
    <ForeName>Xuan</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>167</AuthorID>
    <LastName>Pan</LastName>
    <ForeName>Shangha</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>168</AuthorID>
    <LastName>Jiang</LastName>
    <ForeName>Hongchi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>169</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Lianxin</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>170</AuthorID>
    <LastName>Chadalapaka</LastName>
    <ForeName>Gayathri</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>171</AuthorID>
    <LastName>Jutooru</LastName>
    <ForeName>Indira</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>172</AuthorID>
    <LastName>Burghardt</LastName>
    <ForeName>Robert</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>173</AuthorID>
    <LastName>Safe</LastName>
    <ForeName>Stephen</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>174</AuthorID>
    <LastName>Saidou Balde</LastName>
    <ForeName>El-Hadj</ForeName>
    <Initials>el-H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>175</AuthorID>
    <LastName>M챕galizzi</LastName>
    <ForeName>V챕ronique</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>176</AuthorID>
    <LastName>Cao</LastName>
    <ForeName>Martine</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>177</AuthorID>
    <LastName>Angenot</LastName>
    <ForeName>Luc</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>178</AuthorID>
    <LastName>Kiss</LastName>
    <ForeName>Robert</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>179</AuthorID>
    <LastName>Van Damme</LastName>
    <ForeName>Marc</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>180</AuthorID>
    <LastName>Frederich</LastName>
    <ForeName>Michel</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>181</AuthorID>
    <LastName>Sofronescu</LastName>
    <ForeName>Alina G</ForeName>
    <Initials>AG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>182</AuthorID>
    <LastName>Detillieux</LastName>
    <ForeName>Karen A</ForeName>
    <Initials>KA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>183</AuthorID>
    <LastName>Cattini</LastName>
    <ForeName>Peter A</ForeName>
    <Initials>PA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>184</AuthorID>
    <LastName>Zubovych</LastName>
    <ForeName>Iryna O</ForeName>
    <Initials>IO</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>185</AuthorID>
    <LastName>Straud</LastName>
    <ForeName>Sarah</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>186</AuthorID>
    <LastName>Roth</LastName>
    <ForeName>Michael G</ForeName>
    <Initials>MG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>187</AuthorID>
    <LastName>Sauane</LastName>
    <ForeName>Moira</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>188</AuthorID>
    <LastName>Su</LastName>
    <ForeName>Zao-Zhong</ForeName>
    <Initials>ZZ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>189</AuthorID>
    <LastName>Dash</LastName>
    <ForeName>Rupesh</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>190</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Xiang</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>191</AuthorID>
    <LastName>Norris</LastName>
    <ForeName>James S</ForeName>
    <Initials>JS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>192</AuthorID>
    <LastName>Sarkar</LastName>
    <ForeName>Devanand</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>193</AuthorID>
    <LastName>Lee</LastName>
    <ForeName>Seok-Geun</ForeName>
    <Initials>SG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>194</AuthorID>
    <LastName>Allegood</LastName>
    <ForeName>Jeremy C</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>195</AuthorID>
    <LastName>Dent</LastName>
    <ForeName>Paul</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>196</AuthorID>
    <LastName>Spiegel</LastName>
    <ForeName>Sarah</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>197</AuthorID>
    <LastName>Fisher</LastName>
    <ForeName>Paul B</ForeName>
    <Initials>PB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>198</AuthorID>
    <LastName>Wittstock</LastName>
    <ForeName>Matthias</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>199</AuthorID>
    <LastName>Grossmann</LastName>
    <ForeName>Annette</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>200</AuthorID>
    <LastName>Kunesch</LastName>
    <ForeName>Erwin</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>201</AuthorID>
    <LastName>Walter</LastName>
    <ForeName>Uwe</ForeName>
    <Initials>U</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>202</AuthorID>
    <LastName>Benecke</LastName>
    <ForeName>Reiner</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>203</AuthorID>
    <LastName>Wolters</LastName>
    <ForeName>Alexander</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>204</AuthorID>
    <LastName>Serra</LastName>
    <ForeName>Arm챕nio</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>205</AuthorID>
    <LastName>Pineiro</LastName>
    <ForeName>Marta</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>206</AuthorID>
    <LastName>Santos</LastName>
    <ForeName>Catarina Isabel</ForeName>
    <Initials>CI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>207</AuthorID>
    <LastName>Gonsalves</LastName>
    <ForeName>Ant처nio Manuel d'A Rocha</ForeName>
    <Initials>AM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>208</AuthorID>
    <LastName>Abrantes</LastName>
    <ForeName>Margarida</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>209</AuthorID>
    <LastName>Laranjo</LastName>
    <ForeName>Mafalda</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>210</AuthorID>
    <LastName>Botelho</LastName>
    <ForeName>Maria Filomena</ForeName>
    <Initials>MF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>211</AuthorID>
    <LastName>Dingley</LastName>
    <ForeName>Stephen</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>212</AuthorID>
    <LastName>Polyak</LastName>
    <ForeName>Erzsebet</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>213</AuthorID>
    <LastName>Lightfoot</LastName>
    <ForeName>Richard</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>214</AuthorID>
    <LastName>Ostrovsky</LastName>
    <ForeName>Julian</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>215</AuthorID>
    <LastName>Rao</LastName>
    <ForeName>Meera</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>216</AuthorID>
    <LastName>Greco</LastName>
    <ForeName>Todd</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>217</AuthorID>
    <LastName>Ischiropoulos</LastName>
    <ForeName>Harry</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>218</AuthorID>
    <LastName>Falk</LastName>
    <ForeName>Marni J</ForeName>
    <Initials>MJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>219</AuthorID>
    <LastName>Magri</LastName>
    <ForeName>Maymouna</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>220</AuthorID>
    <LastName>Yatim</LastName>
    <ForeName>Ahmad</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>221</AuthorID>
    <LastName>Benne</LastName>
    <ForeName>Clarisse</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>222</AuthorID>
    <LastName>Balbo</LastName>
    <ForeName>Mich챔le</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>223</AuthorID>
    <LastName>Henry</LastName>
    <ForeName>Adeline</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>224</AuthorID>
    <LastName>Serraf</LastName>
    <ForeName>Alain</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>225</AuthorID>
    <LastName>Sakano</LastName>
    <ForeName>Seiji</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>226</AuthorID>
    <LastName>Gazzolo</LastName>
    <ForeName>Louis</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>227</AuthorID>
    <LastName>L챕vy</LastName>
    <ForeName>Yves</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>228</AuthorID>
    <LastName>Leli챔vre</LastName>
    <ForeName>Jean-Daniel</ForeName>
    <Initials>JD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>229</AuthorID>
    <LastName>de Abreu</LastName>
    <ForeName>Leonardo Araujo</ForeName>
    <Initials>LA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>230</AuthorID>
    <LastName>Fabres</LastName>
    <ForeName>Arianne</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>231</AuthorID>
    <LastName>Esteves</LastName>
    <ForeName>Eliane</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>232</AuthorID>
    <LastName>Masuda</LastName>
    <ForeName>Aoi</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>233</AuthorID>
    <Suffix>Jr</Suffix>
    <LastName>da Silva Vaz</LastName>
    <ForeName>Itabajara</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>234</AuthorID>
    <LastName>Daffre</LastName>
    <ForeName>Sirlei</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>235</AuthorID>
    <LastName>Logullo</LastName>
    <ForeName>Carlos</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>236</AuthorID>
    <LastName>Cense</LastName>
    <ForeName>Barry</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>237</AuthorID>
    <LastName>Koperda</LastName>
    <ForeName>Erik</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>238</AuthorID>
    <LastName>Brown</LastName>
    <ForeName>Jeffrey M</ForeName>
    <Initials>JM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>239</AuthorID>
    <LastName>Kocaoglu</LastName>
    <ForeName>Omer P</ForeName>
    <Initials>OP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>240</AuthorID>
    <LastName>Gao</LastName>
    <ForeName>Weihua</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>241</AuthorID>
    <LastName>Jonnal</LastName>
    <ForeName>Ravi S</ForeName>
    <Initials>RS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>242</AuthorID>
    <LastName>Miller</LastName>
    <ForeName>Donald T</ForeName>
    <Initials>DT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>243</AuthorID>
    <LastName>Paupe</LastName>
    <ForeName>Vincent</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>244</AuthorID>
    <LastName>Dassa</LastName>
    <ForeName>Emmanuel P</ForeName>
    <Initials>EP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>245</AuthorID>
    <LastName>Goncalves</LastName>
    <ForeName>Sergio</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>246</AuthorID>
    <LastName>Auch챔re</LastName>
    <ForeName>Fran챌oise</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>247</AuthorID>
    <LastName>L철nn</LastName>
    <ForeName>Maria</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>248</AuthorID>
    <LastName>Holmgren</LastName>
    <ForeName>Arne</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>249</AuthorID>
    <LastName>Rustin</LastName>
    <ForeName>Pierre</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>250</AuthorID>
    <LastName>Keck</LastName>
    <ForeName>Kathy</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>251</AuthorID>
    <LastName>Volper</LastName>
    <ForeName>Esther M</ForeName>
    <Initials>EM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>252</AuthorID>
    <LastName>Spengler</LastName>
    <ForeName>Ryan M</ForeName>
    <Initials>RM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>253</AuthorID>
    <LastName>Long</LastName>
    <ForeName>Dang D</ForeName>
    <Initials>DD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>254</AuthorID>
    <LastName>Chan</LastName>
    <ForeName>Chi Y</ForeName>
    <Initials>CY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>255</AuthorID>
    <LastName>Ding</LastName>
    <ForeName>Ye</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>256</AuthorID>
    <LastName>McCaffrey</LastName>
    <ForeName>Anton P</ForeName>
    <Initials>AP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>257</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>Fei</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>258</AuthorID>
    <LastName>Ivanov</LastName>
    <ForeName>Ivan</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>259</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Rui</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>260</AuthorID>
    <LastName>Khedr</LastName>
    <ForeName>E M</ForeName>
    <Initials>EM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>261</AuthorID>
    <LastName>Rothwell</LastName>
    <ForeName>J C</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>262</AuthorID>
    <LastName>Ahmed</LastName>
    <ForeName>M A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>263</AuthorID>
    <LastName>Awad</LastName>
    <ForeName>E M</ForeName>
    <Initials>EM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>264</AuthorID>
    <LastName>Galal</LastName>
    <ForeName>O</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>265</AuthorID>
    <LastName>Roupie</LastName>
    <ForeName>Virginie</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>266</AuthorID>
    <LastName>Leroy</LastName>
    <ForeName>Baptiste</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>267</AuthorID>
    <LastName>Rosseels</LastName>
    <ForeName>Val챕rie</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>268</AuthorID>
    <LastName>Piersoel</LastName>
    <ForeName>Virginie</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>269</AuthorID>
    <LastName>No챘l-Georis</LastName>
    <ForeName>Isabelle</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>270</AuthorID>
    <LastName>Romano</LastName>
    <ForeName>Marta</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>271</AuthorID>
    <LastName>Govaerts</LastName>
    <ForeName>Marc</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>272</AuthorID>
    <LastName>Letesson</LastName>
    <ForeName>Jean-Jacques</ForeName>
    <Initials>JJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>273</AuthorID>
    <LastName>Wattiez</LastName>
    <ForeName>Ruddy</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>274</AuthorID>
    <LastName>Huygen</LastName>
    <ForeName>Kris</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>275</AuthorID>
    <LastName>Dorival</LastName>
    <ForeName>C챕line</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>276</AuthorID>
    <LastName>Brizzi</LastName>
    <ForeName>Fanny</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>277</AuthorID>
    <LastName>Sol-Foulon</LastName>
    <ForeName>Nathalie</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>278</AuthorID>
    <LastName>Six</LastName>
    <ForeName>Emmanuelle</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>279</AuthorID>
    <LastName>Andr챕-Schmutz</LastName>
    <ForeName>Isabelle</ForeName>
    <Initials>I</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>280</AuthorID>
    <LastName>Cavazzana-Calvo</LastName>
    <ForeName>Marina</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>281</AuthorID>
    <LastName>Coulombel</LastName>
    <ForeName>Laure</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>282</AuthorID>
    <LastName>Estaquier</LastName>
    <ForeName>J챕r척me</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>283</AuthorID>
    <LastName>Schwartz</LastName>
    <ForeName>Olivier</ForeName>
    <Initials>O</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>284</AuthorID>
    <LastName>Nagaoka</LastName>
    <ForeName>Yasuo</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>285</AuthorID>
    <LastName>Otsuki</LastName>
    <ForeName>Kota</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>286</AuthorID>
    <LastName>Fujita</LastName>
    <ForeName>Tetsuro</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>287</AuthorID>
    <LastName>Uesato</LastName>
    <ForeName>Shinichi</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>288</AuthorID>
    <LastName>Hiestand</LastName>
    <ForeName>Peter C</ForeName>
    <Initials>PC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>289</AuthorID>
    <LastName>Rausch</LastName>
    <ForeName>Martin</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>290</AuthorID>
    <LastName>Meier</LastName>
    <ForeName>Daniela Piani</ForeName>
    <Initials>DP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>291</AuthorID>
    <LastName>Foster</LastName>
    <ForeName>Carolyn A</ForeName>
    <Initials>CA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>292</AuthorID>
    <LastName>Panjarian</LastName>
    <ForeName>Shoghag</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>293</AuthorID>
    <LastName>Kozhaya</LastName>
    <ForeName>Lina</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>294</AuthorID>
    <LastName>Arayssi</LastName>
    <ForeName>Sawsan</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>295</AuthorID>
    <LastName>Yehia</LastName>
    <ForeName>Maisaa</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>296</AuthorID>
    <LastName>Bielawski</LastName>
    <ForeName>Jacek</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>297</AuthorID>
    <LastName>Bielawska</LastName>
    <ForeName>Alicja</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>298</AuthorID>
    <LastName>Usta</LastName>
    <ForeName>Julnar</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>299</AuthorID>
    <LastName>Hannun</LastName>
    <ForeName>Yusuf A</ForeName>
    <Initials>YA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>300</AuthorID>
    <LastName>Obeid</LastName>
    <ForeName>Lina M</ForeName>
    <Initials>LM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>301</AuthorID>
    <LastName>Dbaibo</LastName>
    <ForeName>Ghassan S</ForeName>
    <Initials>GS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>302</AuthorID>
    <LastName>Tsatsanis</LastName>
    <ForeName>Christos</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>303</AuthorID>
    <LastName>Vaporidi</LastName>
    <ForeName>Katerina</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>304</AuthorID>
    <LastName>Zacharioudaki</LastName>
    <ForeName>Vassiliki</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>305</AuthorID>
    <LastName>Androulidaki</LastName>
    <ForeName>Ariadne</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>306</AuthorID>
    <LastName>Sykulev</LastName>
    <ForeName>Yuri</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>307</AuthorID>
    <LastName>Margioris</LastName>
    <ForeName>Andrew N</ForeName>
    <Initials>AN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>308</AuthorID>
    <LastName>Tsichlis</LastName>
    <ForeName>Philip N</ForeName>
    <Initials>PN</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>309</AuthorID>
    <LastName>Frank</LastName>
    <ForeName>William E</ForeName>
    <Initials>WE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>310</AuthorID>
    <LastName>Ralph</LastName>
    <ForeName>Heather C</ForeName>
    <Initials>HC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>311</AuthorID>
    <LastName>Tahir</LastName>
    <ForeName>Mohammad A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>312</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Yi-Guang</ForeName>
    <Initials>YG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>313</AuthorID>
    <LastName>Jiang</LastName>
    <ForeName>Yi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>314</AuthorID>
    <LastName>Li</LastName>
    <ForeName>Wen-Jun</ForeName>
    <Initials>WJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>315</AuthorID>
    <LastName>Cui</LastName>
    <ForeName>Xiao-Long</ForeName>
    <Initials>XL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>316</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>Li-Hua</ForeName>
    <Initials>LH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>317</AuthorID>
    <LastName>Janossy</LastName>
    <ForeName>George</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>318</AuthorID>
    <LastName>Barry</LastName>
    <ForeName>Simon M</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>319</AuthorID>
    <LastName>Breen</LastName>
    <ForeName>Ronan A M</ForeName>
    <Initials>RA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>320</AuthorID>
    <LastName>Hardy</LastName>
    <ForeName>Gareth A D</ForeName>
    <Initials>GA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>321</AuthorID>
    <LastName>Lipman</LastName>
    <ForeName>Marc</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>322</AuthorID>
    <LastName>Kern</LastName>
    <ForeName>Florian</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>323</AuthorID>
    <LastName>Rea</LastName>
    <ForeName>Shane L</ForeName>
    <Initials>SL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>324</AuthorID>
    <LastName>Ventura</LastName>
    <ForeName>Natascia</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>325</AuthorID>
    <LastName>Johnson</LastName>
    <ForeName>Thomas E</ForeName>
    <Initials>TE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>326</AuthorID>
    <LastName>Rajcani</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>327</AuthorID>
    <LastName>Le Stunff</LastName>
    <ForeName>Herv챕</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>328</AuthorID>
    <LastName>Giussani</LastName>
    <ForeName>Paola</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>329</AuthorID>
    <LastName>Maceyka</LastName>
    <ForeName>Michael</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>330</AuthorID>
    <LastName>L챕pine</LastName>
    <ForeName>Sandrine</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>331</AuthorID>
    <LastName>Milstien</LastName>
    <ForeName>Sheldon</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>332</AuthorID>
    <LastName>Avanzino</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>333</AuthorID>
    <LastName>Teo</LastName>
    <ForeName>J T H</ForeName>
    <Initials>JT</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>334</AuthorID>
    <LastName>Fikri</LastName>
    <ForeName>Youssef</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>335</AuthorID>
    <LastName>Nyabenda</LastName>
    <ForeName>Jean</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>336</AuthorID>
    <LastName>Content</LastName>
    <ForeName>Jean</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>337</AuthorID>
    <LastName>Fontaine</LastName>
    <ForeName>V챕ronique</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>338</AuthorID>
    <LastName>Mascaux</LastName>
    <ForeName>Corinne</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>339</AuthorID>
    <LastName>Weyn</LastName>
    <ForeName>Christine</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>340</AuthorID>
    <LastName>Bernis</LastName>
    <ForeName>Aurore</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>341</AuthorID>
    <LastName>Celio</LastName>
    <ForeName>Nathalie</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>342</AuthorID>
    <LastName>Lef챔vre</LastName>
    <ForeName>Philippe</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>343</AuthorID>
    <LastName>Kaufman</LastName>
    <ForeName>Leonard</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>344</AuthorID>
    <LastName>Garbar</LastName>
    <ForeName>Christian</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>345</AuthorID>
    <LastName>Crevel</LastName>
    <ForeName>R W R</ForeName>
    <Initials>RW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>346</AuthorID>
    <LastName>Cooper</LastName>
    <ForeName>K J</ForeName>
    <Initials>KJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>347</AuthorID>
    <LastName>Poulsen</LastName>
    <ForeName>L K</ForeName>
    <Initials>LK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>348</AuthorID>
    <LastName>Hummelshoj</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>349</AuthorID>
    <LastName>Bindslev-Jensen</LastName>
    <ForeName>C</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>350</AuthorID>
    <LastName>Burks</LastName>
    <ForeName>A W</ForeName>
    <Initials>AW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>351</AuthorID>
    <LastName>Sampson</LastName>
    <ForeName>H A</ForeName>
    <Initials>HA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>352</AuthorID>
    <LastName>Ellinger</LastName>
    <ForeName>Erin R</ForeName>
    <Initials>ER</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>353</AuthorID>
    <LastName>Krishack</LastName>
    <ForeName>Paulette A</ForeName>
    <Initials>PA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>354</AuthorID>
    <LastName>Jung</LastName>
    <ForeName>Patrick</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>355</AuthorID>
    <LastName>Beyerle</LastName>
    <ForeName>Astrid</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>356</AuthorID>
    <LastName>Humpich</LastName>
    <ForeName>Marek</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>357</AuthorID>
    <LastName>Neumann-Haefelin</LastName>
    <ForeName>Tobias</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>358</AuthorID>
    <LastName>Lanfermann</LastName>
    <ForeName>Heinrich</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>359</AuthorID>
    <LastName>Ziemann</LastName>
    <ForeName>Ulf</ForeName>
    <Initials>U</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>360</AuthorID>
    <LastName>Chiba</LastName>
    <ForeName>Kenji</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>361</AuthorID>
    <LastName>Matsuyuki</LastName>
    <ForeName>Hirofumi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>362</AuthorID>
    <LastName>Maeda</LastName>
    <ForeName>Yasuhiro</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>363</AuthorID>
    <LastName>Sugahara</LastName>
    <ForeName>Kunio</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>364</AuthorID>
    <LastName>Gomez</LastName>
    <ForeName>German G</ForeName>
    <Initials>GG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>365</AuthorID>
    <LastName>Varella-Garcia</LastName>
    <ForeName>Marileila</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>366</AuthorID>
    <LastName>Kruse</LastName>
    <ForeName>Carol A</ForeName>
    <Initials>CA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>367</AuthorID>
    <LastName>Lee</LastName>
    <ForeName>Shin-Hee</ForeName>
    <Initials>SH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>368</AuthorID>
    <LastName>Yang</LastName>
    <ForeName>Jung-Ik</ForeName>
    <Initials>JI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>369</AuthorID>
    <LastName>Hong</LastName>
    <ForeName>Suck-Min</ForeName>
    <Initials>SM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>370</AuthorID>
    <LastName>Hahm</LastName>
    <ForeName>Dae-Hyun</ForeName>
    <Initials>DH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>371</AuthorID>
    <LastName>Lee</LastName>
    <ForeName>Shin-Young</ForeName>
    <Initials>SY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>372</AuthorID>
    <LastName>Kim</LastName>
    <ForeName>Il-Hwan</ForeName>
    <Initials>IH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>373</AuthorID>
    <LastName>Choi</LastName>
    <ForeName>Sang-Yun</ForeName>
    <Initials>SY</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>374</AuthorID>
    <LastName>Thierbach</LastName>
    <ForeName>Ren챕</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>375</AuthorID>
    <LastName>Schulz</LastName>
    <ForeName>Tim J</ForeName>
    <Initials>TJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>376</AuthorID>
    <LastName>Isken</LastName>
    <ForeName>Frank</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>377</AuthorID>
    <LastName>Voigt</LastName>
    <ForeName>Anja</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>378</AuthorID>
    <LastName>Mietzner</LastName>
    <ForeName>Brun</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>379</AuthorID>
    <LastName>Drewes</LastName>
    <ForeName>Gunnar</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>380</AuthorID>
    <LastName>von Kleist-Retzow</LastName>
    <ForeName>J체rgen-Christoph</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>381</AuthorID>
    <LastName>Wiesner</LastName>
    <ForeName>Rudolf J</ForeName>
    <Initials>RJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>382</AuthorID>
    <LastName>Magnuson</LastName>
    <ForeName>Mark A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>383</AuthorID>
    <LastName>Puccio</LastName>
    <ForeName>H챕l챔ne</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>384</AuthorID>
    <LastName>Pfeiffer</LastName>
    <ForeName>Andreas F H</ForeName>
    <Initials>AF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>385</AuthorID>
    <LastName>Steinberg</LastName>
    <ForeName>Pablo</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>386</AuthorID>
    <LastName>Ristow</LastName>
    <ForeName>Michael</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>387</AuthorID>
    <LastName>Tang</LastName>
    <ForeName>Lin</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>388</AuthorID>
    <LastName>Andrade</LastName>
    <ForeName>M Amparo</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>389</AuthorID>
    <LastName>Siles-Lucas</LastName>
    <ForeName>Mar</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>390</AuthorID>
    <LastName>P챕rez Arellano</LastName>
    <ForeName>Jos챕 Luis</ForeName>
    <Initials>JL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>391</AuthorID>
    <LastName>Pou Barreto</LastName>
    <ForeName>Cristina</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>392</AuthorID>
    <LastName>Valladares</LastName>
    <ForeName>Basilio</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>393</AuthorID>
    <LastName>Espinoza</LastName>
    <ForeName>Elsa</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>394</AuthorID>
    <LastName>Muro</LastName>
    <ForeName>Antonio</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>395</AuthorID>
    <LastName>Garvey</LastName>
    <ForeName>Marjorie A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>396</AuthorID>
    <LastName>Barker</LastName>
    <ForeName>Christopher A</ForeName>
    <Initials>CA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>397</AuthorID>
    <LastName>Bartko</LastName>
    <ForeName>John J</ForeName>
    <Initials>JJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>398</AuthorID>
    <LastName>Denckla</LastName>
    <ForeName>Martha B</ForeName>
    <Initials>MB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>399</AuthorID>
    <LastName>Wassermann</LastName>
    <ForeName>Eric M</ForeName>
    <Initials>EM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>400</AuthorID>
    <LastName>Castellanos</LastName>
    <ForeName>F Xavier</ForeName>
    <Initials>FX</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>401</AuthorID>
    <LastName>Dell</LastName>
    <ForeName>Mary Lynn</ForeName>
    <Initials>ML</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>402</AuthorID>
    <LastName>Wood</LastName>
    <ForeName>Moira D</ForeName>
    <Initials>MD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>403</AuthorID>
    <LastName>Huang</LastName>
    <ForeName>Yajue</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>404</AuthorID>
    <LastName>Bibbo</LastName>
    <ForeName>Marluce</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>405</AuthorID>
    <LastName>Zayour</LastName>
    <ForeName>Dany H</ForeName>
    <Initials>DH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>406</AuthorID>
    <LastName>Selman</LastName>
    <ForeName>Warren R</ForeName>
    <Initials>WR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>407</AuthorID>
    <LastName>Arafah</LastName>
    <ForeName>Baha M</ForeName>
    <Initials>BM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>408</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Xiaoying</ForeName>
    <Initials>X</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>409</AuthorID>
    <LastName>Yu</LastName>
    <ForeName>Chang-An</ForeName>
    <Initials>CA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>410</AuthorID>
    <LastName>Yu</LastName>
    <ForeName>Linda</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>411</AuthorID>
    <LastName>Fr챕d챕rich</LastName>
    <ForeName>Michel</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>412</AuthorID>
    <LastName>Tits</LastName>
    <ForeName>Monique</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>413</AuthorID>
    <LastName>Goffin</LastName>
    <ForeName>Eric</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>414</AuthorID>
    <LastName>Philippe</LastName>
    <ForeName>Genevi챔ve</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>415</AuthorID>
    <LastName>Grellier</LastName>
    <ForeName>Philippe</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>416</AuthorID>
    <LastName>De Mol</LastName>
    <ForeName>Patrick</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>417</AuthorID>
    <LastName>Hayette</LastName>
    <ForeName>Marie-Pierre</ForeName>
    <Initials>MP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>418</AuthorID>
    <LastName>Dolgachev</LastName>
    <ForeName>Vladislav</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>419</AuthorID>
    <LastName>Farooqui</LastName>
    <ForeName>M Sharjeel</ForeName>
    <Initials>MS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>420</AuthorID>
    <LastName>Kulaeva</LastName>
    <ForeName>Olga I</ForeName>
    <Initials>OI</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>421</AuthorID>
    <LastName>Tainsky</LastName>
    <ForeName>Michael A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>422</AuthorID>
    <LastName>Nagy</LastName>
    <ForeName>Biserka</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>423</AuthorID>
    <LastName>Hanada</LastName>
    <ForeName>Kentaro</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>424</AuthorID>
    <LastName>Separovic</LastName>
    <ForeName>Duska</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>425</AuthorID>
    <LastName>Gould</LastName>
    <ForeName>Victor E</ForeName>
    <Initials>VE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>426</AuthorID>
    <LastName>Manosca</LastName>
    <ForeName>Frances</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>427</AuthorID>
    <LastName>Reddy</LastName>
    <ForeName>Vijaya B</ForeName>
    <Initials>VB</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>428</AuthorID>
    <LastName>Gattuso</LastName>
    <ForeName>Paolo</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>429</AuthorID>
    <LastName>Ramer</LastName>
    <ForeName>Robert</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>430</AuthorID>
    <LastName>Weinzierl</LastName>
    <ForeName>Ulrike</ForeName>
    <Initials>U</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>431</AuthorID>
    <LastName>Schwind</LastName>
    <ForeName>Bianca</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>432</AuthorID>
    <LastName>Brune</LastName>
    <ForeName>Kay</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>433</AuthorID>
    <LastName>Hinz</LastName>
    <ForeName>Burkhard</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>434</AuthorID>
    <LastName>Taffe</LastName>
    <ForeName>Bonita</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>435</AuthorID>
    <LastName>Cameron</LastName>
    <ForeName>Ewan R</ForeName>
    <Initials>ER</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>436</AuthorID>
    <LastName>Blyth</LastName>
    <ForeName>Karen</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>437</AuthorID>
    <LastName>Hanlon</LastName>
    <ForeName>Linda</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>438</AuthorID>
    <LastName>Kilbey</LastName>
    <ForeName>Anna</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>439</AuthorID>
    <LastName>Mackay</LastName>
    <ForeName>Nancy</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>440</AuthorID>
    <LastName>Stewart</LastName>
    <ForeName>Monica</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>441</AuthorID>
    <LastName>Terry</LastName>
    <ForeName>Anne</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>442</AuthorID>
    <LastName>Vaillant</LastName>
    <ForeName>Francois</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>443</AuthorID>
    <LastName>Wotton</LastName>
    <ForeName>Sandy</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>444</AuthorID>
    <LastName>Neil</LastName>
    <ForeName>James C</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>445</AuthorID>
    <LastName>Uchida</LastName>
    <ForeName>Yoshikazu</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>446</AuthorID>
    <LastName>Nardo</LastName>
    <ForeName>Anna Di</ForeName>
    <Initials>AD</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>447</AuthorID>
    <LastName>Collins</LastName>
    <ForeName>Vanessa</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>448</AuthorID>
    <LastName>Elias</LastName>
    <ForeName>Peter M</ForeName>
    <Initials>PM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>449</AuthorID>
    <LastName>Holleran</LastName>
    <ForeName>Walter M</ForeName>
    <Initials>WM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>450</AuthorID>
    <LastName>Bentires-Alj</LastName>
    <ForeName>Mohamed</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>451</AuthorID>
    <LastName>Greimers</LastName>
    <ForeName>Roland</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>452</AuthorID>
    <LastName>Gielen</LastName>
    <ForeName>Jacques</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>453</AuthorID>
    <LastName>Bours</LastName>
    <ForeName>Vincent</ForeName>
    <Initials>V</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>454</AuthorID>
    <LastName>Merville</LastName>
    <ForeName>Marie-Paule</ForeName>
    <Initials>MP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>455</AuthorID>
    <LastName>Kroesen</LastName>
    <ForeName>Bart-Jan</ForeName>
    <Initials>BJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>456</AuthorID>
    <LastName>Jacobs</LastName>
    <ForeName>Susan</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>457</AuthorID>
    <LastName>Pettus</LastName>
    <ForeName>Benjamin J</ForeName>
    <Initials>BJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>458</AuthorID>
    <LastName>Sietsma</LastName>
    <ForeName>Hannie</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>459</AuthorID>
    <LastName>Kok</LastName>
    <ForeName>Jan Willem</ForeName>
    <Initials>JW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>460</AuthorID>
    <LastName>de Leij</LastName>
    <ForeName>Lou F M H</ForeName>
    <Initials>LF</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>461</AuthorID>
    <LastName>Im</LastName>
    <ForeName>Dong Soon</ForeName>
    <Initials>DS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>462</AuthorID>
    <LastName>Wispriyono</LastName>
    <ForeName>Bambang</ForeName>
    <Initials>B</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>463</AuthorID>
    <LastName>Schmelz</LastName>
    <ForeName>Eva</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>464</AuthorID>
    <LastName>Pelayo</LastName>
    <ForeName>Homer</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>465</AuthorID>
    <LastName>Kozutsumi</LastName>
    <ForeName>Yasunori</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>466</AuthorID>
    <LastName>Kanazawa</LastName>
    <ForeName>Takayuki</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>467</AuthorID>
    <LastName>Sun</LastName>
    <ForeName>Yidi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>468</AuthorID>
    <LastName>Yamaji</LastName>
    <ForeName>Toshiyuki</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>469</AuthorID>
    <LastName>Yamamoto</LastName>
    <ForeName>Harumi</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>470</AuthorID>
    <LastName>Takematsu</LastName>
    <ForeName>Hiromu</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>471</AuthorID>
    <LastName>Matsumoto</LastName>
    <ForeName>Seiichi</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>472</AuthorID>
    <LastName>Kawaguchi</LastName>
    <ForeName>Noriyoshi</ForeName>
    <Initials>N</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>473</AuthorID>
    <LastName>Manabe</LastName>
    <ForeName>Jun</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>474</AuthorID>
    <LastName>Matsushita</LastName>
    <ForeName>Yasushi</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>475</AuthorID>
    <LastName>Hansen</LastName>
    <ForeName>P O</ForeName>
    <Initials>PO</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>476</AuthorID>
    <LastName>Svensson</LastName>
    <ForeName>P</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>477</AuthorID>
    <LastName>Arendt-Nielsen</LastName>
    <ForeName>L</ForeName>
    <Initials>L</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>478</AuthorID>
    <LastName>Jensen</LastName>
    <ForeName>T S</ForeName>
    <Initials>TS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>479</AuthorID>
    <LastName>Feng</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>480</AuthorID>
    <LastName>Bussi챔re</LastName>
    <ForeName>F</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>481</AuthorID>
    <LastName>Hekimi</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>482</AuthorID>
    <LastName>Couti챰o-Rodr챠guez</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>483</AuthorID>
    <LastName>Hern찼ndez-Cruz</LastName>
    <ForeName>P</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>484</AuthorID>
    <LastName>Giles-R챠os</LastName>
    <ForeName>H</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>485</AuthorID>
    <LastName>Markt</LastName>
    <ForeName>J C</ForeName>
    <Initials>JC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>486</AuthorID>
    <LastName>Mizuno</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>487</AuthorID>
    <LastName>Ito</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>488</AuthorID>
    <LastName>Aoyama</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>489</AuthorID>
    <LastName>Kume</LastName>
    <ForeName>H</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>490</AuthorID>
    <LastName>Nakayama</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>491</AuthorID>
    <LastName>Yamaki</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>492</AuthorID>
    <LastName>Inamoto</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>493</AuthorID>
    <LastName>Murao</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>494</AuthorID>
    <LastName>Yokoyama</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>495</AuthorID>
    <LastName>Kitazawa</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>496</AuthorID>
    <LastName>Maeda</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>497</AuthorID>
    <LastName>Hens</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>498</AuthorID>
    <LastName>Schr철dl</LastName>
    <ForeName>F</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>499</AuthorID>
    <LastName>Brehmer</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>500</AuthorID>
    <LastName>Adriaensen</LastName>
    <ForeName>D</ForeName>
    <Initials>D</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>501</AuthorID>
    <LastName>Neuhuber</LastName>
    <ForeName>W</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>502</AuthorID>
    <LastName>Scheuermann</LastName>
    <ForeName>D W</ForeName>
    <Initials>DW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>503</AuthorID>
    <LastName>Schemann</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>504</AuthorID>
    <LastName>Timmermans</LastName>
    <ForeName>J P</ForeName>
    <Initials>JP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>505</AuthorID>
    <LastName>Brayman</LastName>
    <ForeName>A A</ForeName>
    <Initials>AA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>506</AuthorID>
    <LastName>Coppage</LastName>
    <ForeName>M L</ForeName>
    <Initials>ML</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>507</AuthorID>
    <LastName>Vaidya</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>508</AuthorID>
    <LastName>Miller</LastName>
    <ForeName>M W</ForeName>
    <Initials>MW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>509</AuthorID>
    <LastName>Visioli</LastName>
    <ForeName>A G</ForeName>
    <Initials>AG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>510</AuthorID>
    <LastName>Rivens</LastName>
    <ForeName>I H</ForeName>
    <Initials>IH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>511</AuthorID>
    <LastName>ter Haar</LastName>
    <ForeName>G R</ForeName>
    <Initials>GR</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>512</AuthorID>
    <LastName>Horwich</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>513</AuthorID>
    <LastName>Huddart</LastName>
    <ForeName>R A</ForeName>
    <Initials>RA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>514</AuthorID>
    <LastName>Moskovic</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>515</AuthorID>
    <LastName>Padhani</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>516</AuthorID>
    <LastName>Glees</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>517</AuthorID>
    <LastName>Morgan</LastName>
    <ForeName>A J</ForeName>
    <Initials>AJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>518</AuthorID>
    <LastName>Jacob</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>519</AuthorID>
    <LastName>Rezende</LastName>
    <ForeName>S A</ForeName>
    <Initials>SA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>520</AuthorID>
    <LastName>Gollob</LastName>
    <ForeName>K J</ForeName>
    <Initials>KJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>521</AuthorID>
    <LastName>Correa-Oliveira</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>522</AuthorID>
    <LastName>Goes</LastName>
    <ForeName>A M</ForeName>
    <Initials>AM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>523</AuthorID>
    <LastName>Chen</LastName>
    <ForeName>Y H</ForeName>
    <Initials>YH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>524</AuthorID>
    <LastName>Dierich</LastName>
    <ForeName>M P</ForeName>
    <Initials>MP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>525</AuthorID>
    <LastName>Schmelz</LastName>
    <ForeName>E M</ForeName>
    <Initials>EM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>526</AuthorID>
    <LastName>Dombrink-Kurtzman</LastName>
    <ForeName>M A</ForeName>
    <Initials>MA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>527</AuthorID>
    <LastName>Roberts</LastName>
    <ForeName>P C</ForeName>
    <Initials>PC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>528</AuthorID>
    <LastName>Kozutsumi</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>529</AuthorID>
    <LastName>Kawasaki</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>530</AuthorID>
    <Suffix>Jr</Suffix>
    <LastName>Merrill</LastName>
    <ForeName>A H</ForeName>
    <Initials>AH</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>531</AuthorID>
    <LastName>Xiao</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>532</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>W</ForeName>
    <Initials>W</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>533</AuthorID>
    <LastName>Zhao</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>534</AuthorID>
    <LastName>Speth</LastName>
    <ForeName>C</ForeName>
    <Initials>C</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>535</AuthorID>
    <LastName>Okamura</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>536</AuthorID>
    <LastName>Oku</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>537</AuthorID>
    <LastName>Fujii</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>538</AuthorID>
    <LastName>Otsuki</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>539</AuthorID>
    <LastName>Adachi</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>540</AuthorID>
    <LastName>Morimoto</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>541</AuthorID>
    <LastName>Takemura</LastName>
    <ForeName>H</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>542</AuthorID>
    <LastName>Hatta</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>543</AuthorID>
    <LastName>Yamada</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>544</AuthorID>
    <LastName>Ohshika</LastName>
    <ForeName>H</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>545</AuthorID>
    <LastName>Tsuji</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>546</AuthorID>
    <LastName>Kaneko</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>547</AuthorID>
    <LastName>Yamaguchi</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>548</AuthorID>
    <LastName>Goto</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>549</AuthorID>
    <LastName>Fujita</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>550</AuthorID>
    <LastName>Inoue</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>551</AuthorID>
    <LastName>Yamamoto</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>552</AuthorID>
    <LastName>Ikumoto</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>553</AuthorID>
    <LastName>Sasaki</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>554</AuthorID>
    <LastName>Toyama</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>555</AuthorID>
    <LastName>Chiba</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>556</AuthorID>
    <LastName>Hoshino</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>557</AuthorID>
    <LastName>Okumoto</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>558</AuthorID>
    <LastName>Masuda</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>559</AuthorID>
    <LastName>Andoh</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>560</AuthorID>
    <LastName>Shimura</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>561</AuthorID>
    <LastName>Ohkawara</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>562</AuthorID>
    <LastName>Hosoda</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>563</AuthorID>
    <LastName>Hashimoto</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>564</AuthorID>
    <LastName>Sasaki</LastName>
    <ForeName>H</ForeName>
    <Initials>H</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>565</AuthorID>
    <LastName>Takishima</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>566</AuthorID>
    <LastName>Chopra</LastName>
    <ForeName>D P</ForeName>
    <Initials>DP</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>567</AuthorID>
    <LastName>Xue-Hu</LastName>
    <ForeName>I C</ForeName>
    <Initials>IC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>568</AuthorID>
    <LastName>Brody</LastName>
    <ForeName>B A</ForeName>
    <Initials>BA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>569</AuthorID>
    <LastName>Hunter</LastName>
    <ForeName>E</ForeName>
    <Initials>E</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>570</AuthorID>
    <LastName>Nishimura</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>571</AuthorID>
    <LastName>Kumamoto</LastName>
    <ForeName>Y</ForeName>
    <Initials>Y</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>572</AuthorID>
    <LastName>Hirose</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>573</AuthorID>
    <LastName>Shibuya</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>574</AuthorID>
    <LastName>Tsukamoto</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>575</AuthorID>
    <LastName>Ohya</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>576</AuthorID>
    <LastName>Shimada</LastName>
    <ForeName>K</ForeName>
    <Initials>K</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>577</AuthorID>
    <LastName>Yanagisawa</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>578</AuthorID>
    <LastName>Nakayama</LastName>
    <ForeName>F</ForeName>
    <Initials>F</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>579</AuthorID>
    <LastName>Paulsson</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>580</AuthorID>
    <LastName>Wadstr철m</LastName>
    <ForeName>T</ForeName>
    <Initials>T</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>581</AuthorID>
    <LastName>Wu</LastName>
    <ForeName>H Q</ForeName>
    <Initials>HQ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>582</AuthorID>
    <LastName>Lai</LastName>
    <ForeName>Z W</ForeName>
    <Initials>ZW</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>583</AuthorID>
    <LastName>Xu</LastName>
    <ForeName>H G</ForeName>
    <Initials>HG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>584</AuthorID>
    <LastName>Song</LastName>
    <ForeName>R K</ForeName>
    <Initials>RK</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>585</AuthorID>
    <LastName>Ma</LastName>
    <ForeName>T G</ForeName>
    <Initials>TG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>586</AuthorID>
    <LastName>Shi</LastName>
    <ForeName>N A</ForeName>
    <Initials>NA</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>587</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>R M</ForeName>
    <Initials>RM</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>588</AuthorID>
    <LastName>Liu</LastName>
    <ForeName>Y G</ForeName>
    <Initials>YG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>589</AuthorID>
    <LastName>Milei</LastName>
    <ForeName>J</ForeName>
    <Initials>J</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>590</AuthorID>
    <LastName>Storino</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>591</AuthorID>
    <LastName>Cabrera</LastName>
    <ForeName>E J</ForeName>
    <Initials>EJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>592</AuthorID>
    <LastName>Sergio</LastName>
    <ForeName>S L</ForeName>
    <Initials>SL</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>593</AuthorID>
    <LastName>Brotzu</LastName>
    <ForeName>G</ForeName>
    <Initials>G</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>594</AuthorID>
    <LastName>Carboni</LastName>
    <ForeName>M G</ForeName>
    <Initials>MG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>595</AuthorID>
    <LastName>Falchi</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>596</AuthorID>
    <LastName>Montisci</LastName>
    <ForeName>R</ForeName>
    <Initials>R</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>597</AuthorID>
    <LastName>Petruzzo</LastName>
    <ForeName>P</ForeName>
    <Initials>P</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>598</AuthorID>
    <LastName>Dorn</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>599</AuthorID>
    <LastName>Bernstein</LastName>
    <ForeName>H G</ForeName>
    <Initials>HG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>600</AuthorID>
    <LastName>Rinne</LastName>
    <ForeName>A</ForeName>
    <Initials>A</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>601</AuthorID>
    <LastName>Ziegler</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>602</AuthorID>
    <LastName>Hahn</LastName>
    <ForeName>H J</ForeName>
    <Initials>HJ</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>603</AuthorID>
    <LastName>Ansorge</LastName>
    <ForeName>S</ForeName>
    <Initials>S</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>604</AuthorID>
    <LastName>N첬챰ez</LastName>
    <ForeName>R G</ForeName>
    <Initials>RG</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>605</AuthorID>
    <LastName>Rapaport</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>606</AuthorID>
    <LastName>Kitabchi</LastName>
    <ForeName>A E</ForeName>
    <Initials>AE</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>607</AuthorID>
    <LastName>Duckworth</LastName>
    <ForeName>W C</ForeName>
    <Initials>WC</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>608</AuthorID>
    <LastName>Brush</LastName>
    <ForeName>J S</ForeName>
    <Initials>JS</Initials>
  </T_Authors>
  <T_Authors>
    <AuthorID>609</AuthorID>
    <LastName>Heinemann</LastName>
    <ForeName>M</ForeName>
    <Initials>M</Initials>
  </T_Authors>
  <T_Journals>
    <JournalID>1</JournalID>
    <Title>The Cochrane database of systematic reviews</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>2</JournalID>
    <Title>PloS one</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>3</JournalID>
    <Title>Journal of the Academy of Nutrition and Dietetics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>4</JournalID>
    <Title>Vaccine</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>5</JournalID>
    <Title>Acta clinica Belgica</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>6</JournalID>
    <Title>The American journal of sports medicine</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>7</JournalID>
    <Title>Journal of cosmetic dermatology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>8</JournalID>
    <Title>Molecular and biochemical parasitology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>9</JournalID>
    <Title>International journal of cancer. Journal international du cancer</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>10</JournalID>
    <Title>Phytotherapy research : PTR</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>11</JournalID>
    <Title>BMC molecular biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>12</JournalID>
    <Title>Journal of chromatographic science</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>13</JournalID>
    <Title>European journal of internal medicine</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>14</JournalID>
    <Title>Planta medica</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>15</JournalID>
    <Title>Human brain mapping</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>16</JournalID>
    <Title>Microbes and infection / Institut Pasteur</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>17</JournalID>
    <Title>Journal of food protection</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>18</JournalID>
    <Title>Anatomical record (Hoboken, N.J. : 2007)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>19</JournalID>
    <Title>International journal of cosmetic science</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>20</JournalID>
    <Title>Cancer gene therapy</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>21</JournalID>
    <Title>Mitochondrion</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>22</JournalID>
    <Title>PLoS pathogens</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>23</JournalID>
    <Title>European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>24</JournalID>
    <Title>Journal of cellular biochemistry</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>25</JournalID>
    <Title>Molecular cancer research : MCR</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>26</JournalID>
    <Title>International journal of oncology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>27</JournalID>
    <Title>Cardiovascular research</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>28</JournalID>
    <Title>Molecular biology of the cell</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>29</JournalID>
    <Title>Journal of cellular physiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>30</JournalID>
    <Title>Journal of neurology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>31</JournalID>
    <Title>Photochemistry and photobiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>32</JournalID>
    <Title>European journal of immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>33</JournalID>
    <Title>Comparative biochemistry and physiology. Part B, Biochemistry &amp; molecular biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>34</JournalID>
    <Title>Optics express</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>35</JournalID>
    <Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>36</JournalID>
    <Title>Journal of molecular endocrinology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>37</JournalID>
    <Title>Neurophysiologie clinique = Clinical neurophysiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>38</JournalID>
    <Title>Virology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>39</JournalID>
    <Title>Biological &amp; pharmaceutical bulletin</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>40</JournalID>
    <Title>Progress in drug research. Fortschritte der Arzneimittelforschung. Progr챔s des recherches pharmaceutiques</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>41</JournalID>
    <Title>Prostaglandins &amp; other lipid mediators</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>42</JournalID>
    <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>43</JournalID>
    <Title>Journal of forensic sciences</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>44</JournalID>
    <Title>Wei sheng wu xue bao = Acta microbiologica Sinica</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>45</JournalID>
    <Title>Cytometry. Part B, Clinical cytometry</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>46</JournalID>
    <Title>PLoS biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>47</JournalID>
    <Title>Acta virologica</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>48</JournalID>
    <Title>The Journal of biological chemistry</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>49</JournalID>
    <Title>The Journal of physiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>50</JournalID>
    <Title>Immunogenetics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>51</JournalID>
    <Title>Journal of clinical microbiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>52</JournalID>
    <Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>53</JournalID>
    <Title>Journal of the neurological sciences</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>54</JournalID>
    <Title>Cellular &amp; molecular immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>55</JournalID>
    <Title>Cancer genetics and cytogenetics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>56</JournalID>
    <Title>BioFactors (Oxford, England)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>57</JournalID>
    <Title>Human molecular genetics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>58</JournalID>
    <Title>Gene</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>59</JournalID>
    <Title>Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>60</JournalID>
    <Title>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>61</JournalID>
    <Title>Acta cytologica</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>62</JournalID>
    <Title>Pharmacology &amp; therapeutics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>63</JournalID>
    <Title>The Journal of clinical endocrinology and metabolism</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>64</JournalID>
    <Title>Diagnostic cytopathology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>65</JournalID>
    <Title>Molecular pharmacology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>66</JournalID>
    <Title>Experimental cell research</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>67</JournalID>
    <Title>Blood cells, molecules &amp; diseases</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>68</JournalID>
    <Title>Pituitary</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>69</JournalID>
    <Title>The Journal of investigative dermatology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>70</JournalID>
    <Title>The Journal of pharmacology and experimental therapeutics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>71</JournalID>
    <Title>Trends in pharmacological sciences</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>72</JournalID>
    <Title>Biochimica et biophysica acta</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>73</JournalID>
    <Title>International journal of clinical oncology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>74</JournalID>
    <Title>Developmental cell</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>75</JournalID>
    <Title>Archives of medical research</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>76</JournalID>
    <Title>The Journal of prosthetic dentistry</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>77</JournalID>
    <Title>Biochemical and biophysical research communications</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>78</JournalID>
    <Title>Pathology international</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>79</JournalID>
    <Title>The Journal of comparative neurology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>80</JournalID>
    <Title>Ultrasound in medicine &amp; biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>81</JournalID>
    <Title>European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>82</JournalID>
    <Title>Immunology letters</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>83</JournalID>
    <Title>Immunobiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>84</JournalID>
    <Title>Toxicology and applied pharmacology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>85</JournalID>
    <Title>Nihon Sanka Fujinka Gakkai zasshi</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>86</JournalID>
    <Title>Life sciences</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>87</JournalID>
    <Title>The Japanese journal of antibiotics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>88</JournalID>
    <Title>The Journal of antibiotics</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>89</JournalID>
    <Title>Respiration physiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>90</JournalID>
    <Title>Journal of virology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>91</JournalID>
    <Title>Kansensh흲gaku zasshi. The Journal of the Japanese Association for Infectious Diseases</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>92</JournalID>
    <Title>Hepatology (Baltimore, Md.)</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>93</JournalID>
    <Title>FEMS microbiology immunology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>94</JournalID>
    <Title>Journal of Tongji Medical University = Tong ji yi ke da xue xue bao</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>95</JournalID>
    <Title>Japanese heart journal</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>96</JournalID>
    <Title>International journal of immunopharmacology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>97</JournalID>
    <Title>Artery</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>98</JournalID>
    <Title>The Anatomical record</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>99</JournalID>
    <Title>Cardiology</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>100</JournalID>
    <Title>American heart journal</Title>
  </T_Journals>
  <T_Journals>
    <JournalID>101</JournalID>
    <Title>The Journal of clinical investigation</Title>
  </T_Journals>
  <T_JournalRelease>
    <JournalRelease>1469-493X</JournalRelease>
    <JournalID>1</JournalID>
    <Year>2013</Year>
    <Volume>3</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1932-6203</JournalRelease>
    <JournalID>2</JournalID>
    <Year>2013</Year>
    <Volume>8</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>2212-2672</JournalRelease>
    <JournalID>3</JournalID>
    <Year>2013May</Year>
    <Volume>113</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1873-2518</JournalRelease>
    <JournalID>4</JournalID>
    <Year>2012Nov20</Year>
    <Volume>30 Suppl 5</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0001-5512</JournalRelease>
    <JournalID>5</JournalID>
    <Year>2012 Sep-Oct</Year>
    <Volume>67</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1552-3365</JournalRelease>
    <JournalID>6</JournalID>
    <Year>2012Nov</Year>
    <Volume>40</Volume>
    <Issue>11</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1473-2165</JournalRelease>
    <JournalID>7</JournalID>
    <Year>2012Jun</Year>
    <Volume>11</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1872-9428</JournalRelease>
    <JournalID>8</JournalID>
    <Year>2012Aug</Year>
    <Volume>184</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-0215</JournalRelease>
    <JournalID>9</JournalID>
    <Year>2013Jan1</Year>
    <Volume>132</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1099-1573</JournalRelease>
    <JournalID>10</JournalID>
    <Year>2013Mar</Year>
    <Volume>27</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1471-2199</JournalRelease>
    <JournalID>11</JournalID>
    <Year>2012</Year>
    <Volume>13</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1945-239X</JournalRelease>
    <JournalID>12</JournalID>
    <Year>2012Mar</Year>
    <Volume>50</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1879-0828</JournalRelease>
    <JournalID>13</JournalID>
    <Year>2012Mar</Year>
    <Volume>23</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1439-0221</JournalRelease>
    <JournalID>14</JournalID>
    <Year>2012Mar</Year>
    <Volume>78</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-0193</JournalRelease>
    <JournalID>15</JournalID>
    <Year>2013Feb</Year>
    <Volume>34</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1769-714X</JournalRelease>
    <JournalID>16</JournalID>
    <Year>2012Jan</Year>
    <Volume>14</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1944-9097</JournalRelease>
    <JournalID>17</JournalID>
    <Year>2011Aug</Year>
    <Volume>74</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1932-8494</JournalRelease>
    <JournalID>18</JournalID>
    <Year>2011May</Year>
    <Volume>294</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1468-2494</JournalRelease>
    <JournalID>19</JournalID>
    <Year>2011Oct</Year>
    <Volume>33</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1476-5500</JournalRelease>
    <JournalID>20</JournalID>
    <Year>2011Jun</Year>
    <Volume>18</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1872-8278</JournalRelease>
    <JournalID>21</JournalID>
    <Year>2011Jan</Year>
    <Volume>11</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1553-7374</JournalRelease>
    <JournalID>22</JournalID>
    <Year>2010</Year>
    <Volume>6</Volume>
    <Issue>9</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1473-5709</JournalRelease>
    <JournalID>23</JournalID>
    <Year>2011Jan</Year>
    <Volume>20</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-4644</JournalRelease>
    <JournalID>24</JournalID>
    <Year>2010Sep1</Year>
    <Volume>111</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1557-3125</JournalRelease>
    <JournalID>25</JournalID>
    <Year>2010May</Year>
    <Volume>8</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1791-2423</JournalRelease>
    <JournalID>26</JournalID>
    <Year>2010Apr</Year>
    <Volume>36</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1755-3245</JournalRelease>
    <JournalID>27</JournalID>
    <Year>2010Jul1</Year>
    <Volume>87</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1939-4586</JournalRelease>
    <JournalID>28</JournalID>
    <Year>2010Mar15</Year>
    <Volume>21</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1097-4652</JournalRelease>
    <JournalID>29</JournalID>
    <Year>2010Mar</Year>
    <Volume>222</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1432-1459</JournalRelease>
    <JournalID>30</JournalID>
    <Year>2010Apr</Year>
    <Volume>257</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1751-1097</JournalRelease>
    <JournalID>31</JournalID>
    <Year>2010 Jan-Feb</Year>
    <Volume>86</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1521-4141</JournalRelease>
    <JournalID>32</JournalID>
    <Year>2009May</Year>
    <Volume>39</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1879-1107</JournalRelease>
    <JournalID>33</JournalID>
    <Year>2009Jun</Year>
    <Volume>153</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1094-4087</JournalRelease>
    <JournalID>34</JournalID>
    <Year>2009Mar2</Year>
    <Volume>17</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1525-0024</JournalRelease>
    <JournalID>35</JournalID>
    <Year>2009Mar</Year>
    <Volume>17</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1479-6813</JournalRelease>
    <JournalID>36</JournalID>
    <Year>2009Jan</Year>
    <Volume>42</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0987-7053</JournalRelease>
    <JournalID>37</JournalID>
    <Year>2008Aug</Year>
    <Volume>38</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0264-410X</JournalRelease>
    <JournalID>4</JournalID>
    <Year>2008Sep2</Year>
    <Volume>26</Volume>
    <Issue>37</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0042-6822</JournalRelease>
    <JournalID>38</JournalID>
    <Year>2008Jul20</Year>
    <Volume>377</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0918-6158</JournalRelease>
    <JournalID>39</JournalID>
    <Year>2008Jun</Year>
    <Volume>31</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0071-786X</JournalRelease>
    <JournalID>40</JournalID>
    <Year>2008</Year>
    <Volume>66</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1098-8823</JournalRelease>
    <JournalID>41</JournalID>
    <Year>2008Jun</Year>
    <Volume>86</Volume>
    <Issue>1-4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1091-6490</JournalRelease>
    <JournalID>42</JournalID>
    <Year>2008Feb26</Year>
    <Volume>105</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-1198</JournalRelease>
    <JournalID>43</JournalID>
    <Year>2008Jan</Year>
    <Volume>53</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0001-6209</JournalRelease>
    <JournalID>44</JournalID>
    <Year>2007Oct</Year>
    <Volume>47</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1552-4957</JournalRelease>
    <JournalID>45</JournalID>
    <Year>2008</Year>
    <Volume>74 Suppl 1</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1545-7885</JournalRelease>
    <JournalID>46</JournalID>
    <Year>2007Oct2</Year>
    <Volume>5</Volume>
    <Issue>10</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0001-723X</JournalRelease>
    <JournalID>47</JournalID>
    <Year>2007</Year>
    <Volume>51</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-9258</JournalRelease>
    <JournalID>48</JournalID>
    <Year>2007Nov23</Year>
    <Volume>282</Volume>
    <Issue>47</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-3751</JournalRelease>
    <JournalID>49</JournalID>
    <Year>2007Aug15</Year>
    <Volume>583</Volume>
    <Issue>Pt 1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0093-7711</JournalRelease>
    <JournalID>50</JournalID>
    <Year>2007Aug</Year>
    <Volume>59</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0095-1137</JournalRelease>
    <JournalID>51</JournalID>
    <Year>2007Mar</Year>
    <Volume>45</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0278-6915</JournalRelease>
    <JournalID>52</JournalID>
    <Year>2007Jan</Year>
    <Volume>45</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-510X</JournalRelease>
    <JournalID>53</JournalID>
    <Year>2006Dec1</Year>
    <Volume>250</Volume>
    <Issue>1-2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1672-7681</JournalRelease>
    <JournalID>54</JournalID>
    <Year>2006Feb</Year>
    <Volume>3</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0165-4608</JournalRelease>
    <JournalID>55</JournalID>
    <Year>2006Mar</Year>
    <Volume>165</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0951-6433</JournalRelease>
    <JournalID>56</JournalID>
    <Year>2005</Year>
    <Volume>23</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0964-6906</JournalRelease>
    <JournalID>57</JournalID>
    <Year>2005Dec15</Year>
    <Volume>14</Volume>
    <Issue>24</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0378-1119</JournalRelease>
    <JournalID>58</JournalID>
    <Year>2005Dec30</Year>
    <Volume>364</Volume>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1089-8603</JournalRelease>
    <JournalID>59</JournalID>
    <Year>2005Dec</Year>
    <Volume>13</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1388-2457</JournalRelease>
    <JournalID>60</JournalID>
    <Year>2005Aug</Year>
    <Volume>116</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0001-5547</JournalRelease>
    <JournalID>61</JournalID>
    <Year>2005 May-Jun</Year>
    <Volume>49</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0163-7258</JournalRelease>
    <JournalID>62</JournalID>
    <Year>2005Dec</Year>
    <Volume>108</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-972X</JournalRelease>
    <JournalID>63</JournalID>
    <Year>2004Nov</Year>
    <Volume>89</Volume>
    <Issue>11</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0032-0943</JournalRelease>
    <JournalID>14</JournalID>
    <Year>2004Jun</Year>
    <Volume>70</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>8755-1039</JournalRelease>
    <JournalID>64</JournalID>
    <Year>2004Mar</Year>
    <Volume>30</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0026-895X</JournalRelease>
    <JournalID>65</JournalID>
    <Year>2003Nov</Year>
    <Volume>64</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0014-4827</JournalRelease>
    <JournalID>66</JournalID>
    <Year>2003Aug15</Year>
    <Volume>288</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1079-9796</JournalRelease>
    <JournalID>67</JournalID>
    <Year>2003 Mar-Apr</Year>
    <Volume>30</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1386-341X</JournalRelease>
    <JournalID>68</JournalID>
    <Year>2002</Year>
    <Volume>5</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-202X</JournalRelease>
    <JournalID>69</JournalID>
    <Year>2003Apr</Year>
    <Volume>120</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-3565</JournalRelease>
    <JournalID>70</JournalID>
    <Year>2003Mar</Year>
    <Volume>304</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0165-6147</JournalRelease>
    <JournalID>71</JournalID>
    <Year>2003Jan</Year>
    <Volume>24</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0006-3002</JournalRelease>
    <JournalID>72</JournalID>
    <Year>2002May23</Year>
    <Volume>1582</Volume>
    <Issue>1-3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1341-9625</JournalRelease>
    <JournalID>73</JournalID>
    <Year>2002Feb</Year>
    <Volume>7</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1534-5807</JournalRelease>
    <JournalID>74</JournalID>
    <Year>2001Nov</Year>
    <Volume>1</Volume>
    <Issue>5</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0188-4409</JournalRelease>
    <JournalID>75</JournalID>
    <Year>2001 Jul-Aug</Year>
    <Volume>32</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-3913</JournalRelease>
    <JournalID>76</JournalID>
    <Year>2001Feb</Year>
    <Volume>85</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0006-291X</JournalRelease>
    <JournalID>77</JournalID>
    <Year>2000Aug11</Year>
    <Volume>274</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>1320-5463</JournalRelease>
    <JournalID>78</JournalID>
    <Year>2000Jun</Year>
    <Volume>50</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-9967</JournalRelease>
    <JournalID>79</JournalID>
    <Year>2000Jun5</Year>
    <Volume>421</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0301-5629</JournalRelease>
    <JournalID>80</JournalID>
    <Year>1999Jul</Year>
    <Volume>25</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0929-8266</JournalRelease>
    <JournalID>81</JournalID>
    <Year>1999Mar</Year>
    <Volume>9</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0165-2478</JournalRelease>
    <JournalID>82</JournalID>
    <Year>1998Jun</Year>
    <Volume>62</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0171-2985</JournalRelease>
    <JournalID>83</JournalID>
    <Year>1998Feb</Year>
    <Volume>198</Volume>
    <Issue>4</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0041-008X</JournalRelease>
    <JournalID>84</JournalID>
    <Year>1998Feb</Year>
    <Volume>148</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0300-9165</JournalRelease>
    <JournalID>85</JournalID>
    <Year>1995Jan</Year>
    <Volume>47</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0024-3205</JournalRelease>
    <JournalID>86</JournalID>
    <Year>1995</Year>
    <Volume>56</Volume>
    <Issue>18</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0368-2781</JournalRelease>
    <JournalID>87</JournalID>
    <Year>1994Aug</Year>
    <Volume>47</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-8820</JournalRelease>
    <JournalID>88</JournalID>
    <Year>1994Feb</Year>
    <Volume>47</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0034-5687</JournalRelease>
    <JournalID>89</JournalID>
    <Year>1993Jun</Year>
    <Volume>92</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-9541</JournalRelease>
    <JournalID>29</JournalID>
    <Year>1993May</Year>
    <Volume>155</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0022-538X</JournalRelease>
    <JournalID>90</JournalID>
    <Year>1992Jun</Year>
    <Volume>66</Volume>
    <Issue>6</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0387-5911</JournalRelease>
    <JournalID>91</JournalID>
    <Year>1992Feb</Year>
    <Volume>66</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0270-9139</JournalRelease>
    <JournalID>92</JournalID>
    <Year>1991Mar</Year>
    <Volume>13</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0920-8534</JournalRelease>
    <JournalID>93</JournalID>
    <Year>1990May</Year>
    <Volume>2</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0257-716X</JournalRelease>
    <JournalID>94</JournalID>
    <Year>1989</Year>
    <Volume>9</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-4868</JournalRelease>
    <JournalID>95</JournalID>
    <Year>1986May</Year>
    <Volume>27</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0192-0561</JournalRelease>
    <JournalID>96</JournalID>
    <Year>1986</Year>
    <Volume>8</Volume>
    <Issue>8</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0098-6127</JournalRelease>
    <JournalID>97</JournalID>
    <Year>1985</Year>
    <Volume>13</Volume>
    <Issue>2</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0003-276X</JournalRelease>
    <JournalID>98</JournalID>
    <Year>1983Sep</Year>
    <Volume>207</Volume>
    <Issue>1</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0008-6312</JournalRelease>
    <JournalID>99</JournalID>
    <Year>1978</Year>
    <Volume>63</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0002-8703</JournalRelease>
    <JournalID>100</JournalID>
    <Year>1976Sep</Year>
    <Volume>92</Volume>
    <Issue>3</Issue>
  </T_JournalRelease>
  <T_JournalRelease>
    <JournalRelease>0021-9738</JournalRelease>
    <JournalID>101</JournalID>
    <Year>1971Sep</Year>
    <Volume>50</Volume>
    <Issue>9</Issue>
  </T_JournalRelease>
</QueryArticlesSet>